P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
8.718e-14 | -30.07 | nervous system development | biological process | GO:0007399 | 2185 | 28 | 18204 | 50 |
CNTN1,NTM,LSAMP,NTRK2,PLCB1,CTNND2,GPM6A,PRKG1,CTNNA2,CAMK2G,DCLK2,PARD3,SOX5,NAV2,ATP1A2,RORA,NRG3,ERBB4,TNC,RFX4,APOE,TNIK,DGKG,SLC1A2,MSI2,CLU,GFAP,NRXN1 |
9.732e-11 | -23.05 | neurogenesis | biological process | GO:0022008 | 1334 | 20 | 18204 | 50 |
GFAP,RORA,NAV2,CLU,NRXN1,CTNNA2,PRKG1,CTNND2,GPM6A,PARD3,SOX5,DCLK2,APOE,NTM,NTRK2,TNIK,DGKG,TNC,ERBB4,CNTN1 |
1.526e-10 | -22.60 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 19 | 16828 | 48 |
LSAMP,NKAIN3,NTRK2,SOX5,SLC1A2,HPSE2,DCLK2,NAV2,ERBB4,NRG3,PRKG1,LRP1B,TNIK,PARD3,NPAS3,RYR3,CAMK2G,ATP1A2,ADCY2 |
1.526e-10 | -22.60 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 19 | 16828 | 48 |
ADCY2,ATP1A2,NPAS3,RYR3,CAMK2G,PRKG1,LRP1B,TNIK,PARD3,NRG3,DCLK2,ERBB4,NAV2,HPSE2,LSAMP,NTRK2,NKAIN3,SLC1A2,SOX5 |
1.611e-10 | -22.55 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 16 | 16828 | 48 |
RYR3,GPC5,PARD3,PLCB1,LRP1B,ADCY2,ATP1A2,HPSE2,SLC1A2,SOX5,NTRK2,NKAIN3,LSAMP,NRG3,NAV2,ERBB4 |
6.566e-10 | -21.14 | generation of neurons | biological process | GO:0048699 | 1158 | 18 | 18204 | 50 |
PARD3,SOX5,DCLK2,PRKG1,CTNNA2,GPM6A,CTNND2,NRXN1,RORA,GFAP,TNC,ERBB4,CNTN1,NTM,DGKG,TNIK,NTRK2,APOE |
1.689e-09 | -20.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 20 | 16828 | 48 |
LSAMP,RORA,NTRK2,NKAIN3,SOX5,HPSE2,DGKG,ERBB4,NAV2,NRG3,PRKG1,LRP1B,PLCB1,FMN2,PARD3,CTNND2,GPC5,RYR3,NEBL,ADCY2 |
1.689e-09 | -20.20 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 20 | 16828 | 48 |
NEBL,ADCY2,PARD3,FMN2,PLCB1,LRP1B,PRKG1,RYR3,GPC5,CTNND2,ERBB4,NAV2,DGKG,NRG3,SOX5,NTRK2,NKAIN3,RORA,LSAMP,HPSE2 |
1.832e-09 | -20.12 | system development | biological process | GO:0048731 | 3533 | 29 | 18204 | 50 |
PLCB1,NTM,LSAMP,NTRK2,NEBL,CNTN1,NRG3,ATP1A2,RORA,NAV2,SOX5,PARD3,CAMK2G,DCLK2,PRKG1,CTNNA2,CTNND2,GPM6A,SLC1A2,DGKG,TNIK,RFX4,APOE,TNC,ERBB4,NRXN1,GFAP,CLU,MSI2 |
1.844e-09 | -20.11 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 15 | 16828 | 48 |
PARD3,PLCB1,LRP1B,PRKG1,RYR3,NPAS3,GPC5,CTNND2,NEBL,NTRK2,ABLIM1,NRXN1,HPSE2,ERBB4,NRG3 |
1.910e-09 | -20.08 | neuron differentiation | biological process | GO:0030182 | 1081 | 17 | 18204 | 50 |
APOE,NTM,TNIK,DGKG,NTRK2,TNC,ERBB4,CNTN1,GFAP,RORA,NRXN1,PRKG1,CTNNA2,CTNND2,GPM6A,PARD3,DCLK2 |
1.996e-09 | -20.03 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 13 | 16828 | 48 |
ADCY2,GPC5,CTNND2,RYR3,LRP1B,PRKG1,PLCB1,GPM6A,FMN2,NRG3,LSAMP,SOX5,NKAIN3 |
2.172e-09 | -19.95 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 14 | 16828 | 48 |
ERBB4,NRG3,NTRK2,ABLIM1,NRXN1,HPSE2,NEBL,PARD3,PLCB1,LRP1B,PRKG1,RYR3,NPAS3,CTNND2 |
2.215e-09 | -19.93 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 14 | 16828 | 48 |
ABLIM1,NTRK2,HPSE2,NRXN1,ERBB4,NRG3,LRP1B,PRKG1,PARD3,PLCB1,NPAS3,CTNND2,RYR3,NEBL |
2.339e-09 | -19.87 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 23 | 16828 | 48 |
PLCB1,GPM6A,FMN2,LRP1B,RYR3,NKAIN3,NTRK2,SLC1A2,CNTN1,DGKG,ERBB4,NAV2,PARD3,PRKG1,CTNND2,GPC5,NPAS3,ADCY2,SOX5,LSAMP,HPSE2,NRG3,RFX4 |
2.339e-09 | -19.87 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 23 | 16828 | 48 |
RYR3,LRP1B,GPM6A,FMN2,PLCB1,CNTN1,SLC1A2,NKAIN3,NTRK2,ERBB4,DGKG,NAV2,NPAS3,CTNND2,GPC5,PRKG1,PARD3,ADCY2,HPSE2,LSAMP,SOX5,RFX4,NRG3 |
4.712e-09 | -19.17 | cell periphery | cellular component | GO:0071944 | 6020 | 36 | 19108 | 50 |
NRG3,CLU,MAPK10,RYR3,SORBS1,NKAIN3,TRPM3,CTNNA2,NRXN1,CTNND2,HPSE2,GPC5,LRP1B,APOE,DGKG,DTNA,CNTN1,LSAMP,NTM,FMN2,CST3,ERBB4,TNC,ATP1A2,PARD3,ADCY2,CDH20,TNIK,SLC1A2,NTRK2,SLC4A4,PRKG1,MACF1,SLC14A1,NAV2,GPM6A |
4.778e-09 | -19.16 | central nervous system development | biological process | GO:0007417 | 995 | 16 | 18204 | 50 |
PLCB1,SLC1A2,NTRK2,RFX4,CNTN1,ERBB4,NRG3,RORA,GFAP,ATP1A2,CLU,NAV2,DCLK2,CTNNA2,PRKG1,MSI2 |
5.243e-09 | -19.07 | multicellular organism development | biological process | GO:0007275 | 3957 | 30 | 18204 | 50 |
CDH20,MSI2,GFAP,CLU,NRXN1,TNC,ERBB4,APOE,RFX4,SLC1A2,TNIK,DGKG,PRKG1,CTNNA2,GPM6A,CTNND2,PARD3,SOX5,DCLK2,CAMK2G,ATP1A2,RORA,NAV2,NRG3,CNTN1,NEBL,PLCB1,NTRK2,LSAMP,NTM |
5.425e-09 | -19.03 | neuron development | biological process | GO:0048666 | 859 | 15 | 18204 | 50 |
NRXN1,GFAP,DCLK2,PARD3,GPM6A,CTNND2,CTNNA2,PRKG1,NTM,DGKG,TNIK,NTRK2,APOE,CNTN1,TNC |
6.314e-09 | -18.88 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 12 | 16828 | 48 |
LSAMP,TRPM3,NAV2,ERBB4,NRG3,PRKG1,LRP1B,PLCB1,GPM6A,GPC5,CTNND2,RYR3 |
1.088e-08 | -18.34 | mouth | COSMIC cancer mutations | mouth | 9004 | 44 | 16828 | 48 |
DCLK2,CST3,NRG3,RFX4,CLU,LSAMP,ABLIM1,RORA,SLC4A4,SOX5,MACF1,HPSE2,TRPM3,NEBL,CDH20,ADCY2,PRKG1,NTM,PARD3,GPC5,CTNND2,NPAS3,CAMK2G,DTNA,NAV2,ERBB4,DGKG,CNTN1,APOE,NTRK2,TNC,SLC1A2,NRXN1,PITPNC1,ATP1A2,MGAT4C,LRP1B,PLCB1,GPM6A,FMN2,TNIK,SORBS1,GFAP,RYR3 |
1.676e-08 | -17.90 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 39 | 16828 | 48 |
MGAT4C,ATP1A2,PITPNC1,LRP1B,GFAP,PLCB1,FMN2,GPM6A,TNIK,SORBS1,RYR3,ERBB4,NAV2,DGKG,CNTN1,SLC1A2,TNC,NRXN1,NEBL,CDH20,ADCY2,PRKG1,NTM,PARD3,GPC5,CTNND2,DTNA,CAMK2G,DCLK2,CST3,RFX4,NRG3,ABLIM1,RORA,LSAMP,SOX5,SLC4A4,TRPM3,MACF1 |
2.230e-08 | -17.62 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 29 | 16828 | 48 |
NKAIN3,TNC,NTRK2,SLC1A2,CNTN1,NRXN1,NAV2,ERBB4,GLIS3,TNIK,PLCB1,GPM6A,FMN2,LRP1B,RYR3,MGAT4C,SOX5,SLC4A4,LSAMP,RORA,HPSE2,NRG3,NTM,PARD3,PRKG1,CTNND2,GPC5,NEBL,ADCY2 |
2.230e-08 | -17.62 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 29 | 16828 | 48 |
NAV2,ERBB4,GLIS3,NTRK2,NKAIN3,TNC,SLC1A2,CNTN1,NRXN1,MGAT4C,PLCB1,FMN2,GPM6A,TNIK,LRP1B,RYR3,NRG3,SOX5,SLC4A4,LSAMP,RORA,HPSE2,NEBL,ADCY2,NTM,PARD3,PRKG1,CTNND2,GPC5 |
2.935e-08 | -17.34 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 28 | 16828 | 48 |
RORA,CLU,LSAMP,SOX5,HPSE2,MACF1,NRG3,PRKG1,PARD3,GPC5,CTNND2,NEBL,CDH20,ADCY2,CNTN1,SLC1A2,NKAIN3,TNC,NAV2,DGKG,ERBB4,LRP1B,GPM6A,FMN2,TNIK,PLCB1,RYR3,ATP1A2 |
3.024e-08 | -17.31 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 30 | 16828 | 48 |
NRG3,SOX5,RORA,LSAMP,CLU,MACF1,HPSE2,NEBL,ADCY2,CDH20,PARD3,PRKG1,DTNA,GPC5,CTNND2,DGKG,NAV2,ERBB4,SLC1A2,TNC,NTRK2,NKAIN3,CNTN1,ATP1A2,FMN2,PLCB1,TNIK,GPM6A,LRP1B,RYR3 |
3.501e-08 | -17.17 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 35 | 16828 | 48 |
CST3,NRG3,SLC14A1,SLC4A4,SOX5,LSAMP,CLU,MACF1,HPSE2,TRPM3,NEBL,ADCY2,CDH20,NTM,PARD3,PRKG1,DTNA,GPC5,CTNND2,NPAS3,DGKG,NAV2,ERBB4,NTRK2,TNC,NKAIN3,CNTN1,ATP1A2,MGAT4C,SORBS1,PLCB1,FMN2,GPM6A,LRP1B,RYR3 |
3.501e-08 | -17.17 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 35 | 16828 | 48 |
RYR3,LRP1B,FMN2,GPM6A,PLCB1,SORBS1,MGAT4C,ATP1A2,CNTN1,NKAIN3,TNC,NTRK2,ERBB4,NAV2,DGKG,NPAS3,GPC5,CTNND2,DTNA,PRKG1,PARD3,NTM,CDH20,ADCY2,NEBL,TRPM3,MACF1,HPSE2,CLU,LSAMP,SOX5,SLC4A4,NRG3,SLC14A1,CST3 |
6.243e-08 | -16.59 | plasma membrane | cellular component | GO:0005886 | 5538 | 33 | 19108 | 50 |
NTM,CNTN1,DTNA,LSAMP,DGKG,CST3,FMN2,ATP1A2,ERBB4,CDH20,ADCY2,PARD3,PRKG1,SLC4A4,NTRK2,TNIK,SLC1A2,SLC14A1,MACF1,GPM6A,NRG3,MAPK10,TRPM3,NKAIN3,SORBS1,RYR3,CTNNA2,LRP1B,GPC5,HPSE2,NRXN1,CTNND2,APOE |
7.021e-08 | -16.47 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 14 | 19454 | 50 |
ATP1A2,GPM6A,APOE,ABLIM1,CTNND2,NEBL,TNIK,CLU,MAPK10,LSAMP,SORBS1,CTNNA2,SLC1A2,NTM |
7.346e-08 | -16.43 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 19 | 16828 | 48 |
CAMK2G,DTNA,RYR3,CTNND2,GPC5,PARD3,PLCB1,GPM6A,TNIK,LRP1B,PRKG1,NEBL,TRPM3,SOX5,NTRK2,LSAMP,NRG3,ERBB4,NAV2 |
7.535e-08 | -16.40 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 15 | 19454 | 50 |
SLC4A4,APOE,GPM6A,ATP1A2,MSI2,PLCB1,CNTN1,CAMK2G,ABLIM1,TNC,MACF1,TRPM3,CLU,SORBS1,LSAMP |
8.476e-08 | -16.28 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 43 | 16828 | 48 |
PITPNC1,PLCB1,FMN2,TNIK,GPM6A,SORBS1,LRP1B,RYR3,NAV2,DGKG,ERBB4,GLIS3,SLC1A2,APOE,NTRK2,NKAIN3,TNC,CNTN1,MSI2,NRXN1,NEBL,ADCY2,CDH20,PARD3,NTM,PRKG1,DTNA,NPAS3,CTNND2,GPC5,DCLK2,RFX4,SLC14A1,NRG3,SOX5,SLC4A4,ABLIM1,RORA,CLU,LSAMP,TRPM3,MACF1,HPSE2 |
1.308e-07 | -15.85 | cell development | biological process | GO:0048468 | 2236 | 21 | 18204 | 50 |
TNC,CNTN1,NEBL,ERBB4,TNIK,DGKG,NTRK2,NTM,APOE,PARD3,FMN2,DCLK2,CTNNA2,PRKG1,GPM6A,CTNND2,MSI2,NRXN1,GFAP,RORA,CLU |
1.359e-07 | -15.81 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 24 | 16828 | 48 |
RYR3,FMN2,GPM6A,PLCB1,LRP1B,NKAIN3,TNC,NTRK2,SLC1A2,CNTN1,ERBB4,NAV2,CTNND2,GPC5,PARD3,PRKG1,ADCY2,NEBL,HPSE2,TRPM3,SOX5,LSAMP,RFX4,NRG3 |
1.534e-07 | -15.69 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 21 | 16828 | 48 |
ADCY2,CDH20,NEBL,RYR3,GPC5,CTNND2,PARD3,PLCB1,FMN2,GPM6A,LRP1B,PRKG1,NRG3,NAV2,ERBB4,HPSE2,SOX5,SLC1A2,NTRK2,NKAIN3,LSAMP |
1.534e-07 | -15.69 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 21 | 16828 | 48 |
CDH20,ADCY2,NEBL,GPC5,CTNND2,RYR3,PRKG1,LRP1B,PLCB1,FMN2,GPM6A,PARD3,NRG3,ERBB4,NAV2,HPSE2,LSAMP,NTRK2,NKAIN3,SOX5,SLC1A2 |
1.781e-07 | -15.54 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 21 | 16828 | 48 |
SOX5,SLC1A2,NTRK2,NKAIN3,LSAMP,HPSE2,ERBB4,NAV2,NRG3,PARD3,PLCB1,FMN2,GPM6A,LRP1B,PRKG1,RYR3,GPC5,CTNND2,NEBL,ADCY2,CDH20 |
2.064e-07 | -15.39 | anatomical structure development | biological process | GO:0048856 | 5207 | 32 | 18204 | 50 |
CNTN1,NEBL,NTRK2,LSAMP,NTM,PLCB1,CTNND2,GPM6A,CTNNA2,PRKG1,DCLK2,CAMK2G,PARD3,SOX5,NAV2,ATP1A2,RORA,NRG3,ABLIM1,ERBB4,TNC,RFX4,APOE,DGKG,TNIK,SLC1A2,MSI2,CDH20,FMN2,CLU,GFAP,NRXN1 |
2.662e-07 | -15.14 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 15 | 16828 | 48 |
SOX5,SLC1A2,ERBB4,NAV2,DGKG,NRG3,PLCB1,FMN2,PARD3,PRKG1,LRP1B,RYR3,GPC5,ADCY2,CDH20 |
3.141e-07 | -14.97 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 23 | 16828 | 48 |
FMN2,GPM6A,PLCB1,LRP1B,RYR3,ERBB4,NAV2,NTRK2,NKAIN3,TNC,SLC1A2,CNTN1,NEBL,ADCY2,PARD3,PRKG1,GPC5,CTNND2,NRG3,RFX4,SOX5,LSAMP,HPSE2 |
3.366e-07 | -14.90 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 6 | 16828 | 48 |
PLCB1,NKAIN3,GPM6A,LRP1B,LSAMP,CTNND2 |
4.322e-07 | -14.65 | brain development | biological process | GO:0007420 | 724 | 12 | 18204 | 50 |
RORA,ATP1A2,NRG3,PRKG1,CTNNA2,DCLK2,RFX4,SLC1A2,PLCB1,NTRK2,ERBB4,CNTN1 |
4.343e-07 | -14.65 | nodular | COSMIC cancer mutations | nodular | 1515 | 17 | 16828 | 48 |
DCLK2,DGKG,ERBB4,GLIS3,ABLIM1,CNTN1,SLC4A4,NTRK2,MACF1,ATP1A2,NEBL,CDH20,LRP1B,FMN2,PLCB1,NPAS3,CTNND2 |
6.984e-07 | -14.17 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 24 | 16828 | 48 |
PRKG1,PARD3,CTNND2,GPC5,NPAS3,CDH20,ADCY2,LSAMP,RORA,SOX5,HPSE2,NRG3,SLC14A1,LRP1B,FMN2,GPM6A,PLCB1,TNIK,RYR3,TNC,NKAIN3,SLC1A2,ERBB4,NAV2 |
7.803e-07 | -14.06 | telencephalon development | biological process | GO:0021537 | 276 | 8 | 18204 | 50 |
ERBB4,DCLK2,NTRK2,SLC1A2,NRG3,PLCB1,RFX4,ATP1A2 |
8.774e-07 | -13.95 | head development | biological process | GO:0060322 | 774 | 12 | 18204 | 50 |
CNTN1,ERBB4,PLCB1,SLC1A2,NTRK2,RFX4,DCLK2,PRKG1,CTNNA2,NRG3,RORA,ATP1A2 |
8.926e-07 | -13.93 | multicellular organismal process | biological process | GO:0032501 | 6177 | 34 | 18204 | 50 |
GFAP,CLU,NRXN1,CDH20,MSI2,RYR3,APOE,RFX4,SLC1A2,DGKG,TNIK,TNC,ERBB4,ATP1A2,RORA,NAV2,ABLIM1,NRG3,CTNNA2,PRKG1,CTNND2,GPM6A,SOX5,PARD3,CAMK2G,DCLK2,DTNA,PLCB1,NTM,LSAMP,NTRK2,SLC4A4,CNTN1,NEBL |
1.254e-06 | -13.59 | Salivary secretion | KEGG pathways | ko04970 | 90 | 6 | 7161 | 29 |
CST3,RYR3,PRKG1,ADCY2,ATP1A2,PLCB1 |
1.254e-06 | -13.59 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 6 | 7161 | 29 |
RYR3,PRKG1,ATP1A2,ADCY2,PLCB1,CST3 |
1.278e-06 | -13.57 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 15 | 16828 | 48 |
MACF1,HPSE2,NTRK2,TNC,ABLIM1,NRG3,RYR3,CTNND2,TNIK,FMN2,GPM6A,NTM,LRP1B,ADCY2,NEBL |
1.278e-06 | -13.57 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 15 | 16828 | 48 |
LRP1B,GPM6A,FMN2,TNIK,NTM,CTNND2,RYR3,NEBL,ADCY2,ABLIM1,TNC,NTRK2,HPSE2,MACF1,NRG3 |
1.407e-06 | -13.47 | cell junction | cellular component | GO:0030054 | 2224 | 19 | 19108 | 50 |
SORBS1,ATP1A2,PLCB1,ERBB4,TNC,NRG3,CNTN1,DTNA,CLU,NRXN1,CTNND2,GPM6A,APOE,CDH20,CTNNA2,PARD3,TNIK,SLC1A2,NTRK2 |
1.452e-06 | -13.44 | forebrain development | biological process | GO:0030900 | 408 | 9 | 18204 | 50 |
PRKG1,DCLK2,ERBB4,RFX4,ATP1A2,NRG3,PLCB1,SLC1A2,NTRK2 |
1.499e-06 | -13.41 | cell junction organization | biological process | GO:0034330 | 532 | 10 | 18204 | 50 |
TNC,PARD3,ERBB4,CDH20,CTNND2,GPM6A,NRG3,NRXN1,APOE,SORBS1 |
1.570e-06 | -13.36 | Htt (huntingtin) | protein interactions | 15194 | 77 | 5 | 19454 | 50 |
NTM,GFAP,CNTN1,LSAMP,GPM6A |
1.623e-06 | -13.33 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 8 | 19454 | 50 |
MACF1,TNIK,NEBL,DTNA,ABLIM1,CTNNA2,SORBS1,PARD3 |
1.713e-06 | -13.28 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 25 | 16828 | 48 |
RYR3,LRP1B,FMN2,PLCB1,TNIK,PITPNC1,MGAT4C,MSI2,NTRK2,NAV2,ERBB4,GPC5,CTNND2,NPAS3,DTNA,PRKG1,PARD3,ADCY2,HPSE2,MACF1,TRPM3,LSAMP,CLU,SLC4A4,NRG3 |
1.713e-06 | -13.28 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 25 | 16828 | 48 |
DTNA,GPC5,CTNND2,NPAS3,PARD3,PRKG1,ADCY2,MACF1,HPSE2,TRPM3,SLC4A4,CLU,LSAMP,NRG3,RYR3,PLCB1,TNIK,FMN2,LRP1B,PITPNC1,MGAT4C,MSI2,NTRK2,ERBB4,NAV2 |
1.759e-06 | -13.25 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 21 | 16828 | 48 |
ADCY2,CDH20,RYR3,CTNND2,GPC5,TNIK,FMN2,PLCB1,GPM6A,PARD3,PRKG1,LRP1B,NRG3,SLC14A1,ERBB4,NAV2,HPSE2,NKAIN3,SOX5,LSAMP,RORA |
1.935e-06 | -13.16 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 8 | 16828 | 48 |
GPC5,ADCY2,PRKG1,LRP1B,FMN2,NKAIN3,GPM6A,SOX5 |
2.063e-06 | -13.09 | cell differentiation | biological process | GO:0030154 | 3645 | 25 | 18204 | 50 |
PRKG1,CTNNA2,CTNND2,GPM6A,SOX5,PARD3,CAMK2G,DCLK2,RORA,NAV2,CNTN1,NEBL,PLCB1,NTM,NTRK2,MSI2,FMN2,GFAP,CLU,NRXN1,TNC,ERBB4,APOE,TNIK,DGKG |
2.083e-06 | -13.08 | developmental process | biological process | GO:0032502 | 5716 | 32 | 18204 | 50 |
APOE,RFX4,DGKG,TNIK,SLC1A2,ERBB4,TNC,CLU,GFAP,NRXN1,MSI2,CDH20,FMN2,NTRK2,NTM,LSAMP,PLCB1,NEBL,CNTN1,NAV2,RORA,ATP1A2,NRG3,ABLIM1,CTNND2,GPM6A,CTNNA2,PRKG1,DCLK2,CAMK2G,SOX5,PARD3 |
2.096e-06 | -13.08 | cellular developmental process | biological process | GO:0048869 | 3648 | 25 | 18204 | 50 |
PLCB1,NTM,NTRK2,CNTN1,NEBL,RORA,NAV2,CTNNA2,PRKG1,CTNND2,GPM6A,PARD3,SOX5,CAMK2G,DCLK2,APOE,TNIK,DGKG,TNC,ERBB4,GFAP,CLU,NRXN1,MSI2,FMN2 |
2.098e-06 | -13.07 | scalp | COSMIC cancer mutations | scalp | 2110 | 19 | 16828 | 48 |
ERBB4,TNC,SOX5,SLC4A4,LSAMP,CNTN1,RORA,NRXN1,MACF1,NEBL,ATP1A2,PLCB1,SORBS1,FMN2,NTM,GFAP,PRKG1,CAMK2G,GPC5 |
2.165e-06 | -13.04 | neuron projection development | biological process | GO:0031175 | 693 | 11 | 18204 | 50 |
GFAP,NRXN1,CTNND2,GPM6A,PRKG1,CTNNA2,PARD3,APOE,TNIK,CNTN1,TNC |
2.853e-06 | -12.77 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 9 | 18204 | 50 |
GFAP,APOE,DGKG,NTRK2,TNIK,MACF1,CTNNA2,CNTN1,CAMK2G |
2.948e-06 | -12.73 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 19 | 18204 | 50 |
TNC,CNTN1,NEBL,ERBB4,NTRK2,TNIK,APOE,PARD3,SOX5,PRKG1,CTNNA2,CDH20,GPM6A,CTNND2,NRG3,ABLIM1,NRXN1,RORA,CLU |
4.460e-06 | -12.32 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 34 | 16828 | 48 |
CDH20,ADCY2,PRKG1,PARD3,NTM,NPAS3,GPC5,CTNND2,RFX4,NRG3,ABLIM1,RORA,CLU,SOX5,SLC4A4,TRPM3,HPSE2,MACF1,MGAT4C,PITPNC1,LRP1B,GFAP,SORBS1,PLCB1,FMN2,GPM6A,RYR3,NAV2,DGKG,ERBB4,CNTN1,SLC1A2,APOE,TNC |
5.917e-06 | -12.04 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 36 | 16828 | 48 |
CNTN1,SLC1A2,NKAIN3,NTRK2,NRXN1,DGKG,ERBB4,NAV2,GLIS3,LRP1B,TNIK,FMN2,PLCB1,SORBS1,GPM6A,RYR3,PITPNC1,RORA,ABLIM1,LSAMP,SLC4A4,SOX5,TRPM3,HPSE2,MACF1,DCLK2,RFX4,NRG3,PRKG1,NTM,PARD3,NPAS3,GPC5,CTNND2,NEBL,ADCY2 |
6.387e-06 | -11.96 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 36 | 16828 | 48 |
DGKG,ERBB4,NAV2,SLC1A2,TNC,NTRK2,CNTN1,NRXN1,ATP1A2,PITPNC1,GFAP,PLCB1,FMN2,LRP1B,RYR3,CST3,DCLK2,RFX4,SLC14A1,NRG3,SLC4A4,SOX5,RORA,CLU,LSAMP,TRPM3,HPSE2,MACF1,NEBL,ADCY2,CDH20,PARD3,NTM,PRKG1,NPAS3,CTNND2 |
6.387e-06 | -11.96 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 36 | 16828 | 48 |
DGKG,ERBB4,NAV2,CNTN1,SLC1A2,TNC,NTRK2,NRXN1,ATP1A2,PITPNC1,LRP1B,GFAP,PLCB1,FMN2,RYR3,DCLK2,CST3,SLC14A1,RFX4,NRG3,RORA,CLU,LSAMP,SLC4A4,SOX5,TRPM3,HPSE2,MACF1,NEBL,CDH20,ADCY2,PRKG1,NTM,PARD3,NPAS3,CTNND2 |
7.941e-06 | -11.74 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 48 | 16828 | 48 |
DGKG,MSI2,CNTN1,NTRK2,MGAT4C,RYR3,GPM6A,SORBS1,FMN2,GFAP,SLC14A1,DCLK2,TRPM3,ABLIM1,SLC4A4,SOX5,CDH20,ADCY2,CTNND2,NPAS3,PARD3,GLIS3,ERBB4,NAV2,NRXN1,NKAIN3,TNC,APOE,SLC1A2,PITPNC1,ATP1A2,LRP1B,PLCB1,TNIK,RFX4,NRG3,CST3,HPSE2,MACF1,LSAMP,CLU,RORA,NEBL,GPC5,DTNA,CAMK2G,PRKG1,NTM |
8.691e-06 | -11.65 | trunk | COSMIC cancer mutations | trunk | 3554 | 24 | 16828 | 48 |
NEBL,MGAT4C,ATP1A2,CDH20,LRP1B,PARD3,PLCB1,NPAS3,CTNND2,RYR3,DCLK2,DGKG,ERBB4,SLC14A1,NRG3,GLIS3,ABLIM1,LSAMP,SOX5,NTRK2,TNC,HPSE2,MACF1,NRXN1 |
9.200e-06 | -11.60 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 14 | 16828 | 48 |
NEBL,ATP1A2,CDH20,LRP1B,PLCB1,NPAS3,CTNND2,DCLK2,ERBB4,DGKG,GLIS3,ABLIM1,NTRK2,MACF1 |
9.591e-06 | -11.55 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 13 | 18204 | 50 |
TNC,CNTN1,TNIK,APOE,RFX4,PARD3,CTNNA2,PRKG1,CTNND2,GPM6A,ABLIM1,NRXN1,GFAP |
1.097e-05 | -11.42 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 10 | 18204 | 50 |
DGKG,TNIK,NTRK2,GFAP,APOE,CNTN1,CAMK2G,CTNNA2,MACF1,GPM6A |
1.140e-05 | -11.38 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 37 | 16828 | 48 |
ADCY2,CDH20,NEBL,CAMK2G,CTNND2,GPC5,PARD3,PRKG1,RFX4,NRG3,DCLK2,TRPM3,HPSE2,MACF1,SOX5,SLC4A4,RORA,ABLIM1,LSAMP,CLU,ATP1A2,RYR3,TNIK,PLCB1,GPM6A,FMN2,LRP1B,GLIS3,ERBB4,NAV2,DGKG,SLC1A2,NKAIN3,NTRK2,TNC,APOE,CNTN1 |
1.189e-05 | -11.34 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 5 | 16828 | 48 |
LRP1B,PRKG1,PARD3,GPC5,NRG3 |
1.203e-05 | -11.33 | cell junction assembly | biological process | GO:0034329 | 285 | 7 | 18204 | 50 |
NRXN1,NRG3,SORBS1,ERBB4,PARD3,GPM6A,CDH20 |
1.353e-05 | -11.21 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 7 | 19454 | 50 |
DTNA,ABLIM1,TNIK,MACF1,FMN2,PLCB1,PARD3 |
1.366e-05 | -11.20 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 10 | 18204 | 50 |
CAMK2G,CNTN1,GPM6A,MACF1,CTNNA2,NTRK2,TNIK,DGKG,GFAP,APOE |
1.376e-05 | -11.19 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 17 | 16828 | 48 |
HPSE2,MACF1,NRXN1,RORA,CNTN1,SLC4A4,SOX5,ERBB4,NPAS3,RYR3,LRP1B,TNIK,GPM6A,PLCB1,FMN2,MGAT4C,NEBL |
1.395e-05 | -11.18 | larynx | COSMIC cancer mutations | larynx | 1948 | 17 | 16828 | 48 |
NEBL,MGAT4C,FMN2,GPM6A,TNIK,PLCB1,LRP1B,RYR3,NPAS3,ERBB4,SOX5,SLC4A4,CNTN1,RORA,NRXN1,HPSE2,MACF1 |
1.423e-05 | -11.16 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 12 | 16828 | 48 |
CTNND2,GPC5,PARD3,PRKG1,LRP1B,ADCY2,HPSE2,NKAIN3,SOX5,LSAMP,RORA,NRG3 |
1.437e-05 | -11.15 | cell morphogenesis | biological process | GO:0000902 | 687 | 10 | 18204 | 50 |
CNTN1,PARD3,GPM6A,CTNND2,CTNNA2,CDH20,PRKG1,TNIK,NRXN1,CLU |
1.487e-05 | -11.12 | cell projection organization | biological process | GO:0030030 | 1200 | 13 | 18204 | 50 |
PARD3,PRKG1,CTNNA2,GPM6A,CTNND2,ABLIM1,NRXN1,GFAP,TNC,CNTN1,TNIK,APOE,RFX4 |
1.562e-05 | -11.07 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 42 | 16828 | 48 |
LRP1B,FMN2,TNIK,GPM6A,PLCB1,SORBS1,RYR3,MGAT4C,ATP1A2,PITPNC1,CNTN1,TNC,NKAIN3,NTRK2,MSI2,NRXN1,DGKG,NAV2,ERBB4,PRKG1,PARD3,NTM,NPAS3,GPC5,CTNND2,DTNA,CAMK2G,NEBL,CDH20,RORA,ABLIM1,CLU,SOX5,SLC4A4,TRPM3,HPSE2,MACF1,DCLK2,CST3,SLC14A1,RFX4,NRG3 |
1.569e-05 | -11.06 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 43 | 16828 | 48 |
DTNA,NPAS3,CTNND2,GPC5,NTM,PARD3,PRKG1,ADCY2,CDH20,NEBL,TRPM3,MACF1,HPSE2,SOX5,SLC4A4,ABLIM1,RORA,LSAMP,NRG3,RFX4,DCLK2,RYR3,GFAP,GPM6A,PLCB1,FMN2,SORBS1,TNIK,LRP1B,MGAT4C,ATP1A2,PITPNC1,NRXN1,SLC1A2,APOE,NKAIN3,NTRK2,TNC,CNTN1,GLIS3,ERBB4,NAV2,DGKG |
1.569e-05 | -11.06 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 43 | 16828 | 48 |
TRPM3,MACF1,HPSE2,SLC4A4,SOX5,RORA,ABLIM1,LSAMP,RFX4,NRG3,DCLK2,DTNA,NPAS3,CTNND2,GPC5,PARD3,NTM,PRKG1,ADCY2,CDH20,NEBL,NRXN1,SLC1A2,NTRK2,APOE,NKAIN3,TNC,CNTN1,GLIS3,DGKG,ERBB4,NAV2,RYR3,GFAP,TNIK,FMN2,GPM6A,PLCB1,SORBS1,LRP1B,ATP1A2,MGAT4C,PITPNC1 |
1.570e-05 | -11.06 | membrane | cellular component | GO:0016020 | 9220 | 39 | 19108 | 50 |
CTNNA2,HPSE2,GPC5,LRP1B,CTNND2,NRXN1,CAMK2G,APOE,NRG3,MAPK10,GFAP,CLU,SORBS1,TRPM3,NKAIN3,RYR3,PLCB1,ADCY2,CDH20,PARD3,SLC4A4,PRKG1,TNIK,SLC1A2,NTRK2,MACF1,SLC14A1,GPM6A,NTM,DGKG,LSAMP,CNTN1,DTNA,FMN2,MGAT4C,CST3,ATP1A2,ERBB4,TNC |
1.589e-05 | -11.05 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 42 | 16828 | 48 |
PITPNC1,ATP1A2,MGAT4C,LRP1B,SORBS1,GPM6A,FMN2,PLCB1,TNIK,RYR3,NAV2,ERBB4,DGKG,CNTN1,NTRK2,TNC,NKAIN3,MSI2,NRXN1,NEBL,CDH20,PRKG1,NTM,PARD3,CTNND2,GPC5,NPAS3,CAMK2G,DTNA,DCLK2,CST3,NRG3,RFX4,SLC14A1,CLU,ABLIM1,RORA,SOX5,SLC4A4,HPSE2,MACF1,TRPM3 |
1.642e-05 | -11.02 | synapse | cellular component | GO:0045202 | 1473 | 14 | 19108 | 50 |
CLU,NRG3,CNTN1,DTNA,PLCB1,ATP1A2,ERBB4,NTRK2,SLC1A2,TNIK,GPM6A,APOE,CTNND2,NRXN1 |
1.750e-05 | -10.95 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 25 | 16828 | 48 |
PITPNC1,ATP1A2,LRP1B,TNIK,FMN2,PLCB1,GPM6A,RYR3,NAV2,DGKG,ERBB4,GLIS3,NTRK2,TNC,SLC1A2,NEBL,ADCY2,PRKG1,PARD3,CTNND2,NPAS3,CAMK2G,RFX4,SLC4A4,MACF1 |
1.758e-05 | -10.95 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 25 | 16828 | 48 |
RFX4,SLC4A4,MACF1,NEBL,ADCY2,PRKG1,PARD3,CTNND2,NPAS3,CAMK2G,DGKG,NAV2,ERBB4,GLIS3,NTRK2,TNC,SLC1A2,PITPNC1,ATP1A2,LRP1B,PLCB1,GPM6A,TNIK,FMN2,RYR3 |
1.766e-05 | -10.94 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 3 | 19454 | 50 |
NRXN1,CTNND2,CST3 |
1.776e-05 | -10.94 | tibia | COSMIC cancer mutations | tibia | 836 | 11 | 16828 | 48 |
PRKG1,LSAMP,LRP1B,ABLIM1,TNIK,PLCB1,GPM6A,NKAIN3,MACF1,CTNND2,TRPM3 |
1.850e-05 | -10.90 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 8 | 19454 | 50 |
MACF1,SOX5,FMN2,ABLIM1,DTNA,SLC14A1,SORBS1,PARD3 |
1.869e-05 | -10.89 | cell projection | cellular component | GO:0042995 | 2398 | 18 | 19108 | 50 |
PARD3,CTNNA2,ADCY2,NTRK2,SLC1A2,CAMK2G,MACF1,NRXN1,CTNND2,APOE,GPM6A,ABLIM1,CNTN1,DTNA,CLU,GFAP,FMN2,ATP1A2 |
2.022e-05 | -10.81 | humerus | COSMIC cancer mutations | humerus | 546 | 9 | 16828 | 48 |
GPC5,GPM6A,FMN2,NKAIN3,SOX5,PRKG1,LRP1B,ADCY2,NEBL |
2.057e-05 | -10.79 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 25 | 16828 | 48 |
ADCY2,NEBL,NPAS3,CTNND2,CAMK2G,PRKG1,PARD3,RFX4,MACF1,SLC4A4,ATP1A2,PITPNC1,RYR3,LRP1B,PLCB1,TNIK,GPM6A,FMN2,GLIS3,DGKG,ERBB4,NAV2,SLC1A2,NTRK2,TNC |
2.187e-05 | -10.73 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 31 | 16828 | 48 |
NRG3,TRPM3,HPSE2,MACF1,SOX5,RORA,CLU,LSAMP,ADCY2,CDH20,NEBL,CAMK2G,NPAS3,CTNND2,GPC5,PARD3,PRKG1,GLIS3,ERBB4,NAV2,SLC1A2,TNC,APOE,NTRK2,NKAIN3,RYR3,FMN2,SORBS1,GPM6A,PLCB1,LRP1B |
2.291e-05 | -10.68 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 13 | 16828 | 48 |
NRG3,NKAIN3,SOX5,LSAMP,RORA,HPSE2,ADCY2,TNIK,PARD3,PRKG1,LRP1B,GPC5,CTNND2 |
2.334e-05 | -10.67 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 9 | 16828 | 48 |
NTRK2,PLCB1,SLC4A4,PRKG1,LRP1B,RYR3,CTNND2,ERBB4,ADCY2 |
2.401e-05 | -10.64 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 9 | 16828 | 48 |
ERBB4,ADCY2,LRP1B,PRKG1,SLC4A4,NTRK2,PLCB1,CTNND2,RYR3 |
2.463e-05 | -10.61 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 5 | 19454 | 50 |
NTRK2,PARD3,ERBB4,DTNA,ABLIM1 |
2.501e-05 | -10.60 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 17 | 16828 | 48 |
MSI2,TRPM3,MACF1,RORA,ABLIM1,LSAMP,NRG3,ERBB4,NAV2,GPC5,PARD3,GFAP,GPM6A,FMN2,PLCB1,LRP1B,NEBL |
2.613e-05 | -10.55 | glial cell development | biological process | GO:0021782 | 128 | 5 | 18204 | 50 |
PARD3,CNTN1,NTRK2,GFAP,CLU |
2.674e-05 | -10.53 | neuron projection | cellular component | GO:0043005 | 1331 | 13 | 19108 | 50 |
ATP1A2,CNTN1,DTNA,CLU,CAMK2G,CTNND2,GPM6A,APOE,CTNNA2,ADCY2,PARD3,NTRK2,SLC1A2 |
3.271e-05 | -10.33 | synapse organization | biological process | GO:0050808 | 333 | 7 | 18204 | 50 |
NRXN1,NRG3,APOE,ERBB4,TNC,GPM6A,CTNND2 |
3.589e-05 | -10.24 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 5 | 7161 | 29 |
PLCB1,ADCY2,PRKG1,CAMK2G,RYR3 |
3.589e-05 | -10.24 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 5 | 7161 | 29 |
ADCY2,PLCB1,RYR3,CAMK2G,PRKG1 |
3.952e-05 | -10.14 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 17 | 19108 | 50 |
ADCY2,CTNNA2,PARD3,SLC1A2,NTRK2,CTNND2,MACF1,CAMK2G,GPM6A,ABLIM1,APOE,DTNA,CNTN1,GFAP,CLU,FMN2,ATP1A2 |
4.604e-05 | -9.99 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 5 | 16828 | 48 |
PARD3,LRP1B,PRKG1,GPC5,NRG3 |
4.700e-05 | -9.97 | bone | COSMIC cancer mutations | bone | 8157 | 37 | 16828 | 48 |
NEBL,ADCY2,PRKG1,PARD3,GPC5,CTNND2,NPAS3,DTNA,CAMK2G,DCLK2,CST3,NRG3,LSAMP,RORA,ABLIM1,SLC4A4,SOX5,MACF1,HPSE2,TRPM3,ATP1A2,LRP1B,TNIK,PLCB1,FMN2,GPM6A,SORBS1,RYR3,ERBB4,NAV2,DGKG,GLIS3,CNTN1,NTRK2,TNC,NKAIN3,NRXN1 |
4.755e-05 | -9.95 | face | COSMIC cancer mutations | face | 2139 | 17 | 16828 | 48 |
FMN2,GPM6A,PLCB1,GFAP,PARD3,LRP1B,GPC5,NEBL,LSAMP,RORA,ABLIM1,MSI2,MACF1,TRPM3,NAV2,ERBB4,NRG3 |
4.839e-05 | -9.94 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 12 | 16828 | 48 |
CTNND2,LRP1B,PRKG1,NTM,PLCB1,SORBS1,ADCY2,MGAT4C,MACF1,SLC4A4,TNC,ERBB4 |
4.882e-05 | -9.93 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 8 | 18204 | 50 |
PRKG1,CTNNA2,GPM6A,CTNND2,PARD3,CNTN1,TNIK,NRXN1 |
5.002e-05 | -9.90 | LRRC7 (leucine rich repeat containing 7) | protein interactions | 57554 | 28 | 3 | 19454 | 50 |
CAMK2G,CTNND2,ERBB4 |
5.199e-05 | -9.86 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 20 | 16828 | 48 |
ERBB4,DCLK2,HPSE2,MACF1,TRPM3,NTRK2,APOE,TNC,SOX5,ADCY2,CDH20,NEBL,RYR3,CTNND2,GPC5,NPAS3,GPM6A,PARD3,PRKG1,LRP1B |
5.246e-05 | -9.86 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 8 | 18204 | 50 |
NRXN1,TNIK,CNTN1,PARD3,GPM6A,CTNND2,PRKG1,CTNNA2 |
5.463e-05 | -9.81 | cellular component assembly | biological process | GO:0022607 | 2472 | 18 | 18204 | 50 |
APOE,RFX4,SLC1A2,TNIK,TRPM3,ERBB4,NEBL,CNTN1,SORBS1,CLU,ABLIM1,NRG3,NRXN1,CDH20,GPM6A,RYR3,FMN2,PARD3 |
5.634e-05 | -9.78 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 8 | 18204 | 50 |
NRXN1,TNIK,CNTN1,PARD3,CTNND2,GPM6A,PRKG1,CTNNA2 |
5.838e-05 | -9.75 | signaling | biological process | GO:0023052 | 4968 | 27 | 18204 | 50 |
TNC,ERBB4,APOE,SLC1A2,DGKG,TNIK,RYR3,FMN2,CLU,NRXN1,ADCY2,CNTN1,PLCB1,DTNA,NTRK2,PITPNC1,PRKG1,MACF1,CTNND2,PARD3,DCLK2,CAMK2G,RORA,ATP1A2,SORBS1,NRG3,MAPK10 |
6.759e-05 | -9.60 | cellular component organization | biological process | GO:0016043 | 5636 | 29 | 18204 | 50 |
FMN2,CDH20,RYR3,NRXN1,GFAP,CLU,TNC,ERBB4,SLC1A2,TNIK,RFX4,APOE,PARD3,HPSE2,DCLK2,CTNNA2,PRKG1,MACF1,GPM6A,CTNND2,NRG3,ABLIM1,NAV2,SORBS1,CST3,CNTN1,NEBL,TRPM3,PITPNC1 |
6.775e-05 | -9.60 | negative regulation of amyloid-beta formation | biological process | GO:1902430 | 29 | 3 | 18204 | 50 |
APOE,CLU,NTRK2 |
6.848e-05 | -9.59 | cell communication | biological process | GO:0007154 | 5010 | 27 | 18204 | 50 |
PITPNC1,NTRK2,DTNA,PLCB1,CNTN1,ADCY2,MAPK10,NRG3,SORBS1,ATP1A2,RORA,CAMK2G,DCLK2,PARD3,CTNND2,MACF1,PRKG1,TNIK,DGKG,SLC1A2,APOE,ERBB4,TNC,NRXN1,CLU,FMN2,RYR3 |
7.047e-05 | -9.56 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 6 | 16828 | 48 |
ADCY2,GPC5,HPSE2,NRG3,NPAS3,ERBB4 |
7.047e-05 | -9.56 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 6 | 16828 | 48 |
ERBB4,ADCY2,HPSE2,GPC5,NRG3,NPAS3 |
7.224e-05 | -9.54 | Nuclear signaling by ERBB4 | REACTOME pathways | R-HSA-1251985 | 25 | 3 | 10285 | 34 |
GFAP,NRG3,ERBB4 |
7.355e-05 | -9.52 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 2 | 18204 | 50 |
CLU,APOE |
7.355e-05 | -9.52 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 50 |
GFAP,SLC1A2 |
7.355e-05 | -9.52 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 50 |
GFAP,SLC1A2 |
7.385e-05 | -9.51 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 9 | 19454 | 50 |
DTNA,ABLIM1,ERBB4,TNIK,MACF1,FMN2,MSI2,PARD3,PLCB1 |
7.526e-05 | -9.49 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 19 | 16828 | 48 |
RFX4,NRG3,SLC14A1,DGKG,MACF1,CLU,SLC4A4,SLC1A2,NTRK2,ATP1A2,PITPNC1,NPAS3,GPC5,CTNND2,DTNA,RYR3,LRP1B,SORBS1,FMN2 |
7.616e-05 | -9.48 | presynaptic membrane | cellular component | GO:0042734 | 168 | 5 | 19108 | 50 |
GPM6A,ERBB4,SLC1A2,NRXN1,CNTN1 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
NTM,LSAMP,GPM6A |
8.302e-05 | -9.40 | negative regulation of amyloid precursor protein catabolic process | biological process | GO:1902992 | 31 | 3 | 18204 | 50 |
CLU,APOE,NTRK2 |
8.559e-05 | -9.37 | plasma membrane region | cellular component | GO:0098590 | 1278 | 12 | 19108 | 50 |
CNTN1,PARD3,TNIK,SLC1A2,SLC4A4,MACF1,SLC14A1,NRXN1,SORBS1,ERBB4,GPM6A,ATP1A2 |
9.242e-05 | -9.29 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 7 | 19108 | 50 |
GPM6A,PLCB1,ERBB4,APOE,TNIK,SLC1A2,NRG3 |
9.955e-05 | -9.21 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 22 | 16828 | 48 |
TRPM3,HPSE2,MACF1,SOX5,SLC4A4,ABLIM1,NRG3,GPC5,CTNND2,PARD3,ADCY2,NEBL,TNC,NAV2,DGKG,RYR3,GFAP,FMN2,GPM6A,TNIK,LRP1B,ATP1A2 |
1.004e-04 | -9.21 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 22 | 16828 | 48 |
TNIK,GPM6A,FMN2,PARD3,GFAP,LRP1B,RYR3,GPC5,CTNND2,ATP1A2,NEBL,ADCY2,TNC,SLC4A4,SOX5,ABLIM1,MACF1,HPSE2,TRPM3,DGKG,NAV2,NRG3 |
1.099e-04 | -9.12 | negative regulation of amide metabolic process | biological process | GO:0034249 | 34 | 3 | 18204 | 50 |
NTRK2,APOE,CLU |
1.101e-04 | -9.11 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 50 |
SLC1A2,GFAP |
1.101e-04 | -9.11 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 2 | 18204 | 50 |
ERBB4,NRG3 |
1.108e-04 | -9.11 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 12 | 18204 | 50 |
MACF1,CTNNA2,PRKG1,DCLK2,PARD3,FMN2,SORBS1,GFAP,ABLIM1,NEBL,APOE,TNIK |
1.122e-04 | -9.10 | PLCB3 (phospholipase C beta 3) | protein interactions | 5331 | 97 | 4 | 19454 | 50 |
PLCB1,PARD3,PRKG1,CAMK2G |
1.179e-04 | -9.05 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 8 | 18094 | 49 |
TNC,CDH20,NRXN1,CTNNA2,MACF1,CTNND2,CNTN1,GFAP |
1.251e-04 | -8.99 | proteoglycan binding | molecular function | GO:0043394 | 36 | 3 | 18094 | 49 |
TNC,APOE,HPSE2 |
1.293e-04 | -8.95 | adherens junction | cellular component | GO:0005912 | 188 | 5 | 19108 | 50 |
SORBS1,CDH20,CTNNA2,PARD3,CTNND2 |
1.420e-04 | -8.86 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 13 | 16828 | 48 |
NRXN1,TRPM3,SLC4A4,LSAMP,CNTN1,RYR3,CTNND2,GPC5,FMN2,SORBS1,TNIK,PARD3,LRP1B |
1.425e-04 | -8.86 | cellular component organization or biogenesis | biological process | GO:0071840 | 5850 | 29 | 18204 | 50 |
TNC,ERBB4,RFX4,APOE,SLC1A2,TNIK,CDH20,RYR3,FMN2,GFAP,CLU,NRXN1,TRPM3,NEBL,CNTN1,PITPNC1,PRKG1,CTNNA2,CTNND2,GPM6A,MACF1,HPSE2,PARD3,DCLK2,SORBS1,NAV2,CST3,ABLIM1,NRG3 |
1.476e-04 | -8.82 | DZIP1 (DAZ interacting zinc finger protein 1) | protein interactions | 22873 | 40 | 3 | 19454 | 50 |
PARD3,NTRK2,CAMK2G |
1.520e-04 | -8.79 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 31 | 16828 | 48 |
LRP1B,FMN2,PLCB1,TNIK,RYR3,PITPNC1,ATP1A2,CNTN1,NTRK2,NRXN1,NAV2,ERBB4,DGKG,PRKG1,NTM,PARD3,CTNND2,GPC5,CAMK2G,ADCY2,CLU,ABLIM1,RORA,SLC4A4,SOX5,HPSE2,MACF1,TRPM3,DCLK2,NRG3,RFX4 |
1.520e-04 | -8.79 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 31 | 16828 | 48 |
RFX4,NRG3,DCLK2,HPSE2,MACF1,TRPM3,SLC4A4,SOX5,CLU,ABLIM1,RORA,ADCY2,CAMK2G,CTNND2,GPC5,PARD3,NTM,PRKG1,DGKG,ERBB4,NAV2,NRXN1,NTRK2,CNTN1,PITPNC1,ATP1A2,RYR3,FMN2,PLCB1,TNIK,LRP1B |
1.531e-04 | -8.78 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 7 | 19454 | 50 |
ERBB4,CTNND2,CAMK2G,DTNA,FMN2,MACF1,PARD3 |
1.558e-04 | -8.77 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 30 | 16828 | 48 |
GPM6A,PLCB1,SORBS1,FMN2,LRP1B,ATP1A2,MGAT4C,NRXN1,TNC,NTRK2,GLIS3,ERBB4,NAV2,DGKG,DTNA,CAMK2G,GPC5,PARD3,PRKG1,ADCY2,CDH20,NEBL,HPSE2,MACF1,TRPM3,SLC4A4,CLU,ABLIM1,NRG3,RFX4 |
1.569e-04 | -8.76 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 30 | 16828 | 48 |
MGAT4C,ATP1A2,LRP1B,FMN2,PLCB1,GPM6A,SORBS1,ERBB4,DGKG,NAV2,GLIS3,TNC,NTRK2,NRXN1,NEBL,CDH20,ADCY2,PRKG1,PARD3,GPC5,CAMK2G,DTNA,RFX4,NRG3,ABLIM1,CLU,SLC4A4,TRPM3,MACF1,HPSE2 |
1.627e-04 | -8.72 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 5 | 19454 | 50 |
DTNA,CAMK2G,ATP1A2,RYR3,PARD3 |
1.795e-04 | -8.63 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 2 | 19454 | 50 |
NTM,GFAP |
1.886e-04 | -8.58 | cellular component biogenesis | biological process | GO:0044085 | 2716 | 18 | 18204 | 50 |
NRXN1,NRG3,ABLIM1,SORBS1,CLU,PARD3,FMN2,RYR3,GPM6A,CDH20,TNIK,SLC1A2,RFX4,APOE,NEBL,CNTN1,TRPM3,ERBB4 |
1.964e-04 | -8.54 | SH2D1A (SH2 domain containing 1A) | protein interactions | 4068 | 44 | 3 | 19454 | 50 |
LRP1B,CAMK2G,ERBB4 |
1.993e-04 | -8.52 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 21 | 16828 | 48 |
TNC,TRPM3,MACF1,NRXN1,NAV2,DGKG,ERBB4,NRG3,RFX4,GLIS3,LRP1B,PARD3,FMN2,PLCB1,GPC5,CTNND2,NEBL,MGAT4C,ATP1A2,PITPNC1,ADCY2 |
1.996e-04 | -8.52 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 49 |
CDH20,CTNND2,RORA,CTNNA2 |
2.037e-04 | -8.50 | cell adhesion | biological process | GO:0007155 | 942 | 10 | 18204 | 50 |
SORBS1,NRXN1,NTM,LSAMP,CDH20,CTNNA2,CTNND2,PARD3,TNC,CNTN1 |
2.048e-04 | -8.49 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 2 | 18204 | 50 |
NRG3,ERBB4 |
2.048e-04 | -8.49 | protein import | biological process | GO:0017038 | 8 | 2 | 18204 | 50 |
APOE,CLU |
2.162e-04 | -8.44 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 4 | 7161 | 29 |
CAMK2G,PLCB1,ATP1A2,ADCY2 |
2.162e-04 | -8.44 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 4 | 7161 | 29 |
PLCB1,ADCY2,ATP1A2,CAMK2G |
2.276e-04 | -8.39 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 31 | 16828 | 48 |
NRG3,DCLK2,TRPM3,MACF1,HPSE2,ABLIM1,SLC4A4,SOX5,ADCY2,NEBL,NPAS3,CTNND2,GPC5,PRKG1,PARD3,GLIS3,NAV2,ERBB4,NRXN1,CNTN1,TNC,ATP1A2,MGAT4C,PITPNC1,RYR3,LRP1B,PLCB1,GPM6A,FMN2,SORBS1,TNIK |
2.276e-04 | -8.39 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 9 | 16828 | 48 |
NEBL,DTNA,CTNND2,PLCB1,NTRK2,PARD3,SOX5,PRKG1,LRP1B |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.392e-04 | -8.34 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 3 | 19454 | 50 |
GPM6A,TNC,CNTN1 |
2.425e-04 | -8.32 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 45 | 16828 | 48 |
DCLK2,ABLIM1,SLC4A4,SOX5,TRPM3,CDH20,ADCY2,PARD3,CTNND2,NPAS3,DGKG,CNTN1,NTRK2,MSI2,MGAT4C,GPM6A,SORBS1,FMN2,GFAP,RYR3,NRG3,RFX4,LSAMP,CLU,RORA,MACF1,HPSE2,NEBL,PRKG1,NTM,GPC5,CAMK2G,DTNA,NAV2,ERBB4,GLIS3,NKAIN3,TNC,SLC1A2,NRXN1,PITPNC1,ATP1A2,LRP1B,TNIK,PLCB1 |
2.426e-04 | -8.32 | regulation of localization | biological process | GO:0032879 | 2028 | 15 | 18204 | 50 |
DCLK2,CAMK2G,RYR3,PRKG1,CLU,NKAIN3,SORBS1,ATP1A2,GFAP,CNTN1,GPC5,ERBB4,PLCB1,SLC1A2,APOE |
2.501e-04 | -8.29 | postsynapse | cellular component | GO:0098794 | 646 | 8 | 19108 | 50 |
CNTN1,NTRK2,TNIK,CTNND2,ERBB4,GPM6A,ATP1A2,PLCB1 |
2.544e-04 | -8.28 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 11 | 16828 | 48 |
NTRK2,RORA,ERBB4,NAV2,RYR3,CAMK2G,CTNND2,TNIK,PRKG1,LRP1B,MGAT4C |
2.564e-04 | -8.27 | OCLN (occludin) | protein interactions | 100506658 | 495 | 7 | 19454 | 50 |
DTNA,ABLIM1,MACF1,TNIK,FMN2,NTRK2,PARD3 |
2.586e-04 | -8.26 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 7 | 18204 | 50 |
ATP1A2,RORA,SLC1A2,PLCB1,ADCY2,RYR3,TNC |
2.597e-04 | -8.26 | behavior | biological process | GO:0007610 | 619 | 8 | 18204 | 50 |
CNTN1,SLC1A2,PLCB1,NRXN1,NTRK2,ATP1A2,APOE,NAV2 |
2.863e-04 | -8.16 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 7 | 18521 | 50 |
DCLK2,PRKG1,MAPK10,NTRK2,TNIK,CAMK2G,ERBB4 |
2.876e-04 | -8.15 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 11 | 16828 | 48 |
ERBB4,MGAT4C,NAV2,CTNND2,RYR3,CAMK2G,PRKG1,RORA,LRP1B,NTRK2,TNIK |
2.879e-04 | -8.15 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 33 | 16828 | 48 |
NRG3,RFX4,MACF1,HPSE2,SOX5,SLC4A4,ABLIM1,RORA,LSAMP,CLU,ADCY2,CDH20,NEBL,GPC5,CTNND2,PARD3,PRKG1,GLIS3,DGKG,ERBB4,NAV2,SLC1A2,APOE,NKAIN3,NTRK2,TNC,CNTN1,ATP1A2,RYR3,FMN2,PLCB1,GPM6A,LRP1B |
3.047e-04 | -8.10 | bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | bronchioloalveolar_adenocarcinoma | 778 | 9 | 16828 | 48 |
PRKG1,SOX5,NTRK2,TNIK,CTNND2,CAMK2G,DCLK2,ERBB4,ADCY2 |
3.047e-04 | -8.10 | lung-carcinoma-bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-bronchioloalveolar_adenocarcinoma | 778 | 9 | 16828 | 48 |
PRKG1,NTRK2,TNIK,SOX5,CTNND2,CAMK2G,DCLK2,ERBB4,ADCY2 |
3.069e-04 | -8.09 | synapse assembly | biological process | GO:0007416 | 118 | 4 | 18204 | 50 |
ERBB4,NRXN1,NRG3,GPM6A |
3.091e-04 | -8.08 | regulation of amyloid-beta formation | biological process | GO:1902003 | 48 | 3 | 18204 | 50 |
NTRK2,APOE,CLU |
3.150e-04 | -8.06 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 15 | 16828 | 48 |
ATP1A2,NEBL,MGAT4C,CTNND2,SORBS1,FMN2,PLCB1,PARD3,LRP1B,NRG3,NAV2,ERBB4,TNC,ABLIM1,RORA |
3.150e-04 | -8.06 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 15 | 16828 | 48 |
ABLIM1,RORA,TNC,NAV2,ERBB4,NRG3,LRP1B,PARD3,FMN2,SORBS1,PLCB1,CTNND2,MGAT4C,ATP1A2,NEBL |
3.162e-04 | -8.06 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 4 | 19454 | 50 |
ABLIM1,DTNA,PARD3,MACF1 |
3.193e-04 | -8.05 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 24 | 16828 | 48 |
NRG3,RFX4,CLU,ABLIM1,SOX5,MACF1,TRPM3,ADCY2,PRKG1,PARD3,CTNND2,DTNA,NAV2,DGKG,ERBB4,GLIS3,CNTN1,TNC,ATP1A2,MGAT4C,LRP1B,GPM6A,FMN2,RYR3 |
3.193e-04 | -8.05 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 24 | 16828 | 48 |
GLIS3,NAV2,DGKG,ERBB4,TNC,CNTN1,MGAT4C,ATP1A2,RYR3,FMN2,GPM6A,LRP1B,RFX4,NRG3,TRPM3,MACF1,SOX5,ABLIM1,CLU,ADCY2,DTNA,CTNND2,PARD3,PRKG1 |
3.231e-04 | -8.04 | SH2B2 (SH2B adaptor protein 2) | protein interactions | 10603 | 52 | 3 | 19454 | 50 |
SORBS1,NTRK2,ERBB4 |
3.281e-04 | -8.02 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 2 | 18204 | 50 |
NTRK2,ATP1A2 |
3.281e-04 | -8.02 | action potential propagation | biological process | GO:0098870 | 10 | 2 | 18204 | 50 |
NTRK2,ATP1A2 |
3.283e-04 | -8.02 | glial cell differentiation | biological process | GO:0010001 | 219 | 5 | 18204 | 50 |
PARD3,NTRK2,CNTN1,GFAP,CLU |
3.502e-04 | -7.96 | ErbB signaling pathway | KEGG pathways | hsa04012 | 85 | 4 | 7161 | 29 |
CAMK2G,MAPK10,NRG3,ERBB4 |
3.502e-04 | -7.96 | ErbB signaling pathway | KEGG pathways | ko04012 | 85 | 4 | 7161 | 29 |
MAPK10,CAMK2G,ERBB4,NRG3 |
3.502e-04 | -7.96 | Insulin secretion | KEGG pathways | hsa04911 | 85 | 4 | 7161 | 29 |
CAMK2G,PLCB1,ATP1A2,ADCY2 |
3.613e-04 | -7.93 | SYNM (synemin) | protein interactions | 23336 | 54 | 3 | 19454 | 50 |
ERBB4,DTNA,GFAP |
3.636e-04 | -7.92 | interstitial matrix | cellular component | GO:0005614 | 11 | 2 | 19108 | 50 |
NAV2,TNC |
3.661e-04 | -7.91 | SNCA (synuclein alpha) | protein interactions | 6622 | 696 | 8 | 19454 | 50 |
CAMK2G,MACF1,TNIK,GPM6A,APOE,CLU,PLCB1,NTRK2 |
3.702e-04 | -7.90 | EZR (ezrin) | protein interactions | 7430 | 526 | 7 | 19454 | 50 |
ABLIM1,DTNA,TNIK,NEBL,MACF1,MAPK10,SORBS1 |
3.713e-04 | -7.90 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | 217 | 5 | 16828 | 48 |
NAV2,MGAT4C,PLCB1,RFX4,DTNA |
3.722e-04 | -7.90 | Signaling by ERBB4 | REACTOME pathways | R-HSA-1236394 | 43 | 3 | 10285 | 34 |
NRG3,ERBB4,GFAP |
3.778e-04 | -7.88 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 7 | 18204 | 50 |
ATP1A2,APOE,GFAP,NRXN1,NTRK2,NRG3,PLCB1 |
3.824e-04 | -7.87 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 7 | 18204 | 50 |
GFAP,APOE,ATP1A2,NRXN1,NTRK2,PLCB1,NRG3 |
3.863e-04 | -7.86 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 8 | 16828 | 48 |
ERBB4,NEBL,CAMK2G,TNC,PLCB1,SORBS1,FMN2,NTM |
4.182e-04 | -7.78 | myelination | biological process | GO:0042552 | 128 | 4 | 18204 | 50 |
CLU,PARD3,NTRK2,CNTN1 |
4.203e-04 | -7.77 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 2 | 19454 | 50 |
CLU,APOE |
4.290e-04 | -7.75 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 7 | 16828 | 48 |
MACF1,CAMK2G,PRKG1,NTRK2,TNIK,DCLK2,ERBB4 |
4.382e-04 | -7.73 | NK-T_cell_lymphoma | COSMIC cancer mutations | NK-T_cell_lymphoma | 225 | 5 | 16828 | 48 |
DTNA,RFX4,NAV2,MGAT4C,PLCB1 |
4.404e-04 | -7.73 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 50 |
CNTN1,NTM,NTRK2,LSAMP |
4.434e-04 | -7.72 | ensheathment of neurons | biological process | GO:0007272 | 130 | 4 | 18204 | 50 |
CLU,PARD3,CNTN1,NTRK2 |
4.434e-04 | -7.72 | axon ensheathment | biological process | GO:0008366 | 130 | 4 | 18204 | 50 |
CNTN1,NTRK2,PARD3,CLU |
4.561e-04 | -7.69 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 7 | 16828 | 48 |
ERBB4,DCLK2,CAMK2G,MACF1,TNIK,NTRK2,PRKG1 |
4.626e-04 | -7.68 | regulation of amyloid precursor protein catabolic process | biological process | GO:1902991 | 55 | 3 | 18204 | 50 |
NTRK2,CLU,APOE |
4.667e-04 | -7.67 | phosphotransferase activity, alcohol group as acceptor | molecular function | GO:0016773 | 686 | 8 | 18094 | 49 |
MAPK10,NTRK2,DGKG,DCLK2,ERBB4,TNIK,CAMK2G,PRKG1 |
4.695e-04 | -7.66 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 2 | 10285 | 34 |
ERBB4,NRG3 |
4.733e-04 | -7.66 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 49 |
NTRK2,CNTN1,LSAMP,NTM |
4.739e-04 | -7.65 | GnRH signaling pathway | KEGG pathways | ko04912 | 92 | 4 | 7161 | 29 |
MAPK10,CAMK2G,ADCY2,PLCB1 |
4.739e-04 | -7.65 | GnRH signaling pathway | KEGG pathways | hsa04912 | 92 | 4 | 7161 | 29 |
CAMK2G,MAPK10,PLCB1,ADCY2 |
4.797e-04 | -7.64 | Kinase-like_dom_sf | interpro domains | IPR011009 | 523 | 7 | 18521 | 50 |
NTRK2,MAPK10,PRKG1,DCLK2,CAMK2G,ERBB4,TNIK |
4.907e-04 | -7.62 | central_nervous_system-brain-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_III | 1419 | 12 | 16828 | 48 |
ADCY2,GPC5,RYR3,PRKG1,LRP1B,PLCB1,PARD3,NRG3,ERBB4,NAV2,HPSE2,TRPM3 |
5.100e-04 | -7.58 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 6 | 18521 | 50 |
TNIK,ERBB4,CAMK2G,DCLK2,PRKG1,NTRK2 |
5.164e-04 | -7.57 | sarcolemma | cellular component | GO:0042383 | 142 | 4 | 19108 | 50 |
ATP1A2,PRKG1,RYR3,DTNA |
5.336e-04 | -7.54 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 14 | 16828 | 48 |
NEBL,PITPNC1,ADCY2,CDH20,PARD3,FMN2,PLCB1,LRP1B,RYR3,ERBB4,DGKG,TNC,NTRK2,HPSE2 |
5.354e-04 | -7.53 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 4 | 7161 | 29 |
PLCB1,SLC4A4,ATP1A2,ADCY2 |
5.354e-04 | -7.53 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 4 | 7161 | 29 |
ATP1A2,ADCY2,SLC4A4,PLCB1 |
5.365e-04 | -7.53 | extremity | COSMIC cancer mutations | extremity | 1876 | 14 | 16828 | 48 |
DGKG,ERBB4,NTRK2,TNC,HPSE2,PITPNC1,NEBL,CDH20,ADCY2,LRP1B,PLCB1,FMN2,PARD3,RYR3 |
5.583e-04 | -7.49 | regulation of synapse organization | biological process | GO:0050807 | 246 | 5 | 18204 | 50 |
GPM6A,CTNNA2,APOE,NTRK2,NRXN1 |
5.657e-04 | -7.48 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 2 | 18204 | 50 |
CLU,APOE |
5.739e-04 | -7.46 | cell body | cellular component | GO:0044297 | 556 | 7 | 19108 | 50 |
NRXN1,CTNND2,APOE,GPM6A,ATP1A2,SLC1A2,GFAP |
5.776e-04 | -7.46 | C9 (complement C9) | protein interactions | 735 | 14 | 2 | 19454 | 50 |
APOE,CLU |
5.776e-04 | -7.46 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 2 | 19454 | 50 |
GPM6A,CLU |
5.795e-04 | -7.45 | Inflammatory mediator regulation of TRP channels | KEGG pathways | hsa04750 | 97 | 4 | 7161 | 29 |
PLCB1,ADCY2,CAMK2G,MAPK10 |
5.795e-04 | -7.45 | Inflammatory mediator regulation of TRP channels | KEGG pathways | ko04750 | 97 | 4 | 7161 | 29 |
PLCB1,ADCY2,CAMK2G,MAPK10 |
6.009e-04 | -7.42 | regulation of cellular component organization | biological process | GO:0051128 | 2455 | 16 | 18204 | 50 |
NTRK2,DGKG,TNIK,PLCB1,APOE,CNTN1,TNC,NRXN1,NRG3,CLU,CST3,GFAP,CAMK2G,GPM6A,MACF1,CTNNA2 |
6.086e-04 | -7.40 | TNIK (TRAF2 and NCK interacting kinase) | protein interactions | 23043 | 151 | 4 | 19454 | 50 |
MACF1,TNIK,PRKG1,CLU |
6.128e-04 | -7.40 | pancreas-carcinoma-adenocarcinoma | COSMIC cancer mutations | pancreas-carcinoma-adenocarcinoma | 517 | 7 | 16828 | 48 |
LRP1B,DCLK2,TNC,NEBL,MACF1,GPC5,HPSE2 |
6.132e-04 | -7.40 | intracellular signal transduction | biological process | GO:0035556 | 1505 | 12 | 18204 | 50 |
ADCY2,APOE,DGKG,TNIK,PLCB1,RYR3,PRKG1,DCLK2,FMN2,ATP1A2,MAPK10,NRG3 |
6.227e-04 | -7.38 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 5 | 18204 | 50 |
NRXN1,NTRK2,APOE,CTNNA2,GPM6A |
6.388e-04 | -7.36 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 8 | 19454 | 50 |
PARD3,SORBS1,CTNNA2,CTNND2,ABLIM1,NAV2,NEBL,MACF1 |
6.409e-04 | -7.35 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 5 | 18521 | 50 |
DTNA,PLCB1,MACF1,RYR3,DGKG |
6.580e-04 | -7.33 | presynapse | cellular component | GO:0098793 | 569 | 7 | 19108 | 50 |
GPM6A,NTRK2,ERBB4,SLC1A2,TNIK,CNTN1,NRXN1 |
6.588e-04 | -7.33 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 50 |
ATP1A2,SLC4A4 |
6.623e-04 | -7.32 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 17 | 16828 | 48 |
CDH20,NEBL,MGAT4C,ATP1A2,CTNND2,RYR3,LRP1B,PLCB1,PARD3,SLC14A1,NRG3,ERBB4,HPSE2,NRXN1,LSAMP,TNC,SOX5 |
6.654e-04 | -7.32 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 2 | 19454 | 50 |
PARD3,TNIK |
7.079e-04 | -7.25 | Calcium signaling pathway | KEGG pathways | ko04020 | 181 | 5 | 7161 | 29 |
CAMK2G,RYR3,PLCB1,ERBB4,ADCY2 |
7.079e-04 | -7.25 | Calcium signaling pathway | KEGG pathways | hsa04020 | 181 | 5 | 7161 | 29 |
PLCB1,ERBB4,ADCY2,CAMK2G,RYR3 |
7.271e-04 | -7.23 | Transferase(Phosphotransferase) domain 1 | gene3d domains | 1.10.510.10 | 490 | 7 | 14470 | 45 |
ERBB4,DCLK2,TNIK,CAMK2G,PRKG1,NTRK2,MAPK10 |
7.565e-04 | -7.19 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 41 | 16828 | 48 |
SOX5,SLC4A4,CLU,LSAMP,RORA,HPSE2,MACF1,TRPM3,CST3,DCLK2,NRG3,PARD3,NTM,PRKG1,CAMK2G,DTNA,CTNND2,GPC5,NPAS3,NEBL,ADCY2,CDH20,TNC,NTRK2,SLC1A2,CNTN1,NRXN1,MSI2,NAV2,DGKG,ERBB4,GLIS3,TNIK,SORBS1,FMN2,PLCB1,GFAP,LRP1B,RYR3,ATP1A2,MGAT4C |
7.616e-04 | -7.18 | kinase activity | molecular function | GO:0016301 | 739 | 8 | 18094 | 49 |
PRKG1,TNIK,CAMK2G,DCLK2,ERBB4,MAPK10,NTRK2,DGKG |
7.697e-04 | -7.17 | phosphorylation | biological process | GO:0016310 | 729 | 8 | 18204 | 50 |
PRKG1,DCLK2,ERBB4,CAMK2G,DGKG,TNIK,NTRK2,MAPK10 |
8.047e-04 | -7.13 | cell migration | biological process | GO:0016477 | 921 | 9 | 18204 | 50 |
FMN2,ERBB4,GPC5,CDH20,CTNNA2,PRKG1,GPM6A,NRG3,NTRK2 |
8.087e-04 | -7.12 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 2 | 10285 | 34 |
ERBB4,NRG3 |
8.118e-04 | -7.12 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 3 | 10285 | 34 |
RYR3,CAMK2G,ATP1A2 |
8.309e-04 | -7.09 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 5 | 19454 | 50 |
PARD3,PLCB1,SORBS1,NTRK2,DTNA |
8.364e-04 | -7.09 | kidney-Wilms_tumour | COSMIC cancer mutations | kidney-Wilms_tumour | 545 | 7 | 16828 | 48 |
NTRK2,FMN2,TNIK,PRKG1,CAMK2G,ERBB4,DCLK2 |
8.382e-04 | -7.08 | learning | biological process | GO:0007612 | 154 | 4 | 18204 | 50 |
ATP1A2,PLCB1,NTRK2,NRXN1 |
8.382e-04 | -7.08 | hindbrain development | biological process | GO:0030902 | 154 | 4 | 18204 | 50 |
CNTN1,RORA,CTNNA2,PRKG1 |
8.440e-04 | -7.08 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 5 | 19454 | 50 |
PARD3,FMN2,NEBL,SORBS1,PRKG1 |
8.454e-04 | -7.08 | Wilms_tumour | COSMIC cancer mutations | Wilms_tumour | 546 | 7 | 16828 | 48 |
CAMK2G,TNIK,FMN2,NTRK2,PRKG1,ERBB4,DCLK2 |
8.538e-04 | -7.07 | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | 3507 | 20 | 16828 | 48 |
ADCY2,ATP1A2,CTNND2,GPC5,NPAS3,RYR3,PRKG1,LRP1B,FMN2,PLCB1,PARD3,DCLK2,ERBB4,NAV2,DGKG,MACF1,HPSE2,TRPM3,CNTN1,SLC4A4 |
8.657e-04 | -7.05 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 2 | 18204 | 50 |
ATP1A2,APOE |
8.657e-04 | -7.05 | asymmetric cell division | biological process | GO:0008356 | 16 | 2 | 18204 | 50 |
SOX5,PARD3 |
8.683e-04 | -7.05 | protein kinase activity | molecular function | GO:0004672 | 577 | 7 | 18094 | 49 |
CAMK2G,NTRK2,TNIK,MAPK10,ERBB4,DCLK2,PRKG1 |
8.927e-04 | -7.02 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 5 | 18204 | 50 |
SLC1A2,SLC4A4,PRKG1,APOE,ATP1A2 |
9.082e-04 | -7.00 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 18 | 16828 | 48 |
MSI2,TRPM3,MACF1,SLC4A4,NTRK2,CNTN1,NRG3,ERBB4,NAV2,NPAS3,NTM,PARD3,FMN2,LRP1B,PRKG1,ADCY2,ATP1A2,NEBL |
9.082e-04 | -7.00 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 18 | 16828 | 48 |
NRG3,ERBB4,NAV2,MSI2,TRPM3,MACF1,SLC4A4,NTRK2,CNTN1,ADCY2,ATP1A2,NEBL,NPAS3,PARD3,NTM,FMN2,LRP1B,PRKG1 |
9.223e-04 | -6.99 | gliogenesis | biological process | GO:0042063 | 275 | 5 | 18204 | 50 |
CLU,GFAP,NTRK2,CNTN1,PARD3 |
9.341e-04 | -6.98 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 5 | 16828 | 48 |
APOE,SOX5,LRP1B,RYR3,CDH20 |
9.374e-04 | -6.97 | learning or memory | biological process | GO:0007611 | 276 | 5 | 18204 | 50 |
NTRK2,NRXN1,PLCB1,APOE,ATP1A2 |
9.416e-04 | -6.97 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 2 | 10285 | 34 |
NRG3,ERBB4 |
9.687e-04 | -6.94 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 32 | 16828 | 48 |
MACF1,HPSE2,SOX5,LSAMP,CLU,ABLIM1,RORA,NRG3,RFX4,GPC5,CTNND2,PARD3,PRKG1,ADCY2,CDH20,NEBL,TNC,NTRK2,NKAIN3,SLC1A2,CNTN1,GLIS3,NAV2,DGKG,ERBB4,RYR3,PLCB1,FMN2,GPM6A,TNIK,LRP1B,MGAT4C |
9.794e-04 | -6.93 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 2 | 18204 | 50 |
CLU,APOE |
9.794e-04 | -6.93 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 2 | 18204 | 50 |
APOE,CLU |
9.802e-04 | -6.93 | axon development | biological process | GO:0061564 | 420 | 6 | 18204 | 50 |
TNC,PARD3,CNTN1,PRKG1,CTNNA2,NRXN1 |
1.043e-03 | -6.87 | astrocytoma_Grade_III | COSMIC cancer mutations | astrocytoma_Grade_III | 1544 | 12 | 16828 | 48 |
GPC5,RYR3,PRKG1,LRP1B,PLCB1,PARD3,ADCY2,HPSE2,TRPM3,NRG3,ERBB4,NAV2 |
1.048e-03 | -6.86 | skin-head_neck-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-head_neck-malignant_melanoma-superficial_spreading | 923 | 9 | 16828 | 48 |
PLCB1,SORBS1,TNC,LRP1B,CTNND2,MACF1,MGAT4C,ERBB4,ADCY2 |
1.049e-03 | -6.86 | animal organ development | biological process | GO:0048513 | 2846 | 17 | 18204 | 50 |
RFX4,SLC1A2,PLCB1,NTRK2,TNC,ERBB4,NEBL,CNTN1,RORA,ATP1A2,ABLIM1,NRG3,PRKG1,CTNNA2,GPM6A,SOX5,DCLK2 |
1.069e-03 | -6.84 | heparan sulfate proteoglycan binding | molecular function | GO:0043395 | 18 | 2 | 18094 | 49 |
APOE,HPSE2 |
1.075e-03 | -6.84 | actin binding | molecular function | GO:0003779 | 434 | 6 | 18094 | 49 |
SORBS1,FMN2,ABLIM1,CTNNA2,NEBL,MACF1 |
1.084e-03 | -6.83 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 2 | 10285 | 34 |
NRG3,ERBB4 |
1.088e-03 | -6.82 | dendrite | cellular component | GO:0030425 | 620 | 7 | 19108 | 50 |
ADCY2,NTRK2,CLU,CTNND2,GPM6A,ATP1A2,APOE |
1.100e-03 | -6.81 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 2 | 18204 | 50 |
PRKG1,RORA |
1.100e-03 | -6.81 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 2 | 18204 | 50 |
PRKG1,APOE |
1.108e-03 | -6.80 | dendritic tree | cellular component | GO:0097447 | 622 | 7 | 19108 | 50 |
ATP1A2,GPM6A,APOE,CTNND2,CLU,NTRK2,ADCY2 |
1.114e-03 | -6.80 | acral_lentiginous | COSMIC cancer mutations | acral_lentiginous | 745 | 8 | 16828 | 48 |
MACF1,PARD3,TNC,PLCB1,LRP1B,CDH20,NRG3,ERBB4 |
1.115e-03 | -6.80 | astrocyte projection | cellular component | GO:0097449 | 19 | 2 | 19108 | 50 |
SLC1A2,GFAP |
1.155e-03 | -6.76 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 5 | 19454 | 50 |
DTNA,PARD3,SORBS1,NRXN1,MACF1 |
1.181e-03 | -6.74 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 6 | 18094 | 49 |
SLC1A2,GPM6A,RYR3,ATP1A2,SLC4A4,TRPM3 |
1.194e-03 | -6.73 | cytoskeletal protein binding | molecular function | GO:0008092 | 989 | 9 | 18094 | 49 |
MACF1,NEBL,CTNNA2,DCLK2,ABLIM1,SORBS1,CLU,FMN2,APOE |
1.227e-03 | -6.70 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 2 | 18204 | 50 |
APOE,PRKG1 |
1.227e-03 | -6.70 | regulation of amyloid-beta clearance | biological process | GO:1900221 | 19 | 2 | 18204 | 50 |
CLU,APOE |
1.227e-03 | -6.70 | regulation of neurotransmitter uptake | biological process | GO:0051580 | 19 | 2 | 18204 | 50 |
GFAP,ATP1A2 |
1.237e-03 | -6.70 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 2 | 10285 | 34 |
NRG3,ERBB4 |
1.237e-03 | -6.70 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 2 | 10285 | 34 |
ERBB4,NRG3 |
1.243e-03 | -6.69 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 2 | 5310 | 22 |
RYR3,PLCB1 |
1.245e-03 | -6.69 | MAPK9 (mitogen-activated protein kinase 9) | protein interactions | 5601 | 183 | 4 | 19454 | 50 |
CLU,MAPK10,MACF1,GFAP |
1.255e-03 | -6.68 | env (Envelope surface glycoprotein gp160, precursor) | protein interactions | 155971 | 1501 | 11 | 19454 | 50 |
APOE,CST3,MAPK10,PLCB1,CTNNA2,MGAT4C,NTRK2,GFAP,SLC1A2,ADCY2,TNC |
1.283e-03 | -6.66 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 3 | 18204 | 50 |
NTRK2,SLC1A2,GFAP |
1.289e-03 | -6.65 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 6 | 18204 | 50 |
NRXN1,CNTN1,PARD3,CTNND2,PRKG1,CTNNA2 |
1.293e-03 | -6.65 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 9 | 16828 | 48 |
GPC5,MACF1,TRPM3,CNTN1,LRP1B,TNC,FMN2,SLC1A2,PARD3 |
1.293e-03 | -6.65 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 9 | 16828 | 48 |
PARD3,SLC1A2,TNC,FMN2,LRP1B,CNTN1,TRPM3,MACF1,GPC5 |
1.298e-03 | -6.65 | lobular_carcinoma | COSMIC cancer mutations | lobular_carcinoma | 763 | 8 | 16828 | 48 |
CAMK2G,TNIK,NTRK2,LRP1B,PRKG1,CDH20,ERBB4,DCLK2 |
1.298e-03 | -6.65 | breast-carcinoma-lobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-lobular_carcinoma | 763 | 8 | 16828 | 48 |
NTRK2,TNIK,PRKG1,LRP1B,CAMK2G,ERBB4,DCLK2,CDH20 |
1.316e-03 | -6.63 | signal transduction | biological process | GO:0007165 | 4637 | 23 | 18204 | 50 |
CLU,RYR3,FMN2,APOE,DGKG,TNIK,ERBB4,SORBS1,ATP1A2,RORA,NRG3,MAPK10,CTNND2,MACF1,PRKG1,DCLK2,PARD3,PITPNC1,NTRK2,DTNA,PLCB1,ADCY2,CNTN1 |
1.318e-03 | -6.63 | TENM1 (teneurin transmembrane protein 1) | protein interactions | 10178 | 21 | 2 | 19454 | 50 |
SORBS1,MACF1 |
1.318e-03 | -6.63 | SHC4 (SHC adaptor protein 4) | protein interactions | 399694 | 21 | 2 | 19454 | 50 |
NTRK2,ERBB4 |
1.324e-03 | -6.63 | PROTEIN_KINASE_DOM | prosite domains | PS50011 | 480 | 7 | 12186 | 43 |
TNIK,PRKG1,ERBB4,NTRK2,CAMK2G,DCLK2,MAPK10 |
1.326e-03 | -6.63 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 8 | 10285 | 34 |
RYR3,SLC4A4,CAMK2G,SLC1A2,ATP1A2,TRPM3,ADCY2,SLC14A1 |
1.330e-03 | -6.62 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 6 | 16828 | 48 |
DCLK2,ERBB4,CAMK2G,PRKG1,NTRK2,TNIK |
1.330e-03 | -6.62 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 6 | 16828 | 48 |
DCLK2,ERBB4,PRKG1,NTRK2,TNIK,CAMK2G |
1.361e-03 | -6.60 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 50 |
SLC1A2,GFAP |
1.380e-03 | -6.59 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 32 | 16828 | 48 |
DCLK2,CST3,NRG3,RORA,ABLIM1,SOX5,SLC4A4,TRPM3,MACF1,NEBL,ADCY2,PRKG1,PARD3,NPAS3,CTNND2,DTNA,CAMK2G,ERBB4,DGKG,NAV2,GLIS3,CNTN1,TNC,NKAIN3,NTRK2,NRXN1,ATP1A2,LRP1B,FMN2,SORBS1,TNIK,RYR3 |
1.394e-03 | -6.58 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 48 |
ATP1A2,GPC5,PRKG1,PLCB1,GFAP,MACF1,NRXN1,CNTN1,LSAMP,RORA,SLC4A4,SOX5 |
1.414e-03 | -6.56 | Ser/Thr_kinase_AS | interpro domains | IPR008271 | 308 | 5 | 18521 | 50 |
MAPK10,CAMK2G,DCLK2,PRKG1,TNIK |
1.427e-03 | -6.55 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 8 | 19108 | 50 |
CTNND2,NRXN1,GPM6A,ATP1A2,APOE,ADCY2,NTRK2,CLU |
1.429e-03 | -6.55 | axon | cellular component | GO:0030424 | 650 | 7 | 19108 | 50 |
NTRK2,SLC1A2,GPM6A,DTNA,CNTN1,PARD3,CTNNA2 |
1.431e-03 | -6.55 | regulation of amide metabolic process | biological process | GO:0034248 | 81 | 3 | 18204 | 50 |
CLU,APOE,NTRK2 |
1.473e-03 | -6.52 | leg | COSMIC cancer mutations | leg | 969 | 9 | 16828 | 48 |
NEBL,NRG3,LRP1B,PRKG1,CNTN1,SLC4A4,NTM,PLCB1,FMN2 |
1.481e-03 | -6.52 | stress fiber | cellular component | GO:0001725 | 86 | 3 | 19108 | 50 |
SORBS1,ABLIM1,NEBL |
1.481e-03 | -6.52 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 3 | 19108 | 50 |
ABLIM1,NEBL,SORBS1 |
1.495e-03 | -6.51 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 5 | 14470 | 45 |
DGKG,PLCB1,DTNA,MACF1,RYR3 |
1.545e-03 | -6.47 | synaptic signaling | biological process | GO:0099536 | 459 | 6 | 18204 | 50 |
APOE,SLC1A2,DTNA,PLCB1,NRXN1,NTRK2 |
1.546e-03 | -6.47 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-virilizing_syndrome_producing | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-virilizing_syndrome_producing | 298 | 5 | 16828 | 48 |
ATP1A2,FMN2,TNC,LRP1B,CTNND2 |
1.548e-03 | -6.47 | SFN (stratifin) | protein interactions | 2810 | 671 | 7 | 19454 | 50 |
SORBS1,PARD3,ABLIM1,NAV2,TNIK,MACF1,FMN2 |
1.571e-03 | -6.46 | ATP binding | molecular function | GO:0005524 | 1467 | 11 | 18094 | 49 |
ERBB4,DCLK2,NTRK2,DGKG,MAPK10,NAV2,ATP1A2,PRKG1,ADCY2,CAMK2G,TNIK |
1.578e-03 | -6.45 | YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta) | protein interactions | 7533 | 1083 | 9 | 19454 | 50 |
ABLIM1,CAMK2G,NAV2,MACF1,DCLK2,FMN2,PITPNC1,SORBS1,PARD3 |
1.582e-03 | -6.45 | TIMM10B (translocase of inner mitochondrial membrane 10B) | protein interactions | 26515 | 23 | 2 | 19454 | 50 |
HPSE2,MSI2 |
1.587e-03 | -6.45 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 4 | 18204 | 50 |
SLC4A4,SORBS1,PRKG1,RORA |
1.589e-03 | -6.44 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 3 | 18204 | 50 |
CNTN1,ATP1A2,NKAIN3 |
1.597e-03 | -6.44 | protein localization to membrane | biological process | GO:0072657 | 462 | 6 | 18204 | 50 |
TNIK,ERBB4,NRXN1,PARD3,MACF1,APOE |
1.603e-03 | -6.44 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 41 | 16828 | 48 |
ATP1A2,MGAT4C,RYR3,LRP1B,GFAP,SORBS1,PLCB1,TNIK,FMN2,GLIS3,ERBB4,DGKG,NAV2,MSI2,NRXN1,CNTN1,SLC1A2,TNC,NTRK2,CDH20,ADCY2,NEBL,NPAS3,GPC5,CTNND2,DTNA,CAMK2G,PRKG1,PARD3,NTM,NRG3,DCLK2,CST3,TRPM3,HPSE2,MACF1,RORA,LSAMP,CLU,SOX5,SLC4A4 |
1.621e-03 | -6.42 | phosphate-containing compound metabolic process | biological process | GO:0006796 | 1681 | 12 | 18204 | 50 |
ADCY2,ERBB4,PLCB1,TNIK,NTRK2,DGKG,PRKG1,DCLK2,CAMK2G,RORA,ATP1A2,MAPK10 |
1.644e-03 | -6.41 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 3 | 18204 | 50 |
CLU,CNTN1,NTRK2 |
1.649e-03 | -6.41 | negative regulation of muscle contraction | biological process | GO:0045932 | 22 | 2 | 18204 | 50 |
PRKG1,ATP1A2 |
1.655e-03 | -6.40 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 3 | 19454 | 50 |
GPM6A,NTM,CNTN1 |
1.663e-03 | -6.40 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 22 | 16828 | 48 |
CDH20,ADCY2,PRKG1,PARD3,NTM,CTNND2,RFX4,NRG3,SOX5,SLC4A4,MACF1,HPSE2,TRPM3,LRP1B,GPM6A,TNIK,FMN2,PLCB1,SORBS1,RYR3,CNTN1,NTRK2 |
1.664e-03 | -6.40 | cell-cell signaling | biological process | GO:0007267 | 822 | 8 | 18204 | 50 |
APOE,PLCB1,SLC1A2,DTNA,NTRK2,NRXN1,TNC,CAMK2G |
1.700e-03 | -6.38 | vascular transport | biological process | GO:0010232 | 86 | 3 | 18204 | 50 |
SLC4A4,SLC1A2,ATP1A2 |
1.700e-03 | -6.38 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 3 | 18204 | 50 |
SLC4A4,SLC1A2,ATP1A2 |
1.705e-03 | -6.37 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 12 | 18204 | 50 |
ERBB4,NTRK2,PLCB1,APOE,SOX5,PARD3,MACF1,NRXN1,CLU,GFAP,RORA,ATP1A2 |
1.779e-03 | -6.33 | cognition | biological process | GO:0050890 | 319 | 5 | 18204 | 50 |
NRXN1,NTRK2,PLCB1,APOE,ATP1A2 |
1.793e-03 | -6.32 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 6 | 16828 | 48 |
CAMK2G,ERBB4,TNIK,NTRK2,DCLK2,PRKG1 |
1.797e-03 | -6.32 | actomyosin | cellular component | GO:0042641 | 92 | 3 | 19108 | 50 |
SORBS1,ABLIM1,NEBL |
1.800e-03 | -6.32 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 3 | 18094 | 49 |
APOE,CST3,CLU |
1.803e-03 | -6.32 | relaxation of muscle | biological process | GO:0090075 | 23 | 2 | 18204 | 50 |
PRKG1,ATP1A2 |
1.813e-03 | -6.31 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 4 | 16828 | 48 |
LRP1B,RYR3,GPC5,NRG3 |
1.833e-03 | -6.30 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 6 | 16828 | 48 |
TNIK,NTRK2,PRKG1,CAMK2G,ERBB4,DCLK2 |
1.848e-03 | -6.29 | phosphorus metabolic process | biological process | GO:0006793 | 1707 | 12 | 18204 | 50 |
DGKG,TNIK,NTRK2,PLCB1,ADCY2,ERBB4,RORA,ATP1A2,MAPK10,PRKG1,DCLK2,CAMK2G |
1.870e-03 | -6.28 | TNC (tenascin C) | protein interactions | 3371 | 25 | 2 | 19454 | 50 |
CLU,CNTN1 |
1.909e-03 | -6.26 | low-density lipoprotein particle receptor binding | molecular function | GO:0050750 | 24 | 2 | 18094 | 49 |
APOE,CLU |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.913e-03 | -6.26 | human chr10q11.23-q21.1 | chromosome location | human chr10q11.23-q21.1 | 1 | 1 | 26134 | 50 |
PRKG1 |
1.913e-03 | -6.26 | human chr9q21.12-q21.13 | chromosome location | human chr9q21.12-q21.13 | 1 | 1 | 26134 | 50 |
TRPM3 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.913e-03 | -6.26 | human chr12q21.31-q21.32 | chromosome location | human chr12q21.31-q21.32 | 1 | 1 | 26134 | 50 |
MGAT4C |
1.913e-03 | -6.26 | human chr3q27.2-q27.3 | chromosome location | human chr3q27.2-q27.3 | 1 | 1 | 26134 | 50 |
DGKG |
1.913e-03 | -6.26 | human chr10p11.22-p11.21 | chromosome location | human chr10p11.22-p11.21 | 1 | 1 | 26134 | 50 |
PARD3 |
1.913e-03 | -6.26 | human chr4q31.23-q31.3 | chromosome location | human chr4q31.23-q31.3 | 1 | 1 | 26134 | 50 |
DCLK2 |
1.913e-03 | -6.26 | human chr2q22.1-q22.2 | chromosome location | human chr2q22.1-q22.2 | 1 | 1 | 26134 | 50 |
LRP1B |
1.950e-03 | -6.24 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 6 | 12186 | 43 |
TNIK,PRKG1,ERBB4,NTRK2,CAMK2G,DCLK2 |
1.957e-03 | -6.24 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 6 | 16828 | 48 |
NTRK2,TNIK,PRKG1,CAMK2G,ERBB4,DCLK2 |
1.987e-03 | -6.22 | carbohydrate derivative binding | molecular function | GO:0097367 | 2251 | 14 | 18094 | 49 |
MAPK10,NAV2,NTRK2,DCLK2,TNC,ADCY2,PRKG1,ATP1A2,APOE,DGKG,ERBB4,HPSE2,TNIK,CAMK2G |
2.026e-03 | -6.20 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | 1440 | 11 | 16828 | 48 |
NRXN1,RYR3,CTNND2,MACF1,FMN2,CNTN1,LRP1B,RFX4,CDH20,NAV2,NEBL |
2.026e-03 | -6.20 | hairy_cell_leukaemia | COSMIC cancer mutations | hairy_cell_leukaemia | 1440 | 11 | 16828 | 48 |
CNTN1,LRP1B,FMN2,MACF1,CTNND2,RYR3,NRXN1,NAV2,NEBL,RFX4,CDH20 |
2.030e-03 | -6.20 | actin filament bundle | cellular component | GO:0032432 | 96 | 3 | 19108 | 50 |
SORBS1,NEBL,ABLIM1 |
2.035e-03 | -6.20 | skin-neck-malignant_melanoma | COSMIC cancer mutations | skin-neck-malignant_melanoma | 1223 | 10 | 16828 | 48 |
ATP1A2,ERBB4,ADCY2,TNC,PLCB1,LRP1B,CNTN1,TRPM3,CTNND2,GPC5 |
2.047e-03 | -6.19 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 3 | 19454 | 50 |
PARD3,NTRK2,SORBS1 |
2.047e-03 | -6.19 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 3 | 19454 | 50 |
CNTN1,LSAMP,GPM6A |
2.049e-03 | -6.19 | localization | biological process | GO:0051179 | 4474 | 22 | 18204 | 50 |
ATP1A2,SLC14A1,GPM6A,MACF1,PARD3,CAMK2G,DCLK2,PLCB1,PITPNC1,NTRK2,SLC4A4,TRPM3,GFAP,CLU,NRXN1,RYR3,FMN2,APOE,SLC1A2,TNIK,LRP1B,ERBB4 |
2.055e-03 | -6.19 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 41 | 16828 | 48 |
SLC14A1,NRG3,RFX4,DCLK2,TRPM3,HPSE2,MACF1,RORA,ABLIM1,LSAMP,SLC4A4,SOX5,CDH20,ADCY2,NEBL,NPAS3,CTNND2,GPC5,DTNA,CAMK2G,PRKG1,NTM,PARD3,GLIS3,NAV2,DGKG,ERBB4,MSI2,NRXN1,CNTN1,SLC1A2,NTRK2,TNC,NKAIN3,ATP1A2,RYR3,LRP1B,GFAP,FMN2,PLCB1,TNIK |
2.077e-03 | -6.18 | locomotory behavior | biological process | GO:0007626 | 197 | 4 | 18204 | 50 |
NAV2,ATP1A2,APOE,CNTN1 |
2.090e-03 | -6.17 | regulation of small molecule metabolic process | biological process | GO:0062012 | 331 | 5 | 18204 | 50 |
PRKG1,RORA,APOE,SORBS1,SLC4A4 |
2.095e-03 | -6.17 | high-density lipoprotein particle | cellular component | GO:0034364 | 26 | 2 | 19108 | 50 |
APOE,CLU |
2.123e-03 | -6.16 | cell-cell junction | cellular component | GO:0005911 | 513 | 6 | 19108 | 50 |
ATP1A2,CTNND2,SORBS1,PARD3,CDH20,CTNNA2 |
2.132e-03 | -6.15 | establishment of localization | biological process | GO:0051234 | 3887 | 20 | 18204 | 50 |
SLC14A1,GPM6A,MACF1,RYR3,FMN2,PARD3,CAMK2G,GFAP,ATP1A2,CLU,NRXN1,LRP1B,SLC4A4,TRPM3,ERBB4,APOE,SLC1A2,PLCB1,PITPNC1,NTRK2 |
2.136e-03 | -6.15 | neck | COSMIC cancer mutations | neck | 1231 | 10 | 16828 | 48 |
LRP1B,CNTN1,PLCB1,TNC,TRPM3,CTNND2,GPC5,ATP1A2,ERBB4,ADCY2 |
2.141e-03 | -6.15 | virilizing_syndrome_producing | COSMIC cancer mutations | virilizing_syndrome_producing | 321 | 5 | 16828 | 48 |
ATP1A2,FMN2,TNC,LRP1B,CTNND2 |
2.142e-03 | -6.15 | HS-GAG degradation | REACTOME pathways | R-HSA-2024096 | 21 | 2 | 10285 | 34 |
GPC5,HPSE2 |
2.176e-03 | -6.13 | adenyl ribonucleotide binding | molecular function | GO:0032559 | 1528 | 11 | 18094 | 49 |
DGKG,NTRK2,NAV2,MAPK10,ERBB4,DCLK2,CAMK2G,ADCY2,TNIK,ATP1A2,PRKG1 |
2.178e-03 | -6.13 | CXADR (CXADR Ig-like cell adhesion molecule) | protein interactions | 1525 | 357 | 5 | 19454 | 50 |
TNIK,MACF1,NEBL,SORBS1,PARD3 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
DTNA,ABLIM1 |
2.189e-03 | -6.12 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 22 | 19454 | 50 |
DCLK2,NTM,LSAMP,CTNNA2,PARD3,CLU,MACF1,TNIK,TNC,CTNND2,DTNA,CAMK2G,CNTN1,GFAP,PLCB1,PITPNC1,ATP1A2,MSI2,CST3,GPM6A,SLC4A4,APOE |
2.253e-03 | -6.10 | breast-carcinoma-ductal_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductal_carcinoma | 14824 | 48 | 16828 | 48 |
NRG3,RFX4,CST3,MACF1,HPSE2,CLU,LSAMP,RORA,NEBL,CAMK2G,DTNA,GPC5,NTM,PRKG1,GLIS3,NAV2,ERBB4,NRXN1,TNC,NKAIN3,APOE,SLC1A2,PITPNC1,ATP1A2,TNIK,PLCB1,LRP1B,SLC14A1,DCLK2,TRPM3,SOX5,SLC4A4,ABLIM1,ADCY2,CDH20,CTNND2,NPAS3,PARD3,DGKG,MSI2,NTRK2,CNTN1,MGAT4C,RYR3,FMN2,SORBS1,GPM6A,GFAP |
2.272e-03 | -6.09 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 6 | 19108 | 50 |
CTNNA2,ABLIM1,NEBL,FMN2,MACF1,SORBS1 |
2.275e-03 | -6.09 | transport | biological process | GO:0006810 | 3615 | 19 | 18204 | 50 |
NRXN1,CLU,ATP1A2,GFAP,CAMK2G,FMN2,GPM6A,MACF1,RYR3,SLC14A1,PITPNC1,NTRK2,SLC1A2,PLCB1,APOE,TRPM3,ERBB4,SLC4A4,LRP1B |
2.281e-03 | -6.08 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 50 |
DTNA,CTNNA2,CDH20 |
2.304e-03 | -6.07 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 50 |
SLC1A2,GFAP |
2.304e-03 | -6.07 | central nervous system myelination | biological process | GO:0022010 | 26 | 2 | 18204 | 50 |
CNTN1,CLU |
2.304e-03 | -6.07 | axon ensheathment in central nervous system | biological process | GO:0032291 | 26 | 2 | 18204 | 50 |
CLU,CNTN1 |
2.321e-03 | -6.07 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 4 | 19454 | 50 |
RORA,ABLIM1,NKAIN3,GFAP |
2.351e-03 | -6.05 | SHC1 events in ERBB2 signaling | REACTOME pathways | R-HSA-1250196 | 22 | 2 | 10285 | 34 |
ERBB4,NRG3 |
2.370e-03 | -6.05 | YES1 (YES proto-oncogene 1, Src family tyrosine kinase) | protein interactions | 7525 | 364 | 5 | 19454 | 50 |
CAMK2G,MSI2,ERBB4,SLC14A1,GFAP |
2.399e-03 | -6.03 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 4 | 18204 | 50 |
RYR3,GPM6A,TRPM3,PLCB1 |
2.424e-03 | -6.02 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 3 | 19454 | 50 |
SORBS1,CLU,ABLIM1 |
2.455e-03 | -6.01 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 5 | 19454 | 50 |
PARD3,NTRK2,TNIK,ABLIM1,CLU |
2.484e-03 | -6.00 | protein kinase C-activating G protein-coupled receptor signaling pathway | biological process | GO:0007205 | 27 | 2 | 18204 | 50 |
PARD3,DGKG |
2.496e-03 | -5.99 | system process | biological process | GO:0003008 | 2015 | 13 | 18204 | 50 |
ABLIM1,NRXN1,ATP1A2,NAV2,PRKG1,CTNNA2,RYR3,PLCB1,DTNA,SLC1A2,NTRK2,APOE,SLC4A4 |
2.499e-03 | -5.99 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 21 | 16828 | 48 |
SLC1A2,SLC4A4,TNC,ABLIM1,RORA,CNTN1,MACF1,NAV2,ERBB4,RFX4,NRG3,PARD3,FMN2,PLCB1,LRP1B,CTNND2,GPC5,MGAT4C,ATP1A2,NEBL,CDH20 |
2.514e-03 | -5.99 | PLEKHA6 (pleckstrin homology domain containing A6) | protein interactions | 22874 | 29 | 2 | 19454 | 50 |
APOE,PARD3 |
2.519e-03 | -5.98 | Adrenergic signaling in cardiomyocytes | KEGG pathways | hsa04261 | 144 | 4 | 7161 | 29 |
CAMK2G,PLCB1,ATP1A2,ADCY2 |
2.519e-03 | -5.98 | Adrenergic signaling in cardiomyocytes | KEGG pathways | ko04261 | 144 | 4 | 7161 | 29 |
ADCY2,ATP1A2,PLCB1,CAMK2G |
2.520e-03 | -5.98 | PSEN1 (presenilin 1) | protein interactions | 5663 | 222 | 4 | 19454 | 50 |
APOE,DTNA,CTNND2,GFAP |
2.526e-03 | -5.98 | actin filament binding | molecular function | GO:0051015 | 211 | 4 | 18094 | 49 |
ABLIM1,CTNNA2,MACF1,NEBL |
2.570e-03 | -5.96 | Cntnap2 (contactin associated protein-like 2) | protein interactions | 66797 | 1 | 1 | 19454 | 50 |
CNTN1 |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Bdnf (brain derived neurotrophic factor) | protein interactions | 12064 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | App (amyloid beta precursor protein) | protein interactions | 100689222 | 1 | 1 | 19454 | 50 |
LRP1B |
2.570e-03 | -5.96 | IML3 (Iml3p) | protein interactions | 852404 | 1 | 1 | 19454 | 50 |
GFAP |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Itga7 (integrin subunit alpha 7) | protein interactions | 81008 | 1 | 1 | 19454 | 50 |
TNC |
2.570e-03 | -5.96 | Dynlt1 (dynein light chain Tctex-type 1) | protein interactions | 83462 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 50 |
NRXN1 |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.573e-03 | -5.96 | circulatory system process | biological process | GO:0003013 | 508 | 6 | 18204 | 50 |
SLC4A4,PRKG1,SLC1A2,NAV2,ATP1A2,APOE |
2.585e-03 | -5.96 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 11 | 16828 | 48 |
SLC14A1,NRG3,DGKG,MACF1,RYR3,DTNA,GPC5,NPAS3,SORBS1,FMN2,LRP1B |
2.585e-03 | -5.96 | Pkinase | pfam domains | PF00069 | 347 | 5 | 17795 | 49 |
DCLK2,PRKG1,MAPK10,TNIK,CAMK2G |
2.603e-03 | -5.95 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 4 | 19454 | 50 |
ABLIM1,GPM6A,NAV2,MACF1 |
2.617e-03 | -5.95 | perinuclear endoplasmic reticulum lumen | cellular component | GO:0099020 | 1 | 1 | 19108 | 50 |
CLU |
2.620e-03 | -5.94 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 7 | 16828 | 48 |
LRP1B,PRKG1,TNIK,NTRK2,CAMK2G,DCLK2,ERBB4 |
2.647e-03 | -5.93 | organelle organization | biological process | GO:0006996 | 3091 | 17 | 18204 | 50 |
DCLK2,FMN2,PARD3,MACF1,CTNNA2,PRKG1,NRXN1,ABLIM1,NAV2,SORBS1,CLU,GFAP,ERBB4,NEBL,TNIK,RFX4,APOE |
2.670e-03 | -5.93 | glial cell proliferation | biological process | GO:0014009 | 28 | 2 | 18204 | 50 |
GFAP,CLU |
2.677e-03 | -5.92 | central_nervous_system-brainstem-glioma | COSMIC cancer mutations | central_nervous_system-brainstem-glioma | 338 | 5 | 16828 | 48 |
LRP1B,ERBB4,TNC,GPC5,HPSE2 |
2.698e-03 | -5.92 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 3 | 19454 | 50 |
MSI2,ERBB4,RYR3 |
2.700e-03 | -5.91 | SORBS1_SH3 | interpro domains | IPR035606 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | C1_DGKgamma_rpt2 | interpro domains | IPR047475 | 1 | 1 | 18521 | 50 |
DGKG |
2.700e-03 | -5.91 | Clusterin | interpro domains | IPR016016 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | Clusterin_CS | interpro domains | IPR033986 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | SORBS1_SH3_1 | interpro domains | IPR035610 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | Contactin-1_Ig6 | interpro domains | IPR047101 | 1 | 1 | 18521 | 50 |
CNTN1 |
2.700e-03 | -5.91 | Contactin-1_Ig1 | interpro domains | IPR036992 | 1 | 1 | 18521 | 50 |
CNTN1 |
2.700e-03 | -5.91 | Nebulette_SH3 | interpro domains | IPR035631 | 1 | 1 | 18521 | 50 |
NEBL |
2.700e-03 | -5.91 | Contactin-1_Ig3 | interpro domains | IPR047100 | 1 | 1 | 18521 | 50 |
CNTN1 |
2.700e-03 | -5.91 | SORBS1_SH3_2 | interpro domains | IPR035611 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | PLC-beta1_EF | interpro domains | IPR028400 | 1 | 1 | 18521 | 50 |
PLCB1 |
2.700e-03 | -5.91 | PKcGMP_CC | interpro domains | IPR031831 | 1 | 1 | 18521 | 50 |
PRKG1 |
2.700e-03 | -5.91 | NTRK2 | interpro domains | IPR020455 | 1 | 1 | 18521 | 50 |
NTRK2 |
2.708e-03 | -5.91 | brain-derived neurotrophic factor receptor activity | molecular function | GO:0060175 | 1 | 1 | 18094 | 49 |
NTRK2 |
2.708e-03 | -5.91 | metal chelating activity | molecular function | GO:0046911 | 1 | 1 | 18094 | 49 |
APOE |
2.709e-03 | -5.91 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 7 | 16828 | 48 |
DCLK2,ERBB4,PRKG1,LRP1B,NTRK2,TNIK,CAMK2G |
2.724e-03 | -5.91 | transferase activity, transferring phosphorus-containing groups | molecular function | GO:0016772 | 903 | 8 | 18094 | 49 |
DGKG,NTRK2,MAPK10,ERBB4,DCLK2,CAMK2G,TNIK,PRKG1 |
2.747e-03 | -5.90 | trans-synaptic signaling by neuropeptide, modulating synaptic transmission | biological process | GO:0099551 | 1 | 1 | 18204 | 50 |
NTRK2 |
2.747e-03 | -5.90 | positive regulation of transport across blood-brain barrier | biological process | GO:0150201 | 1 | 1 | 18204 | 50 |
APOE |
2.747e-03 | -5.90 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 50 |
CST3 |
2.747e-03 | -5.90 | homologous chromosome movement towards spindle pole in meiosis I anaphase | biological process | GO:0051758 | 1 | 1 | 18204 | 50 |
FMN2 |
2.747e-03 | -5.90 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | response to glyceraldehyde | biological process | GO:1905630 | 1 | 1 | 18204 | 50 |
PLCB1 |
2.747e-03 | -5.90 | trans-synaptic signaling by neuropeptide | biological process | GO:0099540 | 1 | 1 | 18204 | 50 |
NTRK2 |
2.747e-03 | -5.90 | intermediate-density lipoprotein particle clearance | biological process | GO:0071831 | 1 | 1 | 18204 | 50 |
APOE |
2.747e-03 | -5.90 | directional guidance of interneurons involved in migration from the subpallium to the cortex | biological process | GO:0021840 | 1 | 1 | 18204 | 50 |
NRG3 |
2.747e-03 | -5.90 | positive regulation of lipid transport across blood-brain barrier | biological process | GO:1903002 | 1 | 1 | 18204 | 50 |
APOE |
2.747e-03 | -5.90 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | regulation of heparan sulfate proteoglycan binding | biological process | GO:1905858 | 1 | 1 | 18204 | 50 |
APOE |
2.747e-03 | -5.90 | positive regulation of heparan sulfate proteoglycan binding | biological process | GO:1905860 | 1 | 1 | 18204 | 50 |
APOE |
2.747e-03 | -5.90 | regulation of CD24 production | biological process | GO:2000559 | 1 | 1 | 18204 | 50 |
PLCB1 |
2.747e-03 | -5.90 | cellular response to glyceraldehyde | biological process | GO:1905631 | 1 | 1 | 18204 | 50 |
PLCB1 |
2.747e-03 | -5.90 | positive regulation of CD24 production | biological process | GO:2000560 | 1 | 1 | 18204 | 50 |
PLCB1 |
2.747e-03 | -5.90 | regulation of cellular response to very-low-density lipoprotein particle stimulus | biological process | GO:1905890 | 1 | 1 | 18204 | 50 |
APOE |
2.747e-03 | -5.90 | positive regulation of neurofibrillary tangle assembly | biological process | GO:1902998 | 1 | 1 | 18204 | 50 |
CLU |
2.747e-03 | -5.90 | regulation of neuronal signal transduction | biological process | GO:1902847 | 1 | 1 | 18204 | 50 |
CLU |
2.747e-03 | -5.90 | regulation of lipid transport across blood-brain barrier | biological process | GO:1903000 | 1 | 1 | 18204 | 50 |
APOE |
2.747e-03 | -5.90 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 50 |
CST3 |
2.747e-03 | -5.90 | chemorepulsion involved in interneuron migration from the subpallium to the cortex | biological process | GO:0021842 | 1 | 1 | 18204 | 50 |
NRG3 |
2.747e-03 | -5.90 | regulation of transport across blood-brain barrier | biological process | GO:0150200 | 1 | 1 | 18204 | 50 |
APOE |
2.754e-03 | -5.89 | PKcGMP_CC | pfam domains | PF16808 | 1 | 1 | 17795 | 49 |
PRKG1 |
2.777e-03 | -5.89 | cell motility | biological process | GO:0048870 | 1101 | 9 | 18204 | 50 |
FMN2,GPC5,ERBB4,CTNNA2,PRKG1,CDH20,GPM6A,NRG3,NTRK2 |
2.784e-03 | -5.88 | lipoprotein particle receptor binding | molecular function | GO:0070325 | 29 | 2 | 18094 | 49 |
CLU,APOE |
2.837e-03 | -5.86 | Bile secretion | KEGG pathways | hsa04976 | 71 | 3 | 7161 | 29 |
ADCY2,ATP1A2,SLC4A4 |
2.837e-03 | -5.86 | Bile secretion | KEGG pathways | ko04976 | 71 | 3 | 7161 | 29 |
ATP1A2,ADCY2,SLC4A4 |
2.843e-03 | -5.86 | cerebellum development | biological process | GO:0021549 | 103 | 3 | 18204 | 50 |
CNTN1,RORA,PRKG1 |
2.863e-03 | -5.86 | postsynaptic membrane organization | biological process | GO:0001941 | 29 | 2 | 18204 | 50 |
APOE,NRXN1 |
2.863e-03 | -5.86 | myelination in peripheral nervous system | biological process | GO:0022011 | 29 | 2 | 18204 | 50 |
NTRK2,PARD3 |
2.863e-03 | -5.86 | cGMP-mediated signaling | biological process | GO:0019934 | 29 | 2 | 18204 | 50 |
APOE,PRKG1 |
2.863e-03 | -5.86 | peripheral nervous system axon ensheathment | biological process | GO:0032292 | 29 | 2 | 18204 | 50 |
PARD3,NTRK2 |
2.863e-03 | -5.86 | DST (dystonin) | protein interactions | 667 | 230 | 4 | 19454 | 50 |
ATP1A2,PARD3,TNIK,NTRK2 |
2.870e-03 | -5.85 | RYR1 (ryanodine receptor 1) | protein interactions | 6261 | 31 | 2 | 19454 | 50 |
PRKG1,CAMK2G |
2.870e-03 | -5.85 | SH2B1 (SH2B adaptor protein 1) | protein interactions | 25970 | 31 | 2 | 19454 | 50 |
ERBB4,NTRK2 |
2.870e-03 | -5.85 | SH2D1B (SH2 domain containing 1B) | protein interactions | 117157 | 31 | 2 | 19454 | 50 |
ABLIM1,ERBB4 |
2.888e-03 | -5.85 | protein serine kinase activity | molecular function | GO:0106310 | 362 | 5 | 18094 | 49 |
MAPK10,TNIK,CAMK2G,PRKG1,DCLK2 |
2.897e-03 | -5.84 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 8 | 16828 | 48 |
ERBB4,DCLK2,CAMK2G,MACF1,TNIK,NTRK2,CNTN1,PRKG1 |
2.901e-03 | -5.84 | lung-carcinoid-endocrine_tumour | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour | 502 | 6 | 16828 | 48 |
DCLK2,ERBB4,PRKG1,TNIK,NTRK2,CAMK2G |
2.922e-03 | -5.84 | regulation of steroid metabolic process | biological process | GO:0019218 | 104 | 3 | 18204 | 50 |
RORA,APOE,PRKG1 |
2.934e-03 | -5.83 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 7 | 18094 | 49 |
SLC4A4,TRPM3,RYR3,ATP1A2,SLC14A1,SLC1A2,GPM6A |
2.952e-03 | -5.83 | Adherens junction | KEGG pathways | ko04520 | 72 | 3 | 7161 | 29 |
PARD3,CTNNA2,SORBS1 |
2.952e-03 | -5.83 | Adherens junction | KEGG pathways | hsa04520 | 72 | 3 | 7161 | 29 |
CTNNA2,SORBS1,PARD3 |
2.973e-03 | -5.82 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 50 |
CDH20,CTNNA2 |
2.985e-03 | -5.81 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 4 | 16828 | 48 |
PRKG1,LRP1B,NTM,SLC4A4 |
2.986e-03 | -5.81 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 27 | 16828 | 48 |
SOX5,SLC4A4,RORA,ABLIM1,TRPM3,MACF1,CST3,DCLK2,NRG3,PARD3,CAMK2G,DTNA,NPAS3,CTNND2,NEBL,ADCY2,NKAIN3,NTRK2,TNC,CNTN1,DGKG,ERBB4,NAV2,GLIS3,LRP1B,RYR3,ATP1A2 |
2.993e-03 | -5.81 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 8 | 19454 | 50 |
CAMK2G,ABLIM1,NAV2,MACF1,DCLK2,PITPNC1,SORBS1,PARD3 |
3.041e-03 | -5.80 | positive regulation of cell projection organization | biological process | GO:0031346 | 361 | 5 | 18204 | 50 |
CNTN1,NTRK2,APOE,MACF1,GPM6A |
3.041e-03 | -5.80 | regulation of protein catabolic process | biological process | GO:0042176 | 361 | 5 | 18204 | 50 |
FMN2,APOE,GFAP,CST3,CLU |
3.062e-03 | -5.79 | neuron projection regeneration | biological process | GO:0031102 | 30 | 2 | 18204 | 50 |
GFAP,TNC |
3.062e-03 | -5.79 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 2 | 18204 | 50 |
ATP1A2,SLC1A2 |
3.065e-03 | -5.79 | Oxytocin signaling pathway | KEGG pathways | hsa04921 | 152 | 4 | 7161 | 29 |
RYR3,CAMK2G,ADCY2,PLCB1 |
3.065e-03 | -5.79 | Oxytocin signaling pathway | KEGG pathways | ko04921 | 152 | 4 | 7161 | 29 |
PLCB1,ADCY2,CAMK2G,RYR3 |
3.076e-03 | -5.78 | lung-carcinoid-endocrine_tumour-atypical | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour-atypical | 508 | 6 | 16828 | 48 |
TNIK,NTRK2,PRKG1,CAMK2G,ERBB4,DCLK2 |
3.093e-03 | -5.78 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 4 | 19454 | 50 |
DTNA,MACF1,NTRK2,PARD3 |
3.110e-03 | -5.77 | - | gene3d domains | 6.10.250.880 | 1 | 1 | 14470 | 45 |
ERBB4 |
3.145e-03 | -5.76 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 47 | 16828 | 48 |
DCLK2,SLC14A1,ABLIM1,SLC4A4,SOX5,TRPM3,CDH20,ADCY2,PARD3,CTNND2,NPAS3,DGKG,CNTN1,NTRK2,MGAT4C,SORBS1,FMN2,GPM6A,GFAP,RYR3,CST3,NRG3,RFX4,CLU,LSAMP,RORA,HPSE2,MACF1,NEBL,PRKG1,NTM,GPC5,DTNA,CAMK2G,ERBB4,NAV2,GLIS3,TNC,APOE,NKAIN3,SLC1A2,NRXN1,PITPNC1,ATP1A2,LRP1B,PLCB1,TNIK |
3.188e-03 | -5.75 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 4 | 19454 | 50 |
SOX5,GFAP,GPM6A,CAMK2G |
3.188e-03 | -5.75 | CLU (clusterin) | protein interactions | 1191 | 237 | 4 | 19454 | 50 |
TNC,CLU,LRP1B,TNIK |
3.192e-03 | -5.75 | Thyroid hormone synthesis | KEGG pathways | ko04918 | 74 | 3 | 7161 | 29 |
ADCY2,ATP1A2,PLCB1 |
3.192e-03 | -5.75 | Thyroid hormone synthesis | KEGG pathways | hsa04918 | 74 | 3 | 7161 | 29 |
ATP1A2,ADCY2,PLCB1 |
3.220e-03 | -5.74 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 39 | 16828 | 48 |
SOX5,SLC4A4,LSAMP,ABLIM1,RORA,HPSE2,MACF1,TRPM3,NRG3,RFX4,SLC14A1,NTM,PARD3,PRKG1,CAMK2G,CTNND2,GPC5,NPAS3,NEBL,ADCY2,CDH20,TNC,NTRK2,NKAIN3,SLC1A2,CNTN1,NRXN1,MSI2,DGKG,NAV2,ERBB4,GLIS3,TNIK,FMN2,PLCB1,GFAP,LRP1B,RYR3,ATP1A2 |
3.220e-03 | -5.74 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 39 | 16828 | 48 |
NEBL,CDH20,ADCY2,PRKG1,PARD3,NTM,NPAS3,GPC5,CTNND2,CAMK2G,SLC14A1,NRG3,RFX4,ABLIM1,RORA,LSAMP,SOX5,SLC4A4,TRPM3,MACF1,HPSE2,ATP1A2,LRP1B,GFAP,PLCB1,FMN2,TNIK,RYR3,NAV2,ERBB4,DGKG,GLIS3,CNTN1,SLC1A2,NKAIN3,TNC,NTRK2,NRXN1,MSI2 |
3.225e-03 | -5.74 | axonogenesis | biological process | GO:0007409 | 366 | 5 | 18204 | 50 |
PRKG1,CTNNA2,NRXN1,CNTN1,PARD3 |
3.249e-03 | -5.73 | TRPC3 (transient receptor potential cation channel subfamily C member 3) | protein interactions | 7222 | 33 | 2 | 19454 | 50 |
PLCB1,PRKG1 |
3.249e-03 | -5.73 | VLDLR (very low density lipoprotein receptor) | protein interactions | 7436 | 33 | 2 | 19454 | 50 |
APOE,CLU |
3.253e-03 | -5.73 | extracellular matrix | cellular component | GO:0031012 | 559 | 6 | 19108 | 50 |
CLU,NAV2,GPC5,HPSE2,TNC,APOE |
3.253e-03 | -5.73 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 14 | 16828 | 48 |
CTNND2,FMN2,LRP1B,ATP1A2,HPSE2,TRPM3,NTRK2,TNC,SOX5,SLC1A2,CNTN1,RFX4,NRG3,DGKG |
3.259e-03 | -5.73 | caecum | COSMIC cancer mutations | caecum | 14248 | 47 | 16828 | 48 |
TRPM3,ABLIM1,SOX5,SLC4A4,SLC14A1,DCLK2,NPAS3,CTNND2,PARD3,CDH20,ADCY2,CNTN1,NTRK2,DGKG,RYR3,GFAP,FMN2,SORBS1,GPM6A,MGAT4C,HPSE2,MACF1,RORA,CLU,LSAMP,RFX4,NRG3,CST3,GPC5,CAMK2G,DTNA,PRKG1,NTM,NEBL,NRXN1,SLC1A2,NKAIN3,APOE,TNC,GLIS3,ERBB4,NAV2,LRP1B,PLCB1,TNIK,ATP1A2,PITPNC1 |
3.282e-03 | -5.72 | external encapsulating structure | cellular component | GO:0030312 | 560 | 6 | 19108 | 50 |
CLU,APOE,TNC,NAV2,HPSE2,GPC5 |
3.291e-03 | -5.72 | atypical | COSMIC cancer mutations | atypical | 515 | 6 | 16828 | 48 |
ERBB4,DCLK2,TNIK,NTRK2,PRKG1,CAMK2G |
3.329e-03 | -5.71 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 10 | 16828 | 48 |
MACF1,NPAS3,TRPM3,LRP1B,SORBS1,NTM,SLC4A4,NAV2,ATP1A2,ERBB4 |
3.336e-03 | -5.70 | postsynapse organization | biological process | GO:0099173 | 109 | 3 | 18204 | 50 |
NRXN1,CTNND2,APOE |
3.371e-03 | -5.69 | YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma) | protein interactions | 7532 | 1211 | 9 | 19454 | 50 |
MACF1,DCLK2,FMN2,ABLIM1,CAMK2G,NAV2,SORBS1,PARD3,PITPNC1 |
3.404e-03 | -5.68 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 9 | 18204 | 50 |
SLC1A2,PLCB1,NTRK2,ATP1A2,SORBS1,TNC,SOX5,ERBB4,RYR3 |
3.441e-03 | -5.67 | HAX1 (HCLS1 associated protein X-1) | protein interactions | 10456 | 397 | 5 | 19454 | 50 |
CLU,MAPK10,GPM6A,CNTN1,NTM |
3.442e-03 | -5.67 | adenyl nucleotide binding | molecular function | GO:0030554 | 1620 | 11 | 18094 | 49 |
ATP1A2,PRKG1,CAMK2G,ADCY2,TNIK,ERBB4,DCLK2,DGKG,NTRK2,NAV2,MAPK10 |
3.444e-03 | -5.67 | NTKRECEPTOR2 | prints domains | PR01941 | 1 | 1 | 5227 | 18 |
NTRK2 |
3.485e-03 | -5.66 | seminoma | COSMIC cancer mutations | seminoma | 700 | 7 | 16828 | 48 |
DCLK2,CNTN1,PRKG1,ERBB4,NTRK2,TNIK,CAMK2G |
3.519e-03 | -5.65 | EGF-like_dom | interpro domains | IPR000742 | 232 | 4 | 18521 | 50 |
NRG3,NRXN1,TNC,LRP1B |
3.529e-03 | -5.65 | CLUSTERIN_2 | prosite domains | PS00493 | 1 | 1 | 12186 | 43 |
CLU |
3.529e-03 | -5.65 | CLUSTERIN_1 | prosite domains | PS00492 | 1 | 1 | 12186 | 43 |
CLU |
3.659e-03 | -5.61 | tat (Tat) | protein interactions | 155871 | 1718 | 11 | 19454 | 50 |
SORBS1,RYR3,SLC1A2,GFAP,SLC14A1,PLCB1,APOE,ADCY2,TNC,CAMK2G,PRKG1 |
3.692e-03 | -5.60 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 50 |
CTNND2,CTNNA2,PRKG1 |
3.692e-03 | -5.60 | metencephalon development | biological process | GO:0022037 | 113 | 3 | 18204 | 50 |
RORA,PRKG1,CNTN1 |
3.697e-03 | -5.60 | response to auditory stimulus | biological process | GO:0010996 | 33 | 2 | 18204 | 50 |
NRXN1,ATP1A2 |
3.774e-03 | -5.58 | localization within membrane | biological process | GO:0051668 | 549 | 6 | 18204 | 50 |
PARD3,ERBB4,NRXN1,TNIK,APOE,MACF1 |
3.775e-03 | -5.58 | arm | COSMIC cancer mutations | arm | 1331 | 10 | 16828 | 48 |
ATP1A2,ERBB4,NAV2,LRP1B,NTM,SLC4A4,SORBS1,NPAS3,TRPM3,MACF1 |
3.785e-03 | -5.58 | regulation of circadian rhythm | biological process | GO:0042752 | 114 | 3 | 18204 | 50 |
MAPK10,PRKG1,RORA |
3.801e-03 | -5.57 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 29 |
ATP1A2,SLC4A4 |
3.801e-03 | -5.57 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 29 |
SLC4A4,ATP1A2 |
3.803e-03 | -5.57 | anion binding | molecular function | GO:0043168 | 2412 | 14 | 18094 | 49 |
ADCY2,ATP1A2,PRKG1,NTRK2,MAPK10,NAV2,PLCB1,DCLK2,CAMK2G,TNIK,PITPNC1,DGKG,ERBB4,PARD3 |
3.808e-03 | -5.57 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 37 |
MACF1 |
3.829e-03 | -5.57 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 16 | 16828 | 48 |
RYR3,CTNND2,FMN2,TNIK,PARD3,PRKG1,LRP1B,PITPNC1,MACF1,TRPM3,TNC,NKAIN3,SLC4A4,CLU,NRG3,ERBB4 |
3.829e-03 | -5.57 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 16 | 16828 | 48 |
PITPNC1,FMN2,TNIK,PARD3,PRKG1,LRP1B,RYR3,CTNND2,ERBB4,NRG3,TNC,NKAIN3,SLC4A4,CLU,MACF1,TRPM3 |
3.833e-03 | -5.56 | synaptic membrane | cellular component | GO:0097060 | 400 | 5 | 19108 | 50 |
ERBB4,SLC1A2,GPM6A,CNTN1,NRXN1 |
3.857e-03 | -5.56 | PTPRB (protein tyrosine phosphatase receptor type B) | protein interactions | 5787 | 36 | 2 | 19454 | 50 |
CNTN1,TNC |
3.897e-03 | -5.55 | regulation of transport | biological process | GO:0051049 | 1621 | 11 | 18204 | 50 |
CAMK2G,PRKG1,CLU,SORBS1,NKAIN3,GFAP,ATP1A2,CNTN1,PLCB1,SLC1A2,APOE |
3.910e-03 | -5.54 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 49 |
TRPM3,GPM6A,RYR3 |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
NTRK2,LSAMP,CNTN1,NTM |
3.921e-03 | -5.54 | exploration behavior | biological process | GO:0035640 | 34 | 2 | 18204 | 50 |
ATP1A2,APOE |
3.942e-03 | -5.54 | cGMP-PKG signaling pathway | KEGG pathways | hsa04022 | 163 | 4 | 7161 | 29 |
ADCY2,ATP1A2,PLCB1,PRKG1 |
3.942e-03 | -5.54 | cGMP-PKG signaling pathway | KEGG pathways | ko04022 | 163 | 4 | 7161 | 29 |
PRKG1,ATP1A2,ADCY2,PLCB1 |
3.969e-03 | -5.53 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 4 | 19454 | 50 |
ERBB4,TNIK,NTRK2,SORBS1 |
3.976e-03 | -5.53 | salivary_gland-submandibular-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-submandibular-carcinoma-adenoid_cystic_carcinoma | 33 | 2 | 16828 | 48 |
LRP1B,NAV2 |
3.994e-03 | -5.52 | plasma lipoprotein particle | cellular component | GO:0034358 | 36 | 2 | 19108 | 50 |
APOE,CLU |
3.994e-03 | -5.52 | lipoprotein particle | cellular component | GO:1990777 | 36 | 2 | 19108 | 50 |
APOE,CLU |
4.068e-03 | -5.50 | large_intestine-caecum-adenoma | COSMIC cancer mutations | large_intestine-caecum-adenoma | 229 | 4 | 16828 | 48 |
CTNND2,HPSE2,LRP1B,ERBB4 |
4.071e-03 | -5.50 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 50 |
CST3,GPM6A |
4.071e-03 | -5.50 | PRRG4 (proline rich and Gla domain 4) | protein interactions | 79056 | 37 | 2 | 19454 | 50 |
NEBL,ERBB4 |
4.071e-03 | -5.50 | MAGI2 (membrane associated guanylate kinase, WW and PDZ domain containing 2) | protein interactions | 9863 | 37 | 2 | 19454 | 50 |
CTNND2,ERBB4 |
4.079e-03 | -5.50 | regulation of biological quality | biological process | GO:0065008 | 2936 | 16 | 18204 | 50 |
ERBB4,SLC4A4,DGKG,NTRK2,PLCB1,APOE,CAMK2G,GPM6A,MACF1,CTNNA2,PRKG1,NRXN1,CLU,NAV2,GFAP,ATP1A2 |
4.145e-03 | -5.49 | cellular process | biological process | GO:0009987 | 14996 | 48 | 18204 | 50 |
LRP1B,ERBB4,TNC,MGAT4C,TNIK,SLC1A2,RYR3,MSI2,CDH20,CLU,GFAP,NRXN1,ADCY2,CNTN1,NEBL,PLCB1,DTNA,CTNNA2,SLC14A1,DCLK2,CAMK2G,HPSE2,CST3,RORA,ATP1A2,NRG3,ABLIM1,GPC5,RFX4,APOE,DGKG,FMN2,TRPM3,SLC4A4,GLIS3,NTRK2,PITPNC1,NTM,LSAMP,MACF1,CTNND2,GPM6A,PRKG1,SOX5,PARD3,NAV2,SORBS1,MAPK10 |
4.157e-03 | -5.48 | organic substance transport | biological process | GO:0071702 | 1881 | 12 | 18204 | 50 |
LRP1B,SLC4A4,APOE,NTRK2,PITPNC1,SLC1A2,MACF1,SLC14A1,CAMK2G,FMN2,CLU,GFAP |
4.196e-03 | -5.47 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 3 | 16828 | 48 |
RYR3,SOX5,SLC1A2 |
4.215e-03 | -5.47 | glial cell projection | cellular component | GO:0097386 | 37 | 2 | 19108 | 50 |
GFAP,SLC1A2 |
4.267e-03 | -5.46 | Aldosterone synthesis and secretion | KEGG pathways | hsa04925 | 82 | 3 | 7161 | 29 |
CAMK2G,ADCY2,PLCB1 |
4.267e-03 | -5.46 | Aldosterone synthesis and secretion | KEGG pathways | ko04925 | 82 | 3 | 7161 | 29 |
PLCB1,ADCY2,CAMK2G |
4.290e-03 | -5.45 | RORA (RAR related orphan receptor A) | protein interactions | 6095 | 38 | 2 | 19454 | 50 |
GFAP,RORA |
4.290e-03 | -5.45 | MMP3 (matrix metallopeptidase 3) | protein interactions | 4314 | 38 | 2 | 19454 | 50 |
APOE,CLU |
4.354e-03 | -5.44 | Downregulation of ERBB2 signaling | REACTOME pathways | R-HSA-8863795 | 30 | 2 | 10285 | 34 |
NRG3,ERBB4 |
4.370e-03 | -5.43 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 50 |
RYR3,ATP1A2,DTNA |
4.374e-03 | -5.43 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 4 | 10285 | 34 |
ATP1A2,CAMK2G,SORBS1,RYR3 |
4.376e-03 | -5.43 | PROTEIN_KINASE_ST | prosite domains | PS00108 | 308 | 5 | 12186 | 43 |
MAPK10,DCLK2,CAMK2G,PRKG1,TNIK |
4.481e-03 | -5.41 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 13 | 16828 | 48 |
ERBB4,DCLK2,NTRK2,SOX5,SLC4A4,ADCY2,ATP1A2,CAMK2G,DTNA,TNIK,GFAP,PRKG1,LRP1B |
4.487e-03 | -5.41 | testis | COSMIC cancer mutations | testis | 733 | 7 | 16828 | 48 |
PRKG1,NTRK2,TNIK,MACF1,CAMK2G,DCLK2,ERBB4 |
4.494e-03 | -5.41 | DIRAS3 (DIRAS family GTPase 3) | protein interactions | 9077 | 261 | 4 | 19454 | 50 |
MACF1,FMN2,PARD3,DTNA |
4.530e-03 | -5.40 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 8 | 16828 | 48 |
ATP1A2,ERBB4,DCLK2,CAMK2G,MACF1,NTRK2,TNIK,PRKG1 |
4.569e-03 | -5.39 | regulation of system process | biological process | GO:0044057 | 571 | 6 | 18204 | 50 |
PARD3,CAMK2G,NRXN1,PRKG1,APOE,ATP1A2 |
4.603e-03 | -5.38 | organic anion transport | biological process | GO:0015711 | 398 | 5 | 18204 | 50 |
APOE,GFAP,SLC4A4,SLC1A2,NTRK2 |
4.631e-03 | -5.38 | positive regulation of glucose import | biological process | GO:0046326 | 37 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
4.674e-03 | -5.37 | protein-lipid complex | cellular component | GO:0032994 | 39 | 2 | 19108 | 50 |
CLU,APOE |
4.718e-03 | -5.36 | submandibular | COSMIC cancer mutations | submandibular | 36 | 2 | 16828 | 48 |
NAV2,LRP1B |
4.723e-03 | -5.36 | transporter activity | molecular function | GO:0005215 | 1211 | 9 | 18094 | 49 |
PITPNC1,SLC14A1,ATP1A2,APOE,GPM6A,SLC1A2,TRPM3,SLC4A4,RYR3 |
4.744e-03 | -5.35 | SHC2 (SHC adaptor protein 2) | protein interactions | 25759 | 40 | 2 | 19454 | 50 |
NTRK2,ERBB4 |
4.766e-03 | -5.35 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 4 | 10285 | 34 |
RYR3,TRPM3,CAMK2G,ATP1A2 |
4.825e-03 | -5.33 | KIF20A (kinesin family member 20A) | protein interactions | 10112 | 1044 | 8 | 19454 | 50 |
RORA,MSI2,PARD3,GFAP,NAV2,ABLIM1,MACF1,NEBL |
4.880e-03 | -5.32 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 50 |
GFAP,SLC1A2 |
4.907e-03 | -5.32 | EGF_3 | prosite domains | PS50026 | 196 | 4 | 12186 | 43 |
LRP1B,NRG3,TNC,NRXN1 |
4.927e-03 | -5.31 | response to stimulus | biological process | GO:0050896 | 7803 | 31 | 18204 | 50 |
NRXN1,GFAP,CLU,FMN2,RYR3,SLC1A2,TNIK,DGKG,APOE,TNC,ERBB4,MAPK10,NRG3,ATP1A2,RORA,SORBS1,CST3,SOX5,PARD3,DCLK2,PRKG1,CTNNA2,CTNND2,GPM6A,MACF1,DTNA,PLCB1,PITPNC1,NTRK2,CNTN1,ADCY2 |
4.940e-03 | -5.31 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 6 | 18094 | 49 |
TRPM3,SLC4A4,RYR3,ATP1A2,SLC1A2,GPM6A |
4.944e-03 | -5.31 | calcium ion transport | biological process | GO:0006816 | 251 | 4 | 18204 | 50 |
RYR3,GPM6A,PLCB1,TRPM3 |
4.945e-03 | -5.31 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 3 | 19454 | 50 |
GPM6A,CNTN1,NTM |
4.980e-03 | -5.30 | RASSF7 (Ras association domain family member 7) | protein interactions | 8045 | 41 | 2 | 19454 | 50 |
PARD3,CLU |
4.995e-03 | -5.30 | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | 561 | 6 | 16828 | 48 |
ERBB4,RYR3,CAMK2G,TNIK,NTRK2,LRP1B |
5.021e-03 | -5.29 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 15 | 16828 | 48 |
HPSE2,TRPM3,CNTN1,TNC,NTRK2,SOX5,SLC1A2,NRG3,RFX4,DGKG,CTNND2,LRP1B,FMN2,ADCY2,ATP1A2 |
5.038e-03 | -5.29 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 11 | 16828 | 48 |
DGKG,CNTN1,RORA,ABLIM1,MACF1,CDH20,PLCB1,FMN2,SORBS1,CTNND2,DTNA |
5.038e-03 | -5.29 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 11 | 16828 | 48 |
DTNA,CTNND2,PLCB1,FMN2,SORBS1,CDH20,MACF1,ABLIM1,RORA,CNTN1,DGKG |
5.099e-03 | -5.28 | collagen-containing extracellular matrix | cellular component | GO:0062023 | 428 | 5 | 19108 | 50 |
CLU,TNC,APOE,GPC5,NAV2 |
5.127e-03 | -5.27 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 7 | 19454 | 50 |
PARD3,PLCB1,DTNA,ABLIM1,MACF1,TNIK,FMN2 |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | URA1 (dihydroorotate dehydrogenase) | protein interactions | 853664 | 2 | 1 | 19454 | 50 |
GFAP |
5.134e-03 | -5.27 | EST1 (Est1p) | protein interactions | 850934 | 2 | 1 | 19454 | 50 |
NAV2 |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | TRIM39-RPP21 (TRIM39-RPP21 readthrough) | protein interactions | 202658 | 2 | 1 | 19454 | 50 |
PRKG1 |
5.134e-03 | -5.27 | cdh11.S (cadherin 11 S homeolog) | protein interactions | 100337621 | 2 | 1 | 19454 | 50 |
ERBB4 |
5.134e-03 | -5.27 | positive regulation of nitric oxide biosynthetic process | biological process | GO:0045429 | 39 | 2 | 18204 | 50 |
APOE,CLU |
5.134e-03 | -5.27 | olfactory lobe development | biological process | GO:0021988 | 39 | 2 | 18204 | 50 |
ATP1A2,ERBB4 |
5.134e-03 | -5.27 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 2 | 18204 | 50 |
RYR3,SLC1A2 |
5.198e-03 | -5.26 | RDX (radixin) | protein interactions | 5962 | 272 | 4 | 19454 | 50 |
MACF1,NEBL,MAPK10,ABLIM1 |
5.202e-03 | -5.26 | Gap junction | KEGG pathways | hsa04540 | 88 | 3 | 7161 | 29 |
PRKG1,PLCB1,ADCY2 |
5.202e-03 | -5.26 | Gap junction | KEGG pathways | ko04540 | 88 | 3 | 7161 | 29 |
PRKG1,PLCB1,ADCY2 |
5.227e-03 | -5.25 | chylomicron remnant | cellular component | GO:0034360 | 2 | 1 | 19108 | 50 |
APOE |
5.227e-03 | -5.25 | discoidal high-density lipoprotein particle | cellular component | GO:0034365 | 2 | 1 | 19108 | 50 |
APOE |
5.230e-03 | -5.25 | Laminin | gene3d domains | 2.10.25.10 | 226 | 4 | 14470 | 45 |
TNC,NRG3,LRP1B,NRXN1 |
5.265e-03 | -5.25 | FLOT2 (flotillin 2) | protein interactions | 2319 | 273 | 4 | 19454 | 50 |
PARD3,SOX5,SLC14A1,NTRK2 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | cGMP_dep_kinase | interpro domains | IPR002374 | 2 | 1 | 18521 | 50 |
PRKG1 |
5.392e-03 | -5.22 | Formin_Cappuccino_subfam | interpro domains | IPR001265 | 2 | 1 | 18521 | 50 |
FMN2 |
5.392e-03 | -5.22 | Clusterin_C | interpro domains | IPR016015 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | STKc_cGK | interpro domains | IPR035014 | 2 | 1 | 18521 | 50 |
PRKG1 |
5.392e-03 | -5.22 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 1 | 18521 | 50 |
PARD3 |
5.392e-03 | -5.22 | Clusterin-like | interpro domains | IPR000753 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | LRP1-like_beta_prop | interpro domains | IPR032485 | 2 | 1 | 18521 | 50 |
LRP1B |
5.392e-03 | -5.22 | Urea_transporter | interpro domains | IPR004937 | 2 | 1 | 18521 | 50 |
SLC14A1 |
5.392e-03 | -5.22 | PLC-beta_CS | interpro domains | IPR009535 | 2 | 1 | 18521 | 50 |
PLCB1 |
5.392e-03 | -5.22 | Clusterin_N | interpro domains | IPR016014 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Glyco_hydro_79 | interpro domains | IPR005199 | 2 | 1 | 18521 | 50 |
HPSE2 |
5.392e-03 | -5.22 | Contactin-1_2_Ig1 | interpro domains | IPR047102 | 2 | 1 | 18521 | 50 |
CNTN1 |
5.395e-03 | -5.22 | cyclic purine nucleotide metabolic process | biological process | GO:0052652 | 40 | 2 | 18204 | 50 |
ADCY2,RORA |
5.395e-03 | -5.22 | positive regulation of nitric oxide metabolic process | biological process | GO:1904407 | 40 | 2 | 18204 | 50 |
CLU,APOE |
5.402e-03 | -5.22 | prostate-adenoma | COSMIC cancer mutations | prostate-adenoma | 1634 | 11 | 16828 | 48 |
GPC5,NPAS3,PRKG1,LRP1B,PARD3,NEBL,MACF1,TRPM3,SOX5,DCLK2,ERBB4 |
5.409e-03 | -5.22 | heparanase activity | molecular function | GO:0030305 | 2 | 1 | 18094 | 49 |
HPSE2 |
5.409e-03 | -5.22 | cGMP-dependent protein kinase activity | molecular function | GO:0004692 | 2 | 1 | 18094 | 49 |
PRKG1 |
5.410e-03 | -5.22 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 5 | 10285 | 34 |
PLCB1,ADCY2,SLC1A2,CAMK2G,NRXN1 |
5.443e-03 | -5.21 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 4 | 10285 | 34 |
ADCY2,PLCB1,CAMK2G,SLC1A2 |
5.466e-03 | -5.21 | C2CD4B (C2 calcium dependent domain containing 4B) | protein interactions | 388125 | 43 | 2 | 19454 | 50 |
MACF1,LRP1B |
5.467e-03 | -5.21 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 4 | 16828 | 48 |
NAV2,MGAT4C,GLIS3,MACF1 |
5.475e-03 | -5.21 | NEFM (neurofilament medium chain) | protein interactions | 4741 | 139 | 3 | 19454 | 50 |
TNIK,GFAP,APOE |
5.486e-03 | -5.21 | negative regulation of monocyte extravasation | biological process | GO:2000438 | 2 | 1 | 18204 | 50 |
PLCB1 |
5.486e-03 | -5.21 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 50 |
CST3 |
5.486e-03 | -5.21 | mesenchymal-epithelial cell signaling involved in prostate gland development | biological process | GO:0060739 | 2 | 1 | 18204 | 50 |
TNC |
5.486e-03 | -5.21 | establishment of planar polarity involved in nephron morphogenesis | biological process | GO:0072046 | 2 | 1 | 18204 | 50 |
ERBB4 |
5.486e-03 | -5.21 | regulation of neurofibrillary tangle assembly | biological process | GO:1902996 | 2 | 1 | 18204 | 50 |
CLU |
5.486e-03 | -5.21 | cellular response to fluoride | biological process | GO:1902618 | 2 | 1 | 18204 | 50 |
PLCB1 |
5.486e-03 | -5.21 | negative regulation of inositol phosphate biosynthetic process | biological process | GO:0010920 | 2 | 1 | 18204 | 50 |
PRKG1 |
5.486e-03 | -5.21 | phosphatidylinositol catabolic process | biological process | GO:0031161 | 2 | 1 | 18204 | 50 |
PLCB1 |
5.486e-03 | -5.21 | activation of meiosis involved in egg activation | biological process | GO:0060466 | 2 | 1 | 18204 | 50 |
PLCB1 |
5.486e-03 | -5.21 | lipid transport involved in lipid storage | biological process | GO:0010877 | 2 | 1 | 18204 | 50 |
APOE |
5.486e-03 | -5.21 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 50 |
CST3 |
5.500e-03 | -5.20 | Clusterin | pfam domains | PF01093 | 2 | 1 | 17795 | 49 |
CLU |
5.500e-03 | -5.20 | DUF5050 | pfam domains | PF16472 | 2 | 1 | 17795 | 49 |
LRP1B |
5.500e-03 | -5.20 | Glyco_hydro_79n | pfam domains | PF03662 | 2 | 1 | 17795 | 49 |
HPSE2 |
5.500e-03 | -5.20 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 1 | 17795 | 49 |
PARD3 |
5.500e-03 | -5.20 | DUF1154 | pfam domains | PF06631 | 2 | 1 | 17795 | 49 |
PLCB1 |
5.500e-03 | -5.20 | UT | pfam domains | PF03253 | 2 | 1 | 17795 | 49 |
SLC14A1 |
5.614e-03 | -5.18 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 15 | 16828 | 48 |
NPAS3,CTNND2,CAMK2G,RYR3,LRP1B,SORBS1,FMN2,ADCY2,TRPM3,MACF1,RORA,TNC,APOE,GLIS3,NAV2 |
5.614e-03 | -5.18 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 15 | 16828 | 48 |
LRP1B,SORBS1,FMN2,CTNND2,NPAS3,RYR3,CAMK2G,ADCY2,RORA,TNC,APOE,MACF1,TRPM3,NAV2,GLIS3 |
5.653e-03 | -5.18 | protein localization | biological process | GO:0008104 | 1954 | 12 | 18204 | 50 |
PARD3,FMN2,DCLK2,CAMK2G,MACF1,NRXN1,GFAP,CLU,ERBB4,LRP1B,TNIK,APOE |
5.658e-03 | -5.17 | sarcoplasmic reticulum membrane | cellular component | GO:0033017 | 43 | 2 | 19108 | 50 |
CAMK2G,RYR3 |
5.662e-03 | -5.17 | cyclic nucleotide metabolic process | biological process | GO:0009187 | 41 | 2 | 18204 | 50 |
ADCY2,RORA |
5.664e-03 | -5.17 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 39 | 16828 | 48 |
NEBL,ADCY2,CDH20,PARD3,PRKG1,DTNA,CAMK2G,CTNND2,GPC5,NPAS3,RFX4,NRG3,SOX5,CLU,LSAMP,ABLIM1,RORA,MACF1,HPSE2,TRPM3,MGAT4C,ATP1A2,PLCB1,SORBS1,GPM6A,TNIK,FMN2,GFAP,LRP1B,RYR3,ERBB4,NAV2,DGKG,TNC,NKAIN3,NTRK2,SLC1A2,CNTN1,NRXN1 |
5.697e-03 | -5.17 | amino acid transport | biological process | GO:0006865 | 132 | 3 | 18204 | 50 |
GFAP,NTRK2,SLC1A2 |
5.765e-03 | -5.16 | parotid | COSMIC cancer mutations | parotid | 578 | 6 | 16828 | 48 |
TNIK,NTRK2,LRP1B,CAMK2G,RYR3,ERBB4 |
5.817e-03 | -5.15 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 3 | 18204 | 50 |
ATP1A2,RYR3,PLCB1 |
5.840e-03 | -5.14 | cellular macromolecule localization | biological process | GO:0070727 | 1962 | 12 | 18204 | 50 |
PARD3,FMN2,DCLK2,ERBB4,CAMK2G,LRP1B,MACF1,TNIK,NRXN1,GFAP,APOE,CLU |
5.867e-03 | -5.14 | protein serine/threonine kinase activity | molecular function | GO:0004674 | 428 | 5 | 18094 | 49 |
TNIK,MAPK10,CAMK2G,DCLK2,PRKG1 |
5.935e-03 | -5.13 | regulation of amino acid transport | biological process | GO:0051955 | 42 | 2 | 18204 | 50 |
ATP1A2,PRKG1 |
5.935e-03 | -5.13 | Schwann cell development | biological process | GO:0014044 | 42 | 2 | 18204 | 50 |
PARD3,NTRK2 |
5.935e-03 | -5.13 | triglyceride homeostasis | biological process | GO:0070328 | 42 | 2 | 18204 | 50 |
APOE,RORA |
5.939e-03 | -5.13 | regulation of growth | biological process | GO:0040008 | 603 | 6 | 18204 | 50 |
MACF1,ERBB4,TNC,APOE,NRG3,PLCB1 |
5.946e-03 | -5.13 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 49 |
TRPM3,RYR3,GPM6A |
5.946e-03 | -5.12 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 48 |
TNIK,SORBS1,NTM,LRP1B,ADCY2 |
5.997e-03 | -5.12 | prostate | COSMIC cancer mutations | prostate | 13883 | 46 | 16828 | 48 |
NEBL,NTM,PRKG1,DTNA,GPC5,RFX4,NRG3,RORA,LSAMP,CLU,MACF1,HPSE2,ATP1A2,PITPNC1,TNIK,PLCB1,LRP1B,ERBB4,NAV2,GLIS3,SLC1A2,NKAIN3,APOE,TNC,NRXN1,ADCY2,CDH20,PARD3,NPAS3,CTNND2,DCLK2,SLC14A1,SLC4A4,SOX5,ABLIM1,TRPM3,MGAT4C,GFAP,FMN2,GPM6A,SORBS1,RYR3,DGKG,NTRK2,CNTN1,MSI2 |
6.037e-03 | -5.11 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 50 |
MACF1,ABLIM1,CAMK2G |
6.044e-03 | -5.11 | tau protein binding | molecular function | GO:0048156 | 43 | 2 | 18094 | 49 |
CLU,APOE |
6.087e-03 | -5.10 | femur | COSMIC cancer mutations | femur | 1197 | 9 | 16828 | 48 |
FMN2,SLC4A4,LRP1B,RYR3,HPSE2,GPC5,NAV2,ADCY2,NRG3 |
6.090e-03 | -5.10 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 7 | 18204 | 50 |
TRPM3,SLC4A4,RYR3,GPM6A,PLCB1,SLC1A2,ATP1A2 |
6.210e-03 | -5.08 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 45 |
CTNNA2 |
6.210e-03 | -5.08 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 45 |
RYR3 |
6.213e-03 | -5.08 | acylglycerol homeostasis | biological process | GO:0055090 | 43 | 2 | 18204 | 50 |
RORA,APOE |
6.234e-03 | -5.08 | EXTL2 (exostosin like glycosyltransferase 2) | protein interactions | 2135 | 46 | 2 | 19454 | 50 |
CLU,MGAT4C |
6.237e-03 | -5.08 | cell surface receptor protein tyrosine kinase signaling pathway | biological process | GO:0007169 | 428 | 5 | 18204 | 50 |
SORBS1,NRG3,PLCB1,ERBB4,NTRK2 |
6.391e-03 | -5.05 | MOB4 (MOB family member 4, phocein) | protein interactions | 25843 | 147 | 3 | 19454 | 50 |
TNIK,ABLIM1,CAMK2G |
6.420e-03 | -5.05 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 5 | 18204 | 50 |
APOE,NTRK2,NRXN1,SLC1A2,DTNA |
6.498e-03 | -5.04 | positive regulation of glucose transmembrane transport | biological process | GO:0010828 | 44 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
6.512e-03 | -5.03 | LRP2 (LDL receptor related protein 2) | protein interactions | 4036 | 148 | 3 | 19454 | 50 |
CLU,APOE,LRP1B |
6.590e-03 | -5.02 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 20 | 16828 | 48 |
NRXN1,MACF1,TRPM3,SOX5,LSAMP,GLIS3,NAV2,ERBB4,DGKG,RYR3,DTNA,GPC5,CTNND2,PLCB1,TNIK,PARD3,PRKG1,LRP1B,ADCY2,ATP1A2 |
6.640e-03 | -5.01 | bone-femur-chondrosarcoma | COSMIC cancer mutations | bone-femur-chondrosarcoma | 419 | 5 | 16828 | 48 |
LRP1B,NAV2,SLC4A4,HPSE2,ADCY2 |
6.676e-03 | -5.01 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 50 |
RYR3,GPM6A,ATP1A2,TRPM3,PLCB1,SLC4A4 |
6.702e-03 | -5.01 | neurotransmitter transport | biological process | GO:0006836 | 140 | 3 | 18204 | 50 |
SLC1A2,NRXN1,ATP1A2 |
6.772e-03 | -4.99 | HTRA1 (HtrA serine peptidase 1) | protein interactions | 5654 | 48 | 2 | 19454 | 50 |
MGAT4C,APOE |
6.788e-03 | -4.99 | acidic amino acid transport | biological process | GO:0015800 | 45 | 2 | 18204 | 50 |
SLC1A2,NTRK2 |
6.788e-03 | -4.99 | negative regulation of blood coagulation | biological process | GO:0030195 | 45 | 2 | 18204 | 50 |
APOE,PRKG1 |
6.817e-03 | -4.99 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 6 | 18094 | 49 |
TRPM3,SLC4A4,RYR3,ATP1A2,GPM6A,SLC1A2 |
6.875e-03 | -4.98 | transmembrane transport | biological process | GO:0055085 | 1264 | 9 | 18204 | 50 |
GFAP,ATP1A2,PLCB1,SLC1A2,SLC14A1,RYR3,GPM6A,SLC4A4,TRPM3 |
6.875e-03 | -4.98 | Ig_3 | pfam domains | PF13927 | 141 | 3 | 17795 | 49 |
CNTN1,NTM,LSAMP |
6.876e-03 | -4.98 | FORMIN | prints domains | PR00828 | 2 | 1 | 5227 | 18 |
FMN2 |
6.876e-03 | -4.98 | CGMPKINASE | prints domains | PR00104 | 2 | 1 | 5227 | 18 |
PRKG1 |
6.919e-03 | -4.97 | membrane raft | cellular component | GO:0045121 | 290 | 4 | 19108 | 50 |
ADCY2,SORBS1,ATP1A2,SLC1A2 |
6.969e-03 | -4.97 | neuron migration | biological process | GO:0001764 | 142 | 3 | 18204 | 50 |
PRKG1,GPM6A,NTRK2 |
6.969e-03 | -4.97 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 3 | 18204 | 50 |
APOE,SORBS1,SLC4A4 |
7.044e-03 | -4.96 | protein binding | molecular function | GO:0005515 | 13983 | 45 | 18094 | 49 |
NPAS3,SOX5,HPSE2,PARD3,GPC5,MSI2,ATP1A2,SLC1A2,CDH20,ABLIM1,SORBS1,PLCB1,NTRK2,CTNND2,CLU,LSAMP,CNTN1,GLIS3,CST3,GFAP,NRG3,RFX4,TNIK,CAMK2G,MACF1,SLC4A4,DTNA,TNC,NAV2,CTNNA2,PITPNC1,FMN2,NRXN1,NTM,LRP1B,ERBB4,RYR3,PRKG1,APOE,GPM6A,ADCY2,RORA,DCLK2,MAPK10,NEBL |
7.059e-03 | -4.95 | nitrogen compound transport | biological process | GO:0071705 | 1507 | 10 | 18204 | 50 |
SLC1A2,NTRK2,GFAP,APOE,CLU,FMN2,CAMK2G,SLC14A1,LRP1B,MACF1 |
7.084e-03 | -4.95 | negative regulation of hemostasis | biological process | GO:1900047 | 46 | 2 | 18204 | 50 |
APOE,PRKG1 |
7.084e-03 | -4.95 | receptor clustering | biological process | GO:0043113 | 46 | 2 | 18204 | 50 |
NRXN1,APOE |
7.086e-03 | -4.95 | membrane microdomain | cellular component | GO:0098857 | 292 | 4 | 19108 | 50 |
ADCY2,SORBS1,ATP1A2,SLC1A2 |
7.110e-03 | -4.95 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 13 | 16828 | 48 |
DCLK2,ERBB4,SOX5,SLC4A4,NTRK2,ATP1A2,ADCY2,LRP1B,PRKG1,GFAP,TNIK,DTNA,CAMK2G |
7.295e-03 | -4.92 | enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 48 |
MACF1,MGAT4C |
7.295e-03 | -4.92 | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 48 |
MGAT4C,MACF1 |
7.312e-03 | -4.92 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 50 |
ATP1A2,RYR3,GPM6A,PLCB1,SLC4A4,TRPM3 |
7.366e-03 | -4.91 | ion binding | molecular function | GO:0043167 | 6007 | 25 | 18094 | 49 |
ADCY2,RORA,APOE,GLIS3,PRKG1,MAPK10,DCLK2,PITPNC1,DGKG,RYR3,ERBB4,LRP1B,MGAT4C,NRXN1,SLC1A2,ATP1A2,NTRK2,NAV2,PLCB1,DTNA,ABLIM1,CAMK2G,TNIK,MACF1,PARD3 |
7.386e-03 | -4.91 | regulation of neuron migration | biological process | GO:2001222 | 47 | 2 | 18204 | 50 |
CTNNA2,NRG3 |
7.386e-03 | -4.91 | Schwann cell differentiation | biological process | GO:0014037 | 47 | 2 | 18204 | 50 |
PARD3,NTRK2 |
7.521e-03 | -4.89 | adult behavior | biological process | GO:0030534 | 146 | 3 | 18204 | 50 |
NRXN1,SLC1A2,ATP1A2 |
7.525e-03 | -4.89 | CEP19 (centrosomal protein 19) | protein interactions | 84984 | 156 | 3 | 19454 | 50 |
FMN2,PARD3,ABLIM1 |
7.542e-03 | -4.89 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 7 | 18204 | 50 |
ADCY2,RYR3,PRKG1,TNIK,MAPK10,ATP1A2,APOE |
7.601e-03 | -4.88 | CLa | smart domains | SM00035 | 2 | 1 | 9717 | 37 |
CLU |
7.601e-03 | -4.88 | CLb | smart domains | SM00030 | 2 | 1 | 9717 | 37 |
CLU |
7.617e-03 | -4.88 | FAM171B (family with sequence similarity 171 member B) | protein interactions | 165215 | 51 | 2 | 19454 | 50 |
PARD3,NTRK2 |
7.626e-03 | -4.88 | Melanogenesis | KEGG pathways | hsa04916 | 101 | 3 | 7161 | 29 |
PLCB1,ADCY2,CAMK2G |
7.626e-03 | -4.88 | Melanogenesis | KEGG pathways | ko04916 | 101 | 3 | 7161 | 29 |
CAMK2G,ADCY2,PLCB1 |
7.626e-03 | -4.88 | Retrograde endocannabinoid signaling | KEGG pathways | ko04723 | 101 | 3 | 7161 | 29 |
MAPK10,PLCB1,ADCY2 |
7.626e-03 | -4.88 | Retrograde endocannabinoid signaling | KEGG pathways | hsa04723 | 101 | 3 | 7161 | 29 |
MAPK10,PLCB1,ADCY2 |
7.646e-03 | -4.87 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 6 | 18204 | 50 |
SLC4A4,PLCB1,TRPM3,ATP1A2,GPM6A,RYR3 |
7.691e-03 | -4.87 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 50 |
NRXN1 |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | Lep (leptin) | protein interactions | 16846 | 3 | 1 | 19454 | 50 |
CLU |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | NRG3 (neuregulin 3) | protein interactions | 10718 | 3 | 1 | 19454 | 50 |
ERBB4 |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | Itgb1 (integrin subunit beta 1) | protein interactions | 24511 | 3 | 1 | 19454 | 50 |
TNC |
7.691e-03 | -4.87 | Lrrc7 (leucine rich repeat containing 7) | protein interactions | 117284 | 3 | 1 | 19454 | 50 |
CAMK2G |
7.749e-03 | -4.86 | purine ribonucleoside triphosphate binding | molecular function | GO:0035639 | 1804 | 11 | 18094 | 49 |
ATP1A2,PRKG1,ADCY2,CAMK2G,TNIK,ERBB4,DCLK2,NTRK2,DGKG,MAPK10,NAV2 |
7.790e-03 | -4.85 | calcium channel regulator activity | molecular function | GO:0005246 | 49 | 2 | 18094 | 49 |
PRKG1,NRXN1 |
7.832e-03 | -4.85 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 7 | 18204 | 50 |
TNC,RYR3,ADCY2,PLCB1,SLC1A2,RORA,ATP1A2 |
7.834e-03 | -4.85 | cAMP signaling pathway | KEGG pathways | hsa04024 | 198 | 4 | 7161 | 29 |
ADCY2,ATP1A2,CAMK2G,MAPK10 |
7.834e-03 | -4.85 | cAMP signaling pathway | KEGG pathways | ko04024 | 198 | 4 | 7161 | 29 |
ATP1A2,ADCY2,MAPK10,CAMK2G |
7.836e-03 | -4.85 | Glucagon signaling pathway | KEGG pathways | hsa04922 | 102 | 3 | 7161 | 29 |
ADCY2,PLCB1,CAMK2G |
7.836e-03 | -4.85 | Glucagon signaling pathway | KEGG pathways | ko04922 | 102 | 3 | 7161 | 29 |
CAMK2G,PLCB1,ADCY2 |
7.847e-03 | -4.85 | regulation of cell migration | biological process | GO:0030334 | 1061 | 8 | 18204 | 50 |
PLCB1,NRG3,APOE,TNC,ERBB4,CTNNA2,PRKG1,MACF1 |
7.909e-03 | -4.84 | SNAP91 (synaptosome associated protein 91) | protein interactions | 9892 | 52 | 2 | 19454 | 50 |
ERBB4,GPM6A |
8.007e-03 | -4.83 | negative regulation of coagulation | biological process | GO:0050819 | 49 | 2 | 18204 | 50 |
APOE,PRKG1 |
8.007e-03 | -4.83 | oligodendrocyte development | biological process | GO:0014003 | 49 | 2 | 18204 | 50 |
CNTN1,CLU |
8.012e-03 | -4.83 | skin-subungual-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-subungual-malignant_melanoma-acral_lentiginous | 144 | 3 | 16828 | 48 |
CDH20,MACF1,LRP1B |
8.021e-03 | -4.83 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 8 | 19454 | 50 |
PITPNC1,APOE,SORBS1,PARD3,CAMK2G,ABLIM1,NAV2,MACF1 |
8.045e-03 | -4.82 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 5 | 16828 | 48 |
CAMK2G,TNIK,NTRK2,ERBB4,PRKG1 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | SoHo_dom | interpro domains | IPR003127 | 3 | 1 | 18521 | 50 |
SORBS1 |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | TM_ErbB1 | interpro domains | IPR049328 | 3 | 1 | 18521 | 50 |
ERBB4 |
8.078e-03 | -4.82 | DGK_typeI_N_sf | interpro domains | IPR038199 | 3 | 1 | 18521 | 50 |
DGKG |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NTRK_LRRCT | interpro domains | IPR031635 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NTRK | interpro domains | IPR020777 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | Nav/unc-53 | interpro domains | IPR039041 | 3 | 1 | 18521 | 50 |
NAV2 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | DAG_kinase_typeI_N | interpro domains | IPR029477 | 3 | 1 | 18521 | 50 |
DGKG |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Neuregulin | interpro domains | IPR040180 | 3 | 1 | 18521 | 50 |
NRG3 |
8.078e-03 | -4.82 | MAPK_JNK | interpro domains | IPR008351 | 3 | 1 | 18521 | 50 |
MAPK10 |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | PLC-beta_C | interpro domains | IPR014815 | 3 | 1 | 18521 | 50 |
PLCB1 |
8.091e-03 | -4.82 | lipid binding | molecular function | GO:0008289 | 861 | 7 | 18094 | 49 |
PITPNC1,ATP1A2,APOE,RORA,PARD3,PLCB1,DGKG |
8.097e-03 | -4.82 | regulation of nervous system development | biological process | GO:0051960 | 456 | 5 | 18204 | 50 |
MACF1,GFAP,NTRK2,NRXN1,PARD3 |
8.103e-03 | -4.82 | JUN kinase activity | molecular function | GO:0004705 | 3 | 1 | 18094 | 49 |
MAPK10 |
8.103e-03 | -4.82 | epidermal growth factor receptor activity | molecular function | GO:0005006 | 3 | 1 | 18094 | 49 |
ERBB4 |
8.103e-03 | -4.82 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 49 |
SLC1A2 |
8.103e-03 | -4.82 | urea channel activity | molecular function | GO:0015265 | 3 | 1 | 18094 | 49 |
SLC14A1 |
8.103e-03 | -4.82 | neuregulin receptor activity | molecular function | GO:0038131 | 3 | 1 | 18094 | 49 |
ERBB4 |
8.103e-03 | -4.82 | alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity | molecular function | GO:0008454 | 3 | 1 | 18094 | 49 |
MGAT4C |
8.206e-03 | -4.80 | GOLGA6A (golgin A6 family member A) | protein interactions | 342096 | 53 | 2 | 19454 | 50 |
NEBL,GFAP |
8.218e-03 | -4.80 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | central nervous system morphogenesis | biological process | GO:0021551 | 3 | 1 | 18204 | 50 |
ERBB4 |
8.218e-03 | -4.80 | cellular response to ionomycin | biological process | GO:1904637 | 3 | 1 | 18204 | 50 |
PLCB1 |
8.218e-03 | -4.80 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 50 |
CTNNA2 |
8.218e-03 | -4.80 | trans-synaptic signaling by BDNF, modulating synaptic transmission | biological process | GO:0099183 | 3 | 1 | 18204 | 50 |
NTRK2 |
8.218e-03 | -4.80 | Schwann cell proliferation | biological process | GO:0014010 | 3 | 1 | 18204 | 50 |
GFAP |
8.218e-03 | -4.80 | positive regulation of Schwann cell proliferation | biological process | GO:0010625 | 3 | 1 | 18204 | 50 |
GFAP |
8.218e-03 | -4.80 | mammary placode formation | biological process | GO:0060596 | 3 | 1 | 18204 | 50 |
NRG3 |
8.218e-03 | -4.80 | positive regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032805 | 3 | 1 | 18204 | 50 |
APOE |
8.218e-03 | -4.80 | formin-nucleated actin cable organization | biological process | GO:0110009 | 3 | 1 | 18204 | 50 |
FMN2 |
8.218e-03 | -4.80 | formin-nucleated actin cable assembly | biological process | GO:0070649 | 3 | 1 | 18204 | 50 |
FMN2 |
8.218e-03 | -4.80 | protein targeting to lysosome involved in chaperone-mediated autophagy | biological process | GO:0061740 | 3 | 1 | 18204 | 50 |
CLU |
8.218e-03 | -4.80 | vagus nerve development | biological process | GO:0021564 | 3 | 1 | 18204 | 50 |
NAV2 |
8.218e-03 | -4.80 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 50 |
NRXN1 |
8.218e-03 | -4.80 | very-low-density lipoprotein particle clearance | biological process | GO:0034447 | 3 | 1 | 18204 | 50 |
APOE |
8.218e-03 | -4.80 | response to ionomycin | biological process | GO:1904636 | 3 | 1 | 18204 | 50 |
PLCB1 |
8.218e-03 | -4.80 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 50 |
ATP1A2 |
8.218e-03 | -4.80 | regulation of retrograde trans-synaptic signaling by endocanabinoid | biological process | GO:0099178 | 3 | 1 | 18204 | 50 |
PLCB1 |
8.218e-03 | -4.80 | meiotic chromosome movement towards spindle pole | biological process | GO:0016344 | 3 | 1 | 18204 | 50 |
FMN2 |
8.218e-03 | -4.80 | cardiac muscle thin filament assembly | biological process | GO:0071691 | 3 | 1 | 18204 | 50 |
NEBL |
8.218e-03 | -4.80 | immune complex clearance | biological process | GO:0002434 | 3 | 1 | 18204 | 50 |
CLU |
8.218e-03 | -4.80 | bud outgrowth involved in lung branching | biological process | GO:0060447 | 3 | 1 | 18204 | 50 |
TNC |
8.220e-03 | -4.80 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 4 | 16828 | 48 |
LRP1B,ERBB4,ATP1A2,TNIK |
8.238e-03 | -4.80 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 49 |
MACF1 |
8.238e-03 | -4.80 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 49 |
GPM6A |
8.238e-03 | -4.80 | DAG_kinase_N | pfam domains | PF14513 | 3 | 1 | 17795 | 49 |
DGKG |
8.238e-03 | -4.80 | TM_ErbB1 | pfam domains | PF21314 | 3 | 1 | 17795 | 49 |
ERBB4 |
8.238e-03 | -4.80 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | Sorb | pfam domains | PF02208 | 3 | 1 | 17795 | 49 |
SORBS1 |
8.238e-03 | -4.80 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | PLC-beta_C | pfam domains | PF08703 | 3 | 1 | 17795 | 49 |
PLCB1 |
8.238e-03 | -4.80 | LRRCT_2 | pfam domains | PF16920 | 3 | 1 | 17795 | 49 |
NTRK2 |
8.266e-03 | -4.80 | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | 48 | 2 | 16828 | 48 |
PARD3,RYR3 |
8.288e-03 | -4.79 | ear | COSMIC cancer mutations | ear | 624 | 6 | 16828 | 48 |
SLC14A1,NPAS3,TNC,MGAT4C,PRKG1,LRP1B |
8.317e-03 | -4.79 | NGF signalling via TRKA from the plasma membrane | REACTOME pathways | R-HSA-187037 | 387 | 5 | 10285 | 34 |
ERBB4,NTRK2,NRG3,ADCY2,CAMK2G |
8.327e-03 | -4.79 | vasodilation | biological process | GO:0042311 | 50 | 2 | 18204 | 50 |
APOE,PRKG1 |
8.343e-03 | -4.79 | CCDC57 (coiled-coil domain containing 57) | protein interactions | 284001 | 162 | 3 | 19454 | 50 |
DCLK2,GFAP,ABLIM1 |
8.343e-03 | -4.79 | DSCAM (DS cell adhesion molecule) | protein interactions | 1826 | 162 | 3 | 19454 | 50 |
GFAP,MACF1,CLU |
8.397e-03 | -4.78 | regulation of tube diameter | biological process | GO:0035296 | 152 | 3 | 18204 | 50 |
PRKG1,ATP1A2,APOE |
8.397e-03 | -4.78 | blood vessel diameter maintenance | biological process | GO:0097746 | 152 | 3 | 18204 | 50 |
ATP1A2,APOE,PRKG1 |
8.411e-03 | -4.78 | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | 9263 | 35 | 16828 | 48 |
CNTN1,APOE,TNC,NKAIN3,NTRK2,MSI2,NAV2,DGKG,ERBB4,GLIS3,LRP1B,SORBS1,FMN2,PLCB1,TNIK,RYR3,PITPNC1,MGAT4C,ATP1A2,CLU,LSAMP,RORA,SOX5,SLC4A4,MACF1,HPSE2,TRPM3,DCLK2,PRKG1,CTNND2,GPC5,CAMK2G,NEBL,CDH20,ADCY2 |
8.476e-03 | -4.77 | subungual | COSMIC cancer mutations | subungual | 147 | 3 | 16828 | 48 |
CDH20,MACF1,LRP1B |
8.549e-03 | -4.76 | regulation of tube size | biological process | GO:0035150 | 153 | 3 | 18204 | 50 |
APOE,ATP1A2,PRKG1 |
8.604e-03 | -4.76 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 26 | 18204 | 50 |
PITPNC1,NTRK2,DTNA,PLCB1,ADCY2,CNTN1,SORBS1,RORA,ATP1A2,MAPK10,NRG3,CTNND2,MACF1,PRKG1,DCLK2,PARD3,APOE,DGKG,TNIK,SLC1A2,ERBB4,TNC,CLU,GFAP,RYR3,FMN2 |
8.667e-03 | -4.75 | anchoring junction | cellular component | GO:0070161 | 902 | 7 | 19108 | 50 |
TNC,ATP1A2,CTNND2,SORBS1,PARD3,CTNNA2,CDH20 |
8.748e-03 | -4.74 | ZYX (zyxin) | protein interactions | 7791 | 316 | 4 | 19454 | 50 |
SORBS1,NEBL,MACF1,ABLIM1 |
8.771e-03 | -4.74 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 4 | 18204 | 50 |
GFAP,MACF1,NTRK2,NRXN1 |
8.814e-03 | -4.73 | SYN1 (synapsin I) | protein interactions | 6853 | 55 | 2 | 19454 | 50 |
GPM6A,CAMK2G |
8.814e-03 | -4.73 | PLCB1 (phospholipase C beta 1) | protein interactions | 23236 | 55 | 2 | 19454 | 50 |
PLCB1,PARD3 |
8.841e-03 | -4.73 | neuronal cell body | cellular component | GO:0043025 | 489 | 5 | 19108 | 50 |
APOE,GPM6A,ATP1A2,NRXN1,CTNND2 |
8.857e-03 | -4.73 | regeneration | biological process | GO:0031099 | 155 | 3 | 18204 | 50 |
GFAP,ERBB4,TNC |
8.869e-03 | -4.73 | mannosyl-glycoprotein N-acetylglucosaminyltransferases | BIOCYC pathways | META_PWY-7426 | 8 | 1 | 902 | 1 |
MGAT4C |
8.873e-03 | -4.72 | muscle system process | biological process | GO:0003012 | 297 | 4 | 18204 | 50 |
DTNA,PRKG1,ATP1A2,RYR3 |
8.873e-03 | -4.72 | carboxylic acid transport | biological process | GO:0046942 | 297 | 4 | 18204 | 50 |
APOE,GFAP,NTRK2,SLC1A2 |
8.903e-03 | -4.72 | endoplasmic reticulum lumen | cellular component | GO:0005788 | 312 | 4 | 19108 | 50 |
CST3,CLU,APOE,TNC |
8.917e-03 | -4.72 | SCLT1 (sodium channel and clathrin linker 1) | protein interactions | 132320 | 166 | 3 | 19454 | 50 |
NEBL,ABLIM1,ATP1A2 |
8.972e-03 | -4.71 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 3 | 18094 | 49 |
SLC1A2,ATP1A2,SLC4A4 |
8.976e-03 | -4.71 | organic acid transport | biological process | GO:0015849 | 298 | 4 | 18204 | 50 |
GFAP,APOE,SLC1A2,NTRK2 |
8.985e-03 | -4.71 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 26 | 18204 | 50 |
PARD3,HPSE2,SOX5,GPM6A,MACF1,PRKG1,SORBS1,RORA,ATP1A2,CNTN1,SLC4A4,GLIS3,NTRK2,NPAS3,PLCB1,FMN2,NRXN1,CLU,GFAP,ERBB4,GPC5,TNC,TNIK,SLC1A2,APOE,RFX4 |
9.013e-03 | -4.71 | protein autophosphorylation | biological process | GO:0046777 | 156 | 3 | 18204 | 50 |
NTRK2,TNIK,ERBB4 |
9.125e-03 | -4.70 | SEPTIN3 (septin 3) | protein interactions | 55964 | 56 | 2 | 19454 | 50 |
PRKG1,GPM6A |
9.125e-03 | -4.70 | L1CAM (L1 cell adhesion molecule) | protein interactions | 3897 | 56 | 2 | 19454 | 50 |
GPM6A,CNTN1 |
9.125e-03 | -4.70 | CSTL1 (cystatin like 1) | protein interactions | 128817 | 56 | 2 | 19454 | 50 |
APOE,CLU |
9.171e-03 | -4.69 | positive regulation of synaptic transmission | biological process | GO:0050806 | 157 | 3 | 18204 | 50 |
NTRK2,NRXN1,GFAP |
9.200e-03 | -4.69 | Retinoid metabolism and transport | REACTOME pathways | R-HSA-975634 | 44 | 2 | 10285 | 34 |
GPC5,APOE |
9.272e-03 | -4.68 | medullary_carcinoma | COSMIC cancer mutations | medullary_carcinoma | 290 | 4 | 16828 | 48 |
SLC1A2,GFAP,PRKG1,NRG3 |
9.272e-03 | -4.68 | thyroid-carcinoma-medullary_carcinoma | COSMIC cancer mutations | thyroid-carcinoma-medullary_carcinoma | 290 | 4 | 16828 | 48 |
SLC1A2,GFAP,PRKG1,NRG3 |
9.301e-03 | -4.68 | Diacylglycerol kinase alpha | gene3d domains | 1.10.238.110 | 3 | 1 | 14470 | 45 |
DGKG |
9.301e-03 | -4.68 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 45 |
CTNNA2 |
9.301e-03 | -4.68 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 45 |
RYR3 |
9.318e-03 | -4.68 | regulation of platelet activation | biological process | GO:0010543 | 53 | 2 | 18204 | 50 |
PRKG1,APOE |
9.361e-03 | -4.67 | PIAS2 (protein inhibitor of activated STAT 2) | protein interactions | 9063 | 169 | 3 | 19454 | 50 |
GFAP,SOX5,NAV2 |
9.399e-03 | -4.67 | positive regulation of MAPK cascade | biological process | GO:0043410 | 473 | 5 | 18204 | 50 |
NTRK2,TNIK,ERBB4,PLCB1,APOE |
9.401e-03 | -4.67 | postsynaptic density | cellular component | GO:0014069 | 317 | 4 | 19108 | 50 |
CTNND2,TNIK,ERBB4,NTRK2 |
9.442e-03 | -4.66 | NXPH3 (neurexophilin 3) | protein interactions | 11248 | 57 | 2 | 19454 | 50 |
NRXN1,CTNNA2 |
9.608e-03 | -4.65 | Non-integrin membrane-ECM interactions | REACTOME pathways | R-HSA-3000171 | 45 | 2 | 10285 | 34 |
NRXN1,TNC |
9.659e-03 | -4.64 | regulation of alcohol biosynthetic process | biological process | GO:1902930 | 54 | 2 | 18204 | 50 |
APOE,PRKG1 |
9.724e-03 | -4.63 | S_TKc | smart domains | SM00220 | 348 | 5 | 9717 | 37 |
DCLK2,MAPK10,PRKG1,CAMK2G,TNIK |
9.763e-03 | -4.63 | CILK1 (ciliogenesis associated kinase 1) | protein interactions | 22858 | 58 | 2 | 19454 | 50 |
MSI2,CAMK2G |
9.770e-03 | -4.63 | regulation of response to stimulus | biological process | GO:0048583 | 4104 | 19 | 18204 | 50 |
APOE,DGKG,NTRK2,TNIK,PLCB1,ERBB4,GPC5,TNC,SORBS1,CLU,RORA,NRXN1,MAPK10,CTNND2,MACF1,PRKG1,CTNNA2,CAMK2G,FMN2 |
9.819e-03 | -4.62 | positive regulation of neuron projection development | biological process | GO:0010976 | 161 | 3 | 18204 | 50 |
CNTN1,NTRK2,APOE |
9.819e-03 | -4.62 | negative regulation of supramolecular fiber organization | biological process | GO:1902904 | 161 | 3 | 18204 | 50 |
CLU,APOE,CTNNA2 |
9.833e-03 | -4.62 | ROR2 (receptor tyrosine kinase like orphan receptor 2) | protein interactions | 4920 | 327 | 4 | 19454 | 50 |
DTNA,TNIK,SORBS1,PARD3 |
9.883e-03 | -4.62 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 6 | 16828 | 48 |
ERBB4,DCLK2,TNIK,NTRK2,PRKG1,CAMK2G |
9.954e-03 | -4.61 | calcium ion binding | molecular function | GO:0005509 | 683 | 6 | 18094 | 49 |
DGKG,RYR3,MACF1,LRP1B,PLCB1,NRXN1 |
1.001e-02 | -4.60 | intermembrane lipid transfer | biological process | GO:0120009 | 55 | 2 | 18204 | 50 |
PITPNC1,APOE |
1.008e-02 | -4.60 | lipid transfer activity | molecular function | GO:0120013 | 56 | 2 | 18094 | 49 |
PITPNC1,APOE |
1.009e-02 | -4.60 | ADAM17 (ADAM metallopeptidase domain 17) | protein interactions | 6868 | 59 | 2 | 19454 | 50 |
CAMK2G,ERBB4 |
1.010e-02 | -4.59 | purine ribonucleotide binding | molecular function | GO:0032555 | 1871 | 11 | 18094 | 49 |
TNIK,CAMK2G,ADCY2,PRKG1,ATP1A2,NAV2,MAPK10,DGKG,NTRK2,DCLK2,ERBB4 |
1.012e-02 | -4.59 | Cholinergic synapse | KEGG pathways | hsa04725 | 112 | 3 | 7161 | 29 |
CAMK2G,ADCY2,PLCB1 |
1.019e-02 | -4.59 | macromolecule localization | biological process | GO:0033036 | 2376 | 13 | 18204 | 50 |
PITPNC1,TNIK,APOE,ERBB4,LRP1B,NRXN1,GFAP,CLU,FMN2,PARD3,CAMK2G,DCLK2,MACF1 |
1.024e-02 | -4.58 | CALML4 (calmodulin like 4) | protein interactions | 91860 | 4 | 1 | 19454 | 50 |
CAMK2G |
1.024e-02 | -4.58 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 50 |
RORA |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.024e-02 | -4.58 | IGKV@ (immunoglobulin kappa variable cluster) | protein interactions | 3519 | 4 | 1 | 19454 | 50 |
LRP1B |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.029e-02 | -4.58 | LRP1 (LDL receptor related protein 1) | protein interactions | 4035 | 175 | 3 | 19454 | 50 |
CLU,APOE,LRP1B |
1.030e-02 | -4.58 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 18 |
RYR3 |
1.030e-02 | -4.58 | NTKRECEPTOR | prints domains | PR01939 | 3 | 1 | 5227 | 18 |
NTRK2 |
1.030e-02 | -4.58 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 18 |
RORA |
1.030e-02 | -4.58 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 18 |
GPM6A |
1.030e-02 | -4.58 | JNKMAPKINASE | prints domains | PR01772 | 3 | 1 | 5227 | 18 |
MAPK10 |
1.031e-02 | -4.58 | dendritic spine | cellular component | GO:0043197 | 172 | 3 | 19108 | 50 |
ATP1A2,GPM6A,NTRK2 |
1.034e-02 | -4.57 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 24 | 18204 | 50 |
NTRK2,PLCB1,NPAS3,CNTN1,GLIS3,SLC4A4,SORBS1,RORA,GPM6A,MACF1,SOX5,PARD3,HPSE2,APOE,RFX4,TNIK,SLC1A2,ERBB4,GPC5,TNC,CLU,GFAP,NRXN1,FMN2 |
1.036e-02 | -4.57 | release of sequestered calcium ion into cytosol | biological process | GO:0051209 | 56 | 2 | 18204 | 50 |
PLCB1,RYR3 |
1.040e-02 | -4.57 | export from cell | biological process | GO:0140352 | 485 | 5 | 18204 | 50 |
SLC4A4,NTRK2,NRXN1,CAMK2G,ATP1A2 |
1.041e-02 | -4.57 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 4 | 16828 | 48 |
RYR3,MACF1,GPC5,PRKG1 |
1.042e-02 | -4.56 | BTN2A1 (butyrophilin subfamily 2 member A1) | protein interactions | 11120 | 60 | 2 | 19454 | 50 |
FMN2,PLCB1 |
1.043e-02 | -4.56 | intermediate-density lipoprotein particle | cellular component | GO:0034363 | 4 | 1 | 19108 | 50 |
APOE |
1.043e-02 | -4.56 | tenascin complex | cellular component | GO:0090733 | 4 | 1 | 19108 | 50 |
TNC |
1.043e-02 | -4.56 | internode region of axon | cellular component | GO:0033269 | 4 | 1 | 19108 | 50 |
PARD3 |
1.045e-02 | -4.56 | PLC beta mediated events | REACTOME pathways | R-HSA-112043 | 47 | 2 | 10285 | 34 |
ADCY2,PLCB1 |
1.045e-02 | -4.56 | cellular localization | biological process | GO:0051641 | 2660 | 14 | 18204 | 50 |
GFAP,CLU,NRXN1,SLC14A1,MACF1,FMN2,PARD3,CAMK2G,DCLK2,APOE,SLC1A2,TNIK,LRP1B,ERBB4 |
1.049e-02 | -4.56 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 50 |
GFAP,ATP1A2,SLC1A2 |
1.053e-02 | -4.55 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 2 | 5310 | 22 |
SLC1A2,CST3 |
1.053e-02 | -4.55 | side of membrane | cellular component | GO:0098552 | 715 | 6 | 19108 | 50 |
DTNA,LSAMP,CNTN1,NTM,GPC5,GFAP |
1.055e-02 | -4.55 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 43 |
GPM6A |
1.055e-02 | -4.55 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 43 |
CTNNA2 |
1.055e-02 | -4.55 | SOHO | prosite domains | PS50831 | 3 | 1 | 12186 | 43 |
SORBS1 |
1.055e-02 | -4.55 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 43 |
GPM6A |
1.059e-02 | -4.55 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 48 | 16828 | 48 |
RYR3,GPM6A,SORBS1,FMN2,GFAP,MGAT4C,MSI2,NTRK2,CNTN1,DGKG,CTNND2,NPAS3,PARD3,ADCY2,CDH20,TRPM3,SLC4A4,SOX5,ABLIM1,SLC14A1,DCLK2,TNIK,PLCB1,LRP1B,PITPNC1,ATP1A2,NRXN1,TNC,NKAIN3,APOE,SLC1A2,GLIS3,ERBB4,NAV2,DTNA,CAMK2G,GPC5,NTM,PRKG1,NEBL,MACF1,HPSE2,LSAMP,CLU,RORA,NRG3,RFX4,CST3 |
1.062e-02 | -4.54 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 3 | 7161 | 29 |
SLC1A2,ADCY2,PLCB1 |
1.062e-02 | -4.54 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 3 | 7161 | 29 |
PLCB1,ADCY2,SLC1A2 |
1.063e-02 | -4.54 | neuron spine | cellular component | GO:0044309 | 174 | 3 | 19108 | 50 |
NTRK2,ATP1A2,GPM6A |
1.072e-02 | -4.54 | negative regulation of sequestering of calcium ion | biological process | GO:0051283 | 57 | 2 | 18204 | 50 |
RYR3,PLCB1 |
1.072e-02 | -4.54 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 50 |
SLC1A2,ATP1A2 |
1.073e-02 | -4.53 | regulation of developmental growth | biological process | GO:0048638 | 314 | 4 | 18204 | 50 |
ERBB4,PLCB1,MACF1,APOE |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | PLC-beta_C_sf | interpro domains | IPR042531 | 4 | 1 | 18521 | 50 |
PLCB1 |
1.076e-02 | -4.53 | Glyco_transf_54 | interpro domains | IPR006759 | 4 | 1 | 18521 | 50 |
MGAT4C |
1.076e-02 | -4.53 | Tyr_kinase_EGF/ERB/XmrK_rcpt | interpro domains | IPR016245 | 4 | 1 | 18521 | 50 |
ERBB4 |
1.076e-02 | -4.53 | TRPM_tetra_sf | interpro domains | IPR037162 | 4 | 1 | 18521 | 50 |
TRPM3 |
1.076e-02 | -4.53 | ApoA_E | interpro domains | IPR000074 | 4 | 1 | 18521 | 50 |
APOE |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | PLC-beta_PH | interpro domains | IPR037862 | 4 | 1 | 18521 | 50 |
PLCB1 |
1.076e-02 | -4.53 | Nebulin_repeat | interpro domains | IPR000900 | 4 | 1 | 18521 | 50 |
NEBL |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | Ca/CaM-dep_prot_kinase-assoc | interpro domains | IPR013543 | 4 | 1 | 18521 | 50 |
CAMK2G |
1.076e-02 | -4.53 | TRPM_tetra | interpro domains | IPR032415 | 4 | 1 | 18521 | 50 |
TRPM3 |
1.076e-02 | -4.53 | PLC-beta | interpro domains | IPR016280 | 4 | 1 | 18521 | 50 |
PLCB1 |
1.076e-02 | -4.53 | PRKG1 (protein kinase cGMP-dependent 1) | protein interactions | 5592 | 61 | 2 | 19454 | 50 |
TNIK,PRKG1 |
1.077e-02 | -4.53 | oligodendroglioma_Grade_III | COSMIC cancer mutations | oligodendroglioma_Grade_III | 303 | 4 | 16828 | 48 |
GLIS3,MACF1,MGAT4C,NAV2 |
1.077e-02 | -4.53 | ERBB4 (erb-b2 receptor tyrosine kinase 4) | protein interactions | 2066 | 178 | 3 | 19454 | 50 |
NTRK2,NRG3,ERBB4 |
1.078e-02 | -4.53 | ribonucleotide binding | molecular function | GO:0032553 | 1888 | 11 | 18094 | 49 |
NAV2,MAPK10,DGKG,NTRK2,DCLK2,ERBB4,TNIK,CAMK2G,ADCY2,PRKG1,ATP1A2 |
1.079e-02 | -4.53 | very-low-density lipoprotein particle receptor binding | molecular function | GO:0070326 | 4 | 1 | 18094 | 49 |
APOE |
1.079e-02 | -4.53 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 49 |
RYR3 |
1.079e-02 | -4.53 | brain-derived neurotrophic factor binding | molecular function | GO:0048403 | 4 | 1 | 18094 | 49 |
NTRK2 |
1.080e-02 | -4.53 | ACTB (actin beta) | protein interactions | 60 | 958 | 7 | 19454 | 50 |
MACF1,NEBL,FMN2,DTNA,ABLIM1,SORBS1,APOE |
1.080e-02 | -4.53 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 50 |
DTNA,CTNNA2,CDH20 |
1.082e-02 | -4.53 | regulation of cell motility | biological process | GO:2000145 | 1122 | 8 | 18204 | 50 |
CTNNA2,PRKG1,MACF1,TNC,ERBB4,APOE,PLCB1,NRG3 |
1.082e-02 | -4.53 | positive regulation of cellular component organization | biological process | GO:0051130 | 1122 | 8 | 18204 | 50 |
CNTN1,GPM6A,MACF1,PLCB1,NRXN1,NTRK2,APOE,CLU |
1.084e-02 | -4.52 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 47 | 16828 | 48 |
NEBL,PRKG1,NTM,GPC5,DTNA,CAMK2G,NRG3,RFX4,RORA,LSAMP,CLU,MACF1,HPSE2,ATP1A2,PITPNC1,LRP1B,TNIK,PLCB1,NAV2,ERBB4,GLIS3,SLC1A2,APOE,NKAIN3,TNC,NRXN1,CDH20,ADCY2,PARD3,NPAS3,CTNND2,DCLK2,SLC14A1,ABLIM1,SOX5,SLC4A4,TRPM3,MGAT4C,GFAP,GPM6A,FMN2,SORBS1,RYR3,DGKG,CNTN1,NTRK2,MSI2 |
1.085e-02 | -4.52 | adrenal_cortical_adenoma | COSMIC cancer mutations | adrenal_cortical_adenoma | 161 | 3 | 16828 | 48 |
ADCY2,FMN2,LRP1B |
1.088e-02 | -4.52 | G-protein mediated events | REACTOME pathways | R-HSA-112040 | 48 | 2 | 10285 | 34 |
ADCY2,PLCB1 |
1.088e-02 | -4.52 | FCERI mediated MAPK activation | REACTOME pathways | R-HSA-2871796 | 265 | 4 | 10285 | 34 |
NRG3,ERBB4,MAPK10,CAMK2G |
1.094e-02 | -4.52 | negative regulation of protein kinase C signaling | biological process | GO:0090038 | 4 | 1 | 18204 | 50 |
DGKG |
1.094e-02 | -4.52 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | brain-derived neurotrophic factor receptor signaling pathway | biological process | GO:0031547 | 4 | 1 | 18204 | 50 |
NTRK2 |
1.094e-02 | -4.52 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 50 |
SOX5 |
1.094e-02 | -4.52 | response to fluoride | biological process | GO:1902617 | 4 | 1 | 18204 | 50 |
PLCB1 |
1.094e-02 | -4.52 | trans-synaptic signaling by BDNF | biological process | GO:0099191 | 4 | 1 | 18204 | 50 |
NTRK2 |
1.094e-02 | -4.52 | cardiac muscle tissue regeneration | biological process | GO:0061026 | 4 | 1 | 18204 | 50 |
ERBB4 |
1.094e-02 | -4.52 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | response to caloric restriction | biological process | GO:0061771 | 4 | 1 | 18204 | 50 |
APOE |
1.094e-02 | -4.52 | positive regulation of inclusion body assembly | biological process | GO:0090261 | 4 | 1 | 18204 | 50 |
CLU |
1.094e-02 | -4.52 | regulation of phospholipid efflux | biological process | GO:1902994 | 4 | 1 | 18204 | 50 |
APOE |
1.094e-02 | -4.52 | positive regulation of phospholipid efflux | biological process | GO:1902995 | 4 | 1 | 18204 | 50 |
APOE |
1.094e-02 | -4.52 | NMDA glutamate receptor clustering | biological process | GO:0097114 | 4 | 1 | 18204 | 50 |
APOE |
1.094e-02 | -4.52 | regulation of systemic arterial blood pressure by baroreceptor feedback | biological process | GO:0003025 | 4 | 1 | 18204 | 50 |
NAV2 |
1.094e-02 | -4.52 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 50 |
CST3 |
1.097e-02 | -4.51 | Glyco_transf_54 | pfam domains | PF04666 | 4 | 1 | 17795 | 49 |
MGAT4C |
1.097e-02 | -4.51 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 49 |
NKAIN3 |
1.097e-02 | -4.51 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | PH_14 | pfam domains | PF17787 | 4 | 1 | 17795 | 49 |
PLCB1 |
1.097e-02 | -4.51 | CaMKII_AD | pfam domains | PF08332 | 4 | 1 | 17795 | 49 |
CAMK2G |
1.097e-02 | -4.51 | Apolipoprotein | pfam domains | PF01442 | 4 | 1 | 17795 | 49 |
APOE |
1.097e-02 | -4.51 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 49 |
ABLIM1 |
1.097e-02 | -4.51 | TRPM_tetra | pfam domains | PF16519 | 4 | 1 | 17795 | 49 |
TRPM3 |
1.097e-02 | -4.51 | Nebulin | pfam domains | PF00880 | 4 | 1 | 17795 | 49 |
NEBL |
1.097e-02 | -4.51 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 49 |
MACF1 |
1.102e-02 | -4.51 | positive regulation of developmental growth | biological process | GO:0048639 | 168 | 3 | 18204 | 50 |
PLCB1,ERBB4,MACF1 |
1.110e-02 | -4.50 | ARHGAP29 (Rho GTPase activating protein 29) | protein interactions | 9411 | 62 | 2 | 19454 | 50 |
CAMK2G,PARD3 |
1.111e-02 | -4.50 | asymmetric synapse | cellular component | GO:0032279 | 333 | 4 | 19108 | 50 |
CTNND2,TNIK,ERBB4,NTRK2 |
1.117e-02 | -4.49 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 5 | 16828 | 48 |
PRKG1,GPM6A,GPC5,MACF1,RYR3 |
1.128e-02 | -4.48 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 34 |
ATP1A2,CAMK2G,RYR3 |
1.132e-02 | -4.48 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 41 | 16828 | 48 |
CNTN1,SLC1A2,TNC,NTRK2,NRXN1,DGKG,NAV2,ERBB4,GLIS3,LRP1B,TNIK,FMN2,GPM6A,PLCB1,SORBS1,RYR3,ATP1A2,MGAT4C,PITPNC1,RORA,ABLIM1,LSAMP,SOX5,SLC4A4,TRPM3,MACF1,HPSE2,DCLK2,CST3,RFX4,NRG3,PRKG1,PARD3,NTM,NPAS3,GPC5,CTNND2,DTNA,NEBL,CDH20,ADCY2 |
1.137e-02 | -4.48 | small molecule binding | molecular function | GO:0036094 | 6197 | 25 | 18094 | 49 |
MAPK10,DCLK2,ADCY2,RORA,APOE,GLIS3,PRKG1,DGKG,RYR3,LRP1B,ERBB4,MGAT4C,NRXN1,PITPNC1,NTRK2,NAV2,PLCB1,ABLIM1,DTNA,SLC1A2,ATP1A2,MACF1,PARD3,CAMK2G,TNIK |
1.138e-02 | -4.48 | Sorb | smart domains | SM00459 | 3 | 1 | 9717 | 37 |
SORBS1 |
1.138e-02 | -4.48 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 37 |
GPM6A |
1.142e-02 | -4.47 | cervix | COSMIC cancer mutations | cervix | 11793 | 41 | 16828 | 48 |
RFX4,NRG3,CST3,DCLK2,MACF1,HPSE2,TRPM3,SOX5,SLC4A4,LSAMP,ABLIM1,RORA,ADCY2,CDH20,NEBL,DTNA,GPC5,CTNND2,NPAS3,NTM,PARD3,PRKG1,GLIS3,NAV2,DGKG,ERBB4,NRXN1,NTRK2,TNC,SLC1A2,CNTN1,PITPNC1,MGAT4C,ATP1A2,RYR3,SORBS1,PLCB1,FMN2,GPM6A,TNIK,LRP1B |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.144e-02 | -4.47 | PRPH (peripherin) | protein interactions | 5630 | 182 | 3 | 19454 | 50 |
GFAP,SORBS1,ABLIM1 |
1.144e-02 | -4.47 | NLGN2 (neuroligin 2) | protein interactions | 57555 | 63 | 2 | 19454 | 50 |
NRXN1,CLU |
1.145e-02 | -4.47 | protein localization to synapse | biological process | GO:0035418 | 59 | 2 | 18204 | 50 |
NRXN1,ERBB4 |
1.145e-02 | -4.47 | ALB (albumin) | protein interactions | 213 | 342 | 4 | 19454 | 50 |
APOE,CST3,DGKG,GFAP |
1.163e-02 | -4.45 | back | COSMIC cancer mutations | back | 310 | 4 | 16828 | 48 |
TNIK,ATP1A2,ERBB4,LRP1B |
1.179e-02 | -4.44 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 50 |
DTNA,GFAP |
1.182e-02 | -4.44 | regulation of smooth muscle contraction | biological process | GO:0006940 | 60 | 2 | 18204 | 50 |
ATP1A2,PRKG1 |
1.182e-02 | -4.44 | regulation of glucose import | biological process | GO:0046324 | 60 | 2 | 18204 | 50 |
SLC1A2,SORBS1 |
1.182e-02 | -4.44 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 50 |
ATP1A2,SLC4A4 |
1.182e-02 | -4.44 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 2 | 18204 | 50 |
ATP1A2,NTRK2 |
1.194e-02 | -4.43 | Neurotrophin signaling pathway | KEGG pathways | ko04722 | 119 | 3 | 7161 | 29 |
NTRK2,CAMK2G,MAPK10 |
1.194e-02 | -4.43 | Neurotrophin signaling pathway | KEGG pathways | hsa04722 | 119 | 3 | 7161 | 29 |
NTRK2,CAMK2G,MAPK10 |
1.204e-02 | -4.42 | protein phosphorylation | biological process | GO:0006468 | 503 | 5 | 18204 | 50 |
PRKG1,MAPK10,TNIK,NTRK2,ERBB4 |
1.204e-02 | -4.42 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 48 |
SLC4A4,LRP1B,CNTN1,LSAMP,RYR3 |
1.204e-02 | -4.42 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 48 |
RYR3,LSAMP,CNTN1,LRP1B,SLC4A4 |
1.205e-02 | -4.42 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 48 | 16828 | 48 |
NAV2,ERBB4,GLIS3,SLC1A2,APOE,TNC,NKAIN3,NRXN1,ATP1A2,PITPNC1,LRP1B,TNIK,PLCB1,CST3,NRG3,RFX4,RORA,LSAMP,CLU,MACF1,HPSE2,NEBL,PRKG1,NTM,GPC5,CAMK2G,DTNA,DGKG,CNTN1,NTRK2,MSI2,MGAT4C,GFAP,FMN2,SORBS1,GPM6A,RYR3,DCLK2,SLC14A1,ABLIM1,SLC4A4,SOX5,TRPM3,CDH20,ADCY2,PARD3,NPAS3,CTNND2 |
1.216e-02 | -4.41 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | REACTOME pathways | R-HSA-112314 | 146 | 3 | 10285 | 34 |
ADCY2,PLCB1,CAMK2G |
1.220e-02 | -4.41 | regulation of glycoprotein metabolic process | biological process | GO:1903018 | 61 | 2 | 18204 | 50 |
CST3,PLCB1 |
1.222e-02 | -4.40 | Signaling by ERBB2 | REACTOME pathways | R-HSA-1227986 | 51 | 2 | 10285 | 34 |
ERBB4,NRG3 |
1.225e-02 | -4.40 | transmembrane receptor protein tyrosine kinase activity | molecular function | GO:0004714 | 62 | 2 | 18094 | 49 |
NTRK2,ERBB4 |
1.230e-02 | -4.40 | regulation of lipid metabolic process | biological process | GO:0019216 | 327 | 4 | 18204 | 50 |
SORBS1,RORA,APOE,PRKG1 |
1.234e-02 | -4.39 | salivary_gland-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma-adenoid_cystic_carcinoma | 488 | 5 | 16828 | 48 |
RORA,PRKG1,MGAT4C,CTNND2,RYR3 |
1.238e-02 | -4.39 | TRPM, tetramerisation domain | gene3d domains | 1.20.5.1010 | 4 | 1 | 14470 | 45 |
TRPM3 |
1.238e-02 | -4.39 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 45 |
MACF1 |
1.238e-02 | -4.39 | Phospholipase C beta, distal C-terminal domain | gene3d domains | 1.20.1230.10 | 4 | 1 | 14470 | 45 |
PLCB1 |
1.238e-02 | -4.39 | - | gene3d domains | 2.30.29.240 | 4 | 1 | 14470 | 45 |
PLCB1 |
1.247e-02 | -4.38 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 37 |
CNTN1,NTM,NTRK2,LSAMP |
1.248e-02 | -4.38 | Vascular smooth muscle contraction | KEGG pathways | hsa04270 | 121 | 3 | 7161 | 29 |
PLCB1,ADCY2,PRKG1 |
1.248e-02 | -4.38 | Vascular smooth muscle contraction | KEGG pathways | ko04270 | 121 | 3 | 7161 | 29 |
PLCB1,ADCY2,PRKG1 |
1.249e-02 | -4.38 | central nervous system neuron differentiation | biological process | GO:0021953 | 176 | 3 | 18204 | 50 |
DCLK2,NTRK2,RORA |
1.250e-02 | -4.38 | MICB (MHC class I polypeptide-related sequence B) | protein interactions | 4277 | 66 | 2 | 19454 | 50 |
CLU,APOE |
1.253e-02 | -4.38 | postsynaptic specialization | cellular component | GO:0099572 | 345 | 4 | 19108 | 50 |
CTNND2,TNIK,ERBB4,NTRK2 |
1.271e-02 | -4.37 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 49 |
MACF1,CTNNA2,CDH20,CTNND2 |
1.279e-02 | -4.36 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 50 |
NRXN1 |
1.279e-02 | -4.36 | PPP1R17 (protein phosphatase 1 regulatory subunit 17) | protein interactions | 10842 | 5 | 1 | 19454 | 50 |
PRKG1 |
1.279e-02 | -4.36 | ADCYAP1R1 (ADCYAP receptor type I) | protein interactions | 117 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | CAMK2N2 (calcium/calmodulin dependent protein kinase II inhibitor 2) | protein interactions | 94032 | 5 | 1 | 19454 | 50 |
CAMK2G |
1.279e-02 | -4.36 | SLC10A3 (solute carrier family 10 member 3) | protein interactions | 8273 | 5 | 1 | 19454 | 50 |
SORBS1 |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.279e-02 | -4.36 | EPPIN (epididymal peptidase inhibitor) | protein interactions | 57119 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | NRG2 (neuregulin 2) | protein interactions | 9542 | 5 | 1 | 19454 | 50 |
ERBB4 |
1.279e-02 | -4.36 | RFX4 (regulatory factor X4) | protein interactions | 5992 | 5 | 1 | 19454 | 50 |
RFX4 |
1.279e-02 | -4.36 | RVS161 (amphiphysin-like protein RVS161) | protein interactions | 850367 | 5 | 1 | 19454 | 50 |
GFAP |
1.279e-02 | -4.36 | TRPM6 (transient receptor potential cation channel subfamily M member 6) | protein interactions | 140803 | 5 | 1 | 19454 | 50 |
TRPM3 |
1.281e-02 | -4.36 | skin-upper_back-malignant_melanoma | COSMIC cancer mutations | skin-upper_back-malignant_melanoma | 319 | 4 | 16828 | 48 |
CNTN1,ERBB4,MACF1,GPC5 |
1.287e-02 | -4.35 | SHC3 (SHC adaptor protein 3) | protein interactions | 53358 | 67 | 2 | 19454 | 50 |
NTRK2,ERBB4 |
1.287e-02 | -4.35 | PARD6A (par-6 family cell polarity regulator alpha) | protein interactions | 50855 | 67 | 2 | 19454 | 50 |
PARD3,PLCB1 |
1.287e-02 | -4.35 | ARMC1 (armadillo repeat containing 1) | protein interactions | 55156 | 67 | 2 | 19454 | 50 |
CNTN1,GPM6A |
1.298e-02 | -4.34 | regulation of nitric oxide biosynthetic process | biological process | GO:0045428 | 63 | 2 | 18204 | 50 |
APOE,CLU |
1.302e-02 | -4.34 | calcium- and calmodulin-dependent protein kinase complex | cellular component | GO:0005954 | 5 | 1 | 19108 | 50 |
CAMK2G |
1.302e-02 | -4.34 | neurofibrillary tangle | cellular component | GO:0097418 | 5 | 1 | 19108 | 50 |
CLU |
1.304e-02 | -4.34 | SH3_9 | pfam domains | PF14604 | 63 | 2 | 17795 | 49 |
NEBL,SORBS1 |
1.305e-02 | -4.34 | Platelet activation | KEGG pathways | hsa04611 | 123 | 3 | 7161 | 29 |
PRKG1,ADCY2,PLCB1 |
1.310e-02 | -4.34 | temporoparietal | COSMIC cancer mutations | temporoparietal | 61 | 2 | 16828 | 48 |
PARD3,RYR3 |
1.310e-02 | -4.34 | central_nervous_system-cerebrum-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-cerebrum-glioma-astrocytoma_Grade_IV | 61 | 2 | 16828 | 48 |
LRP1B,CNTN1 |
1.313e-02 | -4.33 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 9 | 18204 | 50 |
RYR3,SOX5,TNC,ERBB4,ATP1A2,SORBS1,PLCB1,SLC1A2,NTRK2 |
1.314e-02 | -4.33 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 6 | 18204 | 50 |
PLCB1,SLC4A4,TRPM3,ATP1A2,RYR3,GPM6A |
1.316e-02 | -4.33 | Metabolism of fat-soluble vitamins | REACTOME pathways | R-HSA-6806667 | 53 | 2 | 10285 | 34 |
GPC5,APOE |
1.316e-02 | -4.33 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 1 | 10285 | 34 |
SLC1A2 |
1.316e-02 | -4.33 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 1 | 10285 | 34 |
SLC1A2 |
1.324e-02 | -4.32 | PLCH1 (phospholipase C eta 1) | protein interactions | 23007 | 68 | 2 | 19454 | 50 |
NTRK2,PARD3 |
1.331e-02 | -4.32 | regulation of locomotion | biological process | GO:0040012 | 1164 | 8 | 18204 | 50 |
PLCB1,NRG3,APOE,TNC,ERBB4,CTNNA2,PRKG1,MACF1 |
1.332e-02 | -4.32 | human chr4q21.3 | chromosome location | human chr4q21.3 | 7 | 1 | 26134 | 50 |
MAPK10 |
1.336e-02 | -4.32 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 4 | 16828 | 48 |
LRP1B,SORBS1,NTM,ADCY2 |
1.337e-02 | -4.31 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 2 | 18204 | 50 |
CTNNA2,CTNND2 |
1.337e-02 | -4.31 | actin filament bundle assembly | biological process | GO:0051017 | 64 | 2 | 18204 | 50 |
SORBS1,FMN2 |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | EGF_Tenascin | interpro domains | IPR041161 | 5 | 1 | 18521 | 50 |
TNC |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.347e-02 | -4.31 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 1 | 18094 | 49 |
SLC1A2 |
1.347e-02 | -4.31 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 1 | 18094 | 49 |
NRXN1 |
1.347e-02 | -4.31 | syndecan binding | molecular function | GO:0045545 | 5 | 1 | 18094 | 49 |
TNC |
1.347e-02 | -4.31 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 1 | 18094 | 49 |
SLC1A2 |
1.347e-02 | -4.31 | neurotrophin receptor activity | molecular function | GO:0005030 | 5 | 1 | 18094 | 49 |
NTRK2 |
1.354e-02 | -4.30 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 6 | 19454 | 50 |
MSI2,CLU,NTRK2,GFAP,ERBB4,SLC1A2 |
1.363e-02 | -4.30 | Heparan sulfate/heparin (HS-GAG) metabolism | REACTOME pathways | R-HSA-1638091 | 54 | 2 | 10285 | 34 |
GPC5,HPSE2 |
1.366e-02 | -4.29 | stem cell differentiation | biological process | GO:0048863 | 182 | 3 | 18204 | 50 |
GPM6A,MSI2,ERBB4 |
1.366e-02 | -4.29 | response to prostaglandin D | biological process | GO:0071798 | 5 | 1 | 18204 | 50 |
TNC |
1.366e-02 | -4.29 | positive regulation of dendritic spine maintenance | biological process | GO:1902952 | 5 | 1 | 18204 | 50 |
APOE |
1.366e-02 | -4.29 | AMPA glutamate receptor clustering | biological process | GO:0097113 | 5 | 1 | 18204 | 50 |
APOE |
1.366e-02 | -4.29 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 50 |
ATP1A2 |
1.366e-02 | -4.29 | ERBB2-ERBB4 signaling pathway | biological process | GO:0038135 | 5 | 1 | 18204 | 50 |
ERBB4 |
1.366e-02 | -4.29 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 50 |
NRXN1 |
1.366e-02 | -4.29 | cellular response to prostaglandin D stimulus | biological process | GO:0071799 | 5 | 1 | 18204 | 50 |
TNC |
1.366e-02 | -4.29 | glossopharyngeal nerve development | biological process | GO:0021563 | 5 | 1 | 18204 | 50 |
NAV2 |
1.366e-02 | -4.29 | chylomicron remnant clearance | biological process | GO:0034382 | 5 | 1 | 18204 | 50 |
APOE |
1.366e-02 | -4.29 | central nervous system myelin maintenance | biological process | GO:0032286 | 5 | 1 | 18204 | 50 |
CLU |
1.366e-02 | -4.29 | negative regulation of glutamate secretion | biological process | GO:0014050 | 5 | 1 | 18204 | 50 |
PRKG1 |
1.366e-02 | -4.29 | synaptic signaling via neuropeptide | biological process | GO:0099538 | 5 | 1 | 18204 | 50 |
NTRK2 |
1.366e-02 | -4.29 | polar body extrusion after meiotic divisions | biological process | GO:0040038 | 5 | 1 | 18204 | 50 |
FMN2 |
1.366e-02 | -4.29 | glutamate receptor clustering | biological process | GO:0097688 | 5 | 1 | 18204 | 50 |
APOE |
1.366e-02 | -4.29 | activation of meiosis | biological process | GO:0090427 | 5 | 1 | 18204 | 50 |
PLCB1 |
1.369e-02 | -4.29 | EGF_Tenascin | pfam domains | PF18720 | 5 | 1 | 17795 | 49 |
TNC |
1.369e-02 | -4.29 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 49 |
PITPNC1 |
1.369e-02 | -4.29 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 49 |
CTNNA2 |
1.369e-02 | -4.29 | main axon | cellular component | GO:0044304 | 68 | 2 | 19108 | 50 |
SLC1A2,PARD3 |
1.371e-02 | -4.29 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 18 |
CTNNA2 |
1.377e-02 | -4.29 | positive regulation of synapse assembly | biological process | GO:0051965 | 65 | 2 | 18204 | 50 |
NRXN1,NTRK2 |
1.377e-02 | -4.29 | long-term synaptic potentiation | biological process | GO:0060291 | 65 | 2 | 18204 | 50 |
NTRK2,GFAP |
1.377e-02 | -4.29 | regulation of nitric oxide metabolic process | biological process | GO:0080164 | 65 | 2 | 18204 | 50 |
APOE,CLU |
1.377e-02 | -4.29 | apoptotic mitochondrial changes | biological process | GO:0008637 | 65 | 2 | 18204 | 50 |
CLU,ERBB4 |
1.389e-02 | -4.28 | regulation of Wnt signaling pathway | biological process | GO:0030111 | 339 | 4 | 18204 | 50 |
CTNND2,MACF1,APOE,GPC5 |
1.399e-02 | -4.27 | PCDH20 (protocadherin 20) | protein interactions | 64881 | 70 | 2 | 19454 | 50 |
MGAT4C,CTNNA2 |
1.399e-02 | -4.27 | DUSP10 (dual specificity phosphatase 10) | protein interactions | 11221 | 70 | 2 | 19454 | 50 |
ERBB4,MAPK10 |
1.399e-02 | -4.27 | MTMR9 (myotubularin related protein 9) | protein interactions | 66036 | 70 | 2 | 19454 | 50 |
CLU,ERBB4 |
1.404e-02 | -4.27 | NEBULIN | prosite domains | PS51216 | 4 | 1 | 12186 | 43 |
NEBL |
1.406e-02 | -4.26 | upper_back | COSMIC cancer mutations | upper_back | 328 | 4 | 16828 | 48 |
CNTN1,ERBB4,GPC5,MACF1 |
1.407e-02 | -4.26 | RAB35 (RAB35, member RAS oncogene family) | protein interactions | 11021 | 559 | 5 | 19454 | 50 |
PARD3,PLCB1,FMN2,MACF1,DTNA |
1.414e-02 | -4.26 | PIK3R3 (phosphoinositide-3-kinase regulatory subunit 3) | protein interactions | 8503 | 197 | 3 | 19454 | 50 |
ERBB4,NTRK2,NEBL |
1.418e-02 | -4.26 | ERBB signaling pathway | biological process | GO:0038127 | 66 | 2 | 18204 | 50 |
ERBB4,NRG3 |
1.418e-02 | -4.26 | cardiac muscle cell development | biological process | GO:0055013 | 66 | 2 | 18204 | 50 |
NEBL,PRKG1 |
1.424e-02 | -4.25 | EGF | pfam domains | PF00008 | 66 | 2 | 17795 | 49 |
LRP1B,NRXN1 |
1.425e-02 | -4.25 | DNAJC5 (DnaJ heat shock protein family (Hsp40) member C5) | protein interactions | 80331 | 365 | 4 | 19454 | 50 |
DTNA,CLU,PARD3,MACF1 |
1.425e-02 | -4.25 | skin-ear-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-ear-carcinoma-squamous_cell_carcinoma | 506 | 5 | 16828 | 48 |
PRKG1,TNC,MGAT4C,SLC14A1,NPAS3 |
1.426e-02 | -4.25 | purine nucleotide binding | molecular function | GO:0017076 | 1964 | 11 | 18094 | 49 |
DCLK2,ERBB4,MAPK10,NAV2,NTRK2,DGKG,PRKG1,ATP1A2,TNIK,ADCY2,CAMK2G |
1.435e-02 | -4.24 | skin-ankle-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-ankle-malignant_melanoma-acral_lentiginous | 330 | 4 | 16828 | 48 |
PLCB1,ERBB4,PARD3,NRG3 |
1.437e-02 | -4.24 | AKR7L (aldo-keto reductase family 7 like (gene/pseudogene)) | protein interactions | 246181 | 71 | 2 | 19454 | 50 |
PARD3,MACF1 |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.437e-02 | -4.24 | Gastrin-CREB signalling pathway via PKC and MAPK | REACTOME pathways | R-HSA-881907 | 443 | 5 | 10285 | 34 |
CAMK2G,PLCB1,NRG3,DGKG,ERBB4 |
1.450e-02 | -4.23 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 4 | 16828 | 48 |
ADCY2,LRP1B,SORBS1,NTM |
1.458e-02 | -4.23 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 47 | 16828 | 48 |
SLC14A1,DCLK2,TRPM3,ABLIM1,SOX5,SLC4A4,CDH20,ADCY2,NPAS3,CTNND2,PARD3,DGKG,MSI2,CNTN1,NTRK2,MGAT4C,RYR3,GFAP,FMN2,GPM6A,SORBS1,NRG3,RFX4,CST3,HPSE2,MACF1,RORA,LSAMP,CLU,NEBL,GPC5,CAMK2G,PRKG1,NTM,GLIS3,ERBB4,NAV2,NRXN1,SLC1A2,APOE,NKAIN3,TNC,ATP1A2,PITPNC1,LRP1B,PLCB1,TNIK |
1.459e-02 | -4.23 | cholesterol transport | biological process | GO:0030301 | 67 | 2 | 18204 | 50 |
APOE,CLU |
1.466e-02 | -4.22 | CH | pfam domains | PF00307 | 67 | 2 | 17795 | 49 |
MACF1,NAV2 |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | 14773 | 47 | 16828 | 48 |
TRPM3,ABLIM1,SOX5,SLC4A4,SLC14A1,DCLK2,CTNND2,NPAS3,PARD3,CDH20,ADCY2,MSI2,CNTN1,NTRK2,DGKG,RYR3,FMN2,GPM6A,SORBS1,GFAP,MGAT4C,MACF1,HPSE2,LSAMP,CLU,RORA,NRG3,RFX4,CST3,GPC5,DTNA,CAMK2G,PRKG1,NTM,NEBL,NRXN1,TNC,APOE,SLC1A2,GLIS3,ERBB4,NAV2,LRP1B,TNIK,PLCB1,PITPNC1,ATP1A2 |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | 14773 | 47 | 16828 | 48 |
TNIK,PLCB1,LRP1B,PITPNC1,ATP1A2,NRXN1,TNC,APOE,SLC1A2,GLIS3,NAV2,ERBB4,CAMK2G,DTNA,GPC5,NTM,PRKG1,NEBL,HPSE2,MACF1,CLU,LSAMP,RORA,NRG3,RFX4,CST3,RYR3,SORBS1,GPM6A,FMN2,GFAP,MGAT4C,MSI2,NTRK2,CNTN1,DGKG,CTNND2,NPAS3,PARD3,ADCY2,CDH20,TRPM3,SLC4A4,SOX5,ABLIM1,SLC14A1,DCLK2 |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 14773 | 47 | 16828 | 48 |
DGKG,CNTN1,NTRK2,MSI2,MGAT4C,GPM6A,FMN2,SORBS1,GFAP,RYR3,DCLK2,SLC14A1,ABLIM1,SLC4A4,SOX5,TRPM3,CDH20,ADCY2,PARD3,CTNND2,NPAS3,NAV2,ERBB4,GLIS3,TNC,APOE,SLC1A2,NRXN1,PITPNC1,ATP1A2,LRP1B,PLCB1,TNIK,CST3,RFX4,NRG3,LSAMP,CLU,RORA,HPSE2,MACF1,NEBL,PRKG1,NTM,GPC5,CAMK2G,DTNA |
1.470e-02 | -4.22 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | 14773 | 47 | 16828 | 48 |
SOX5,SLC4A4,ABLIM1,TRPM3,DCLK2,SLC14A1,PARD3,CTNND2,NPAS3,ADCY2,CDH20,NTRK2,CNTN1,MSI2,DGKG,GPM6A,FMN2,SORBS1,GFAP,RYR3,MGAT4C,LSAMP,CLU,RORA,HPSE2,MACF1,CST3,RFX4,NRG3,NTM,PRKG1,DTNA,CAMK2G,GPC5,NEBL,TNC,APOE,SLC1A2,NRXN1,NAV2,ERBB4,GLIS3,TNIK,PLCB1,LRP1B,PITPNC1,ATP1A2 |
1.474e-02 | -4.22 | classic | COSMIC cancer mutations | classic | 14774 | 47 | 16828 | 48 |
PARD3,NPAS3,CTNND2,ADCY2,CDH20,SLC4A4,SOX5,ABLIM1,TRPM3,DCLK2,SLC14A1,GFAP,FMN2,SORBS1,GPM6A,RYR3,MGAT4C,NTRK2,CNTN1,MSI2,DGKG,NTM,PRKG1,CAMK2G,DTNA,GPC5,NEBL,RORA,CLU,LSAMP,HPSE2,MACF1,CST3,NRG3,RFX4,TNIK,PLCB1,LRP1B,ATP1A2,PITPNC1,SLC1A2,APOE,TNC,NRXN1,ERBB4,NAV2,GLIS3 |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.476e-02 | -4.22 | Ppp1cb (protein phosphatase 1 catalytic subunit beta) | protein interactions | 19046 | 72 | 2 | 19454 | 50 |
PARD3,ABLIM1 |
1.490e-02 | -4.21 | medulla | COSMIC cancer mutations | medulla | 14778 | 47 | 16828 | 48 |
PITPNC1,ATP1A2,LRP1B,PLCB1,TNIK,GLIS3,ERBB4,NAV2,NRXN1,APOE,TNC,SLC1A2,NEBL,GPC5,DTNA,CAMK2G,PRKG1,NTM,NRG3,RFX4,CST3,MACF1,HPSE2,CLU,LSAMP,RORA,MGAT4C,RYR3,SORBS1,FMN2,GPM6A,GFAP,DGKG,MSI2,CNTN1,NTRK2,CDH20,ADCY2,CTNND2,NPAS3,PARD3,SLC14A1,DCLK2,TRPM3,ABLIM1,SOX5,SLC4A4 |
1.495e-02 | -4.20 | desmoplastic | COSMIC cancer mutations | desmoplastic | 14779 | 47 | 16828 | 48 |
DGKG,NTRK2,CNTN1,MSI2,MGAT4C,GFAP,FMN2,GPM6A,SORBS1,RYR3,DCLK2,SLC14A1,SOX5,SLC4A4,ABLIM1,TRPM3,ADCY2,CDH20,PARD3,NPAS3,CTNND2,NAV2,ERBB4,GLIS3,SLC1A2,APOE,TNC,NRXN1,ATP1A2,PITPNC1,PLCB1,TNIK,LRP1B,CST3,NRG3,RFX4,RORA,CLU,LSAMP,MACF1,HPSE2,NEBL,NTM,PRKG1,CAMK2G,DTNA,GPC5 |
1.501e-02 | -4.20 | actin filament bundle organization | biological process | GO:0061572 | 68 | 2 | 18204 | 50 |
FMN2,SORBS1 |
1.502e-02 | -4.20 | regulation of protein metabolic process | biological process | GO:0051246 | 2218 | 12 | 18204 | 50 |
ERBB4,RFX4,APOE,TNIK,NTRK2,PLCB1,MSI2,FMN2,PARD3,CLU,CST3,GFAP |
1.510e-02 | -4.19 | regulation of lipid biosynthetic process | biological process | GO:0046890 | 189 | 3 | 18204 | 50 |
APOE,PRKG1,SORBS1 |
1.512e-02 | -4.19 | neuron to neuron synapse | cellular component | GO:0098984 | 365 | 4 | 19108 | 50 |
CTNND2,NTRK2,TNIK,ERBB4 |
1.514e-02 | -4.19 | Dopaminergic synapse | KEGG pathways | ko04728 | 130 | 3 | 7161 | 29 |
PLCB1,CAMK2G,MAPK10 |
1.514e-02 | -4.19 | Dopaminergic synapse | KEGG pathways | hsa04728 | 130 | 3 | 7161 | 29 |
MAPK10,CAMK2G,PLCB1 |
1.515e-02 | -4.19 | NEBU | smart domains | SM00227 | 4 | 1 | 9717 | 37 |
NEBL |
1.526e-02 | -4.18 | cellular response to lipid | biological process | GO:0071396 | 534 | 5 | 18204 | 50 |
RORA,ATP1A2,ADCY2,TNC,PLCB1 |
1.528e-02 | -4.18 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 47 | 16828 | 48 |
LRP1B,PLCB1,TNIK,ATP1A2,NRXN1,APOE,TNC,NKAIN3,SLC1A2,GLIS3,NAV2,ERBB4,GPC5,DTNA,CAMK2G,PRKG1,NTM,NEBL,HPSE2,MACF1,CLU,LSAMP,RORA,RFX4,NRG3,CST3,RYR3,SORBS1,FMN2,GPM6A,GFAP,MGAT4C,MSI2,CNTN1,NTRK2,DGKG,CTNND2,NPAS3,PARD3,CDH20,ADCY2,TRPM3,ABLIM1,SOX5,SLC4A4,SLC14A1,DCLK2 |
1.529e-02 | -4.18 | Endocrine and other factor-regulated calcium reabsorption | KEGG pathways | hsa04961 | 47 | 2 | 7161 | 29 |
ATP1A2,PLCB1 |
1.529e-02 | -4.18 | Endocrine and other factor-regulated calcium reabsorption | KEGG pathways | ko04961 | 47 | 2 | 7161 | 29 |
PLCB1,ATP1A2 |
1.531e-02 | -4.18 | pallium development | biological process | GO:0021543 | 190 | 3 | 18204 | 50 |
PLCB1,DCLK2,NTRK2 |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 50 |
NRXN1 |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | CIBAR2 (CBY1 interacting BAR domain containing 2) | protein interactions | 339145 | 6 | 1 | 19454 | 50 |
CAMK2G |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | Rara (retinoic acid receptor, alpha) | protein interactions | 19401 | 6 | 1 | 19454 | 50 |
MAPK10 |
1.532e-02 | -4.18 | NRG4 (neuregulin 4) | protein interactions | 145957 | 6 | 1 | 19454 | 50 |
ERBB4 |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | LCAT (lecithin-cholesterol acyltransferase) | protein interactions | 3931 | 6 | 1 | 19454 | 50 |
APOE |
1.532e-02 | -4.18 | LBX2 (ladybird homeobox 2) | protein interactions | 85474 | 6 | 1 | 19454 | 50 |
GFAP |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | FXYD7 (FXYD domain containing ion transport regulator 7) | protein interactions | 53822 | 6 | 1 | 19454 | 50 |
APOE |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Taok2 (TAO kinase 2) | protein interactions | 381921 | 6 | 1 | 19454 | 50 |
CLU |
1.532e-02 | -4.18 | Zbtb2 (zinc finger and BTB domain containing 2) | protein interactions | 381990 | 6 | 1 | 19454 | 50 |
SORBS1 |
1.532e-02 | -4.18 | ADCY1 (adenylate cyclase 1) | protein interactions | 107 | 6 | 1 | 19454 | 50 |
ADCY2 |
1.532e-02 | -4.18 | SMOC2 (SPARC related modular calcium binding 2) | protein interactions | 64094 | 6 | 1 | 19454 | 50 |
TNC |
1.535e-02 | -4.18 | Immunoglobulin | interpro domains | IPR013151 | 70 | 2 | 18521 | 50 |
CNTN1,NTM |
1.541e-02 | -4.17 | GJA1 (gap junction protein alpha 1) | protein interactions | 2697 | 572 | 5 | 19454 | 50 |
PARD3,TNIK,MACF1,ERBB4,DTNA |
1.543e-02 | -4.17 | regulation of blood coagulation | biological process | GO:0030193 | 69 | 2 | 18204 | 50 |
APOE,PRKG1 |
1.544e-02 | -4.17 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 6 | 18094 | 49 |
ATP1A2,SLC1A2,GPM6A,TRPM3,SLC4A4,RYR3 |
1.546e-02 | -4.17 | Apolipoprotein | gene3d domains | 1.20.120.20 | 5 | 1 | 14470 | 45 |
APOE |
1.546e-02 | -4.17 | - | gene3d domains | 6.10.140.620 | 5 | 1 | 14470 | 45 |
CAMK2G |
1.550e-02 | -4.17 | LIM | pfam domains | PF00412 | 69 | 2 | 17795 | 49 |
ABLIM1,NEBL |
1.552e-02 | -4.17 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 3 | 19454 | 50 |
NRXN1,ABLIM1,DTNA |
1.554e-02 | -4.16 | TEC (tec protein tyrosine kinase) | protein interactions | 7006 | 74 | 2 | 19454 | 50 |
ERBB4,MSI2 |
1.560e-02 | -4.16 | multivesicular body, internal vesicle | cellular component | GO:0097487 | 6 | 1 | 19108 | 50 |
APOE |
1.560e-02 | -4.16 | PAR polarity complex | cellular component | GO:0120157 | 6 | 1 | 19108 | 50 |
PARD3 |
1.561e-02 | -4.16 | monoatomic ion transport | biological process | GO:0006811 | 964 | 7 | 18204 | 50 |
ATP1A2,RYR3,GPM6A,PLCB1,SLC4A4,SLC1A2,TRPM3 |
1.562e-02 | -4.16 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 34 |
CAMK2G,ATP1A2 |
1.566e-02 | -4.16 | cerebrum | COSMIC cancer mutations | cerebrum | 67 | 2 | 16828 | 48 |
CNTN1,LRP1B |
1.576e-02 | -4.15 | Znf_LIM | interpro domains | IPR001781 | 71 | 2 | 18521 | 50 |
NEBL,ABLIM1 |
1.585e-02 | -4.14 | negative regulation of smooth muscle cell proliferation | biological process | GO:0048662 | 70 | 2 | 18204 | 50 |
APOE,PRKG1 |
1.592e-02 | -4.14 | ig | pfam domains | PF00047 | 70 | 2 | 17795 | 49 |
NTM,CNTN1 |
1.594e-02 | -4.14 | HDAC9 (histone deacetylase 9) | protein interactions | 9734 | 75 | 2 | 19454 | 50 |
GFAP,MAPK10 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GF_recep_IV | interpro domains | IPR032778 | 6 | 1 | 18521 | 50 |
ERBB4 |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Adcy_conserved_dom | interpro domains | IPR009398 | 6 | 1 | 18521 | 50 |
ADCY2 |
1.609e-02 | -4.13 | RIH_dom | interpro domains | IPR000699 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | GLI-like | interpro domains | IPR043359 | 6 | 1 | 18521 | 50 |
GLIS3 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 50 |
NRXN1 |
1.614e-02 | -4.13 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 49 |
ATP1A2 |
1.614e-02 | -4.13 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 49 |
RYR3 |
1.614e-02 | -4.13 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 49 |
SLC4A4 |
1.614e-02 | -4.13 | phosphatidylcholine-sterol O-acyltransferase activator activity | molecular function | GO:0060228 | 6 | 1 | 18094 | 49 |
APOE |
1.628e-02 | -4.12 | regulation of hemostasis | biological process | GO:1900046 | 71 | 2 | 18204 | 50 |
PRKG1,APOE |
1.629e-02 | -4.12 | MKRN2 (makorin ring finger protein 2) | protein interactions | 23609 | 380 | 4 | 19454 | 50 |
PARD3,CNTN1,MACF1,PRKG1 |
1.633e-02 | -4.11 | RYK (receptor like tyrosine kinase) | protein interactions | 6259 | 208 | 3 | 19454 | 50 |
CLU,CNTN1,CTNNA2 |
1.633e-02 | -4.11 | BCL2L1 (BCL2 like 1) | protein interactions | 598 | 208 | 3 | 19454 | 50 |
RYR3,CLU,ABLIM1 |
1.634e-02 | -4.11 | regulation of body fluid levels | biological process | GO:0050878 | 356 | 4 | 18204 | 50 |
APOE,PRKG1,ERBB4,DGKG |
1.637e-02 | -4.11 | cellular response to ether | biological process | GO:0071362 | 6 | 1 | 18204 | 50 |
PLCB1 |
1.637e-02 | -4.11 | vocal learning | biological process | GO:0042297 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.637e-02 | -4.11 | imitative learning | biological process | GO:0098596 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.637e-02 | -4.11 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 50 |
CST3 |
1.637e-02 | -4.11 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 50 |
NRG3 |
1.637e-02 | -4.11 | relaxation of vascular associated smooth muscle | biological process | GO:0060087 | 6 | 1 | 18204 | 50 |
PRKG1 |
1.637e-02 | -4.11 | triglyceride-rich lipoprotein particle clearance | biological process | GO:0071830 | 6 | 1 | 18204 | 50 |
APOE |
1.637e-02 | -4.11 | inositol trisphosphate metabolic process | biological process | GO:0032957 | 6 | 1 | 18204 | 50 |
PLCB1 |
1.637e-02 | -4.11 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 1 | 18204 | 50 |
SLC1A2 |
1.637e-02 | -4.11 | establishment of meiotic spindle localization | biological process | GO:0051295 | 6 | 1 | 18204 | 50 |
FMN2 |
1.637e-02 | -4.11 | regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032803 | 6 | 1 | 18204 | 50 |
APOE |
1.637e-02 | -4.11 | protein targeting to vacuole involved in autophagy | biological process | GO:0071211 | 6 | 1 | 18204 | 50 |
CLU |
1.637e-02 | -4.11 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 50 |
SOX5 |
1.637e-02 | -4.11 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.641e-02 | -4.11 | RYDR_ITPR | pfam domains | PF01365 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | Adcy_cons_dom | pfam domains | PF06327 | 6 | 1 | 17795 | 49 |
ADCY2 |
1.641e-02 | -4.11 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | GF_recep_IV | pfam domains | PF14843 | 6 | 1 | 17795 | 49 |
ERBB4 |
1.641e-02 | -4.11 | RIH_assoc | pfam domains | PF08454 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 49 |
NRXN1 |
1.641e-02 | -4.11 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 49 |
GPC5 |
1.642e-02 | -4.11 | NGF-independant TRKA activation | REACTOME pathways | R-HSA-187024 | 5 | 1 | 10285 | 34 |
NTRK2 |
1.664e-02 | -4.10 | cell-cell adhesion | biological process | GO:0098609 | 546 | 5 | 18204 | 50 |
CTNND2,CDH20,CTNNA2,NRXN1,CNTN1 |
1.676e-02 | -4.09 | ADGRL2 (adhesion G protein-coupled receptor L2) | protein interactions | 23266 | 77 | 2 | 19454 | 50 |
NTRK2,PARD3 |
1.676e-02 | -4.09 | actin cytoskeleton organization | biological process | GO:0030036 | 547 | 5 | 18204 | 50 |
TNIK,NEBL,FMN2,SORBS1,PRKG1 |
1.691e-02 | -4.08 | sarcoplasmic reticulum | cellular component | GO:0016529 | 76 | 2 | 19108 | 50 |
CAMK2G,RYR3 |
1.711e-02 | -4.07 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 18 |
PITPNC1 |
1.711e-02 | -4.07 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 18 |
SLC4A4 |
1.716e-02 | -4.07 | negative regulation of wound healing | biological process | GO:0061045 | 73 | 2 | 18204 | 50 |
PRKG1,APOE |
1.716e-02 | -4.07 | cardiac cell development | biological process | GO:0055006 | 73 | 2 | 18204 | 50 |
NEBL,PRKG1 |
1.717e-02 | -4.06 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 50 |
SOX5,MSI2 |
1.717e-02 | -4.06 | IFIT3 (interferon induced protein with tetratricopeptide repeats 3) | protein interactions | 3437 | 78 | 2 | 19454 | 50 |
ATP1A2,APOE |
1.717e-02 | -4.06 | LRP8 (LDL receptor related protein 8) | protein interactions | 7804 | 78 | 2 | 19454 | 50 |
APOE,CLU |
1.717e-02 | -4.06 | ATOH1 (atonal bHLH transcription factor 1) | protein interactions | 474 | 78 | 2 | 19454 | 50 |
MACF1,GFAP |
1.717e-02 | -4.06 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 15 | 18204 | 50 |
GFAP,RORA,ATP1A2,CST3,CLU,NRXN1,PRKG1,MACF1,PARD3,SOX5,CAMK2G,APOE,PLCB1,NTRK2,ERBB4 |
1.719e-02 | -4.06 | Ca2+ pathway | REACTOME pathways | R-HSA-4086398 | 61 | 2 | 10285 | 34 |
PLCB1,PRKG1 |
1.731e-02 | -4.06 | regulation of developmental process | biological process | GO:0050793 | 2540 | 13 | 18204 | 50 |
NRXN1,RORA,GFAP,CST3,SOX5,PARD3,MACF1,PLCB1,DGKG,NTRK2,TNIK,APOE,ERBB4 |
1.731e-02 | -4.06 | positive regulation of ERK1 and ERK2 cascade | biological process | GO:0070374 | 199 | 3 | 18204 | 50 |
ERBB4,NTRK2,APOE |
1.737e-02 | -4.05 | regulation of cellular process | biological process | GO:0050794 | 11468 | 39 | 18204 | 50 |
ADCY2,SLC4A4,GLIS3,CNTN1,DTNA,NPAS3,PLCB1,PITPNC1,NTRK2,CTNNA2,PRKG1,CTNND2,GPM6A,MACF1,PARD3,HPSE2,SOX5,CAMK2G,DCLK2,ATP1A2,RORA,SORBS1,CST3,NRG3,MAPK10,TNC,ERBB4,GPC5,RFX4,APOE,SLC1A2,DGKG,TNIK,MSI2,RYR3,FMN2,GFAP,CLU,NRXN1 |
1.744e-02 | -4.05 | Activation of PKC Through G Protein-Coupled Receptor | SMPDB pathways | SMP0000749 | 4 | 1 | 1369 | 6 |
PLCB1 |
1.759e-02 | -4.04 | KRTAP3-2 (keratin associated protein 3-2) | protein interactions | 83897 | 79 | 2 | 19454 | 50 |
GFAP,NTM |
1.759e-02 | -4.04 | chondrosarcoma | COSMIC cancer mutations | chondrosarcoma | 1181 | 8 | 16828 | 48 |
HPSE2,SLC4A4,CNTN1,LSAMP,LRP1B,ADCY2,NAV2,ERBB4 |
1.761e-02 | -4.04 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 50 |
ERBB4,TNIK,NTRK2 |
1.761e-02 | -4.04 | regulation of coagulation | biological process | GO:0050818 | 74 | 2 | 18204 | 50 |
APOE,PRKG1 |
1.761e-02 | -4.04 | sterol transport | biological process | GO:0015918 | 74 | 2 | 18204 | 50 |
CLU,APOE |
1.765e-02 | -4.04 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 7 | 18204 | 50 |
NTRK2,ABLIM1,NRG3,CTNNA2,ERBB4,TNC,SOX5 |
1.775e-02 | -4.03 | Apelin signaling pathway | KEGG pathways | hsa04371 | 138 | 3 | 7161 | 29 |
PLCB1,ADCY2,RYR3 |
1.776e-02 | -4.03 | GABA-ergic synapse | cellular component | GO:0098982 | 78 | 2 | 19108 | 50 |
PLCB1,ERBB4 |
1.783e-02 | -4.03 | other | COSMIC cancer mutations | other | 14843 | 47 | 16828 | 48 |
NRG3,RFX4,CST3,HPSE2,MACF1,RORA,LSAMP,CLU,NEBL,GPC5,CAMK2G,DTNA,PRKG1,NTM,GLIS3,NAV2,ERBB4,NRXN1,SLC1A2,APOE,TNC,NKAIN3,ATP1A2,LRP1B,PLCB1,TNIK,SLC14A1,DCLK2,TRPM3,ABLIM1,SLC4A4,SOX5,CDH20,ADCY2,NPAS3,CTNND2,PARD3,DGKG,MSI2,CNTN1,NTRK2,MGAT4C,RYR3,GFAP,SORBS1,FMN2,GPM6A |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.786e-02 | -4.03 | C7 (complement C7) | protein interactions | 730 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | C8B (complement C8 beta chain) | protein interactions | 732 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | SOAT2 (sterol O-acyltransferase 2) | protein interactions | 8435 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | CYP4F8 (cytochrome P450 family 4 subfamily F member 8) | protein interactions | 11283 | 7 | 1 | 19454 | 50 |
CLU |
1.791e-02 | -4.02 | monoatomic cation transport | biological process | GO:0006812 | 766 | 6 | 18204 | 50 |
RYR3,GPM6A,ATP1A2,TRPM3,PLCB1,SLC4A4 |
1.793e-02 | -4.02 | large_cell | COSMIC cancer mutations | large_cell | 14845 | 47 | 16828 | 48 |
TRPM3,SOX5,SLC4A4,ABLIM1,SLC14A1,DCLK2,NPAS3,CTNND2,PARD3,ADCY2,CDH20,MSI2,NTRK2,CNTN1,DGKG,RYR3,GFAP,SORBS1,FMN2,GPM6A,MGAT4C,HPSE2,MACF1,RORA,CLU,LSAMP,RFX4,NRG3,CST3,CAMK2G,DTNA,GPC5,NTM,PRKG1,NEBL,NRXN1,SLC1A2,APOE,TNC,GLIS3,ERBB4,NAV2,TNIK,PLCB1,LRP1B,ATP1A2,PITPNC1 |
1.794e-02 | -4.02 | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-cortisol_producing | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-cortisol_producing | 72 | 2 | 16828 | 48 |
LRP1B,FMN2 |
1.794e-02 | -4.02 | cortisol_producing | COSMIC cancer mutations | cortisol_producing | 72 | 2 | 16828 | 48 |
FMN2,LRP1B |
1.795e-02 | -4.02 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 9 | 16828 | 48 |
ATP1A2,PITPNC1,RFX4,CLU,SLC4A4,SLC1A2,NTRK2,FMN2,CTNND2 |
1.795e-02 | -4.02 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 9 | 16828 | 48 |
CTNND2,CLU,SLC4A4,SLC1A2,FMN2,NTRK2,RFX4,ATP1A2,PITPNC1 |
1.801e-02 | -4.02 | MAP2 (microtubule associated protein 2) | protein interactions | 4133 | 80 | 2 | 19454 | 50 |
APOE,GPM6A |
1.825e-02 | -4.00 | calmodulin binding | molecular function | GO:0005516 | 206 | 3 | 18094 | 49 |
RYR3,CAMK2G,PLCB1 |
1.841e-02 | -3.99 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 48 |
MACF1,NAV2 |
1.850e-02 | -3.99 | PRKCA (protein kinase C alpha) | protein interactions | 5578 | 395 | 4 | 19454 | 50 |
GFAP,PLCB1,GPM6A,PRKG1 |
1.852e-02 | -3.99 | regulation of axon extension | biological process | GO:0030516 | 76 | 2 | 18204 | 50 |
APOE,MACF1 |
1.852e-02 | -3.99 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 45 |
MACF1 |
1.852e-02 | -3.99 | Single helix bin | gene3d domains | 1.20.5.490 | 6 | 1 | 14470 | 45 |
PRKG1 |
1.852e-02 | -3.99 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 1 | 14470 | 45 |
RYR3 |
1.852e-02 | -3.99 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 45 |
MACF1 |
1.875e-02 | -3.98 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 1 | 18521 | 50 |
SLC1A2 |
1.875e-02 | -3.98 | Intermed_filament_DNA-bd | interpro domains | IPR006821 | 7 | 1 | 18521 | 50 |
GFAP |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Furin-like_Cys-rich_dom | interpro domains | IPR006211 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Rcpt_L-dom_sf | interpro domains | IPR036941 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Ammonium/urea_transptr | interpro domains | IPR029020 | 7 | 1 | 18521 | 50 |
SLC14A1 |
1.875e-02 | -3.98 | Rcpt_L-dom | interpro domains | IPR000494 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 1 | 18521 | 50 |
SLC1A2 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 1 | 18521 | 50 |
SLC1A2 |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.881e-02 | -3.97 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 49 |
ATP1A2 |
1.881e-02 | -3.97 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 49 |
PITPNC1 |
1.881e-02 | -3.97 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 49 |
ATP1A2 |
1.881e-02 | -3.97 | mitogen-activated protein kinase p38 binding | molecular function | GO:0048273 | 7 | 1 | 18094 | 49 |
PRKG1 |
1.881e-02 | -3.97 | calcium-dependent protein serine/threonine phosphatase activity | molecular function | GO:0004723 | 7 | 1 | 18094 | 49 |
CAMK2G |
1.889e-02 | -3.97 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 48 |
MACF1,NAV2 |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.898e-02 | -3.96 | regulation of organic acid transport | biological process | GO:0032890 | 77 | 2 | 18204 | 50 |
ATP1A2,PRKG1 |
1.898e-02 | -3.96 | neural retina development | biological process | GO:0003407 | 77 | 2 | 18204 | 50 |
NTRK2,GPM6A |
1.898e-02 | -3.96 | cellular response to interleukin-1 | biological process | GO:0071347 | 77 | 2 | 18204 | 50 |
RORA,PLCB1 |
1.898e-02 | -3.96 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 50 |
ATP1A2,NRXN1 |
1.898e-02 | -3.96 | positive regulation of axonogenesis | biological process | GO:0050772 | 77 | 2 | 18204 | 50 |
NTRK2,MACF1 |
1.907e-02 | -3.96 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 50 |
RYR3 |
1.907e-02 | -3.96 | chaperone-mediated autophagy | biological process | GO:0061684 | 7 | 1 | 18204 | 50 |
CLU |
1.907e-02 | -3.96 | positive regulation of receptor catabolic process | biological process | GO:2000646 | 7 | 1 | 18204 | 50 |
APOE |
1.907e-02 | -3.96 | very-low-density lipoprotein particle remodeling | biological process | GO:0034372 | 7 | 1 | 18204 | 50 |
APOE |
1.907e-02 | -3.96 | regulation of monocyte extravasation | biological process | GO:2000437 | 7 | 1 | 18204 | 50 |
PLCB1 |
1.907e-02 | -3.96 | high-density lipoprotein particle clearance | biological process | GO:0034384 | 7 | 1 | 18204 | 50 |
APOE |
1.907e-02 | -3.96 | observational learning | biological process | GO:0098597 | 7 | 1 | 18204 | 50 |
NRXN1 |
1.907e-02 | -3.96 | interneuron migration from the subpallium to the cortex | biological process | GO:0021830 | 7 | 1 | 18204 | 50 |
NRG3 |
1.907e-02 | -3.96 | peripheral nervous system axon regeneration | biological process | GO:0014012 | 7 | 1 | 18204 | 50 |
TNC |
1.907e-02 | -3.96 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 50 |
CTNNA2 |
1.907e-02 | -3.96 | chromosome movement towards spindle pole | biological process | GO:0051305 | 7 | 1 | 18204 | 50 |
FMN2 |
1.907e-02 | -3.96 | parallel actin filament bundle assembly | biological process | GO:0030046 | 7 | 1 | 18204 | 50 |
FMN2 |
1.907e-02 | -3.96 | relaxation of smooth muscle | biological process | GO:0044557 | 7 | 1 | 18204 | 50 |
PRKG1 |
1.907e-02 | -3.96 | regulation of testosterone biosynthetic process | biological process | GO:2000224 | 7 | 1 | 18204 | 50 |
PRKG1 |
1.912e-02 | -3.96 | Recep_L_domain | pfam domains | PF01030 | 7 | 1 | 17795 | 49 |
ERBB4 |
1.912e-02 | -3.96 | Furin-like | pfam domains | PF00757 | 7 | 1 | 17795 | 49 |
ERBB4 |
1.912e-02 | -3.96 | Filament_head | pfam domains | PF04732 | 7 | 1 | 17795 | 49 |
GFAP |
1.912e-02 | -3.96 | SDF | pfam domains | PF00375 | 7 | 1 | 17795 | 49 |
SLC1A2 |
1.923e-02 | -3.95 | Signalling by NGF | REACTOME pathways | R-HSA-166520 | 477 | 5 | 10285 | 34 |
CAMK2G,NRG3,ERBB4,NTRK2,ADCY2 |
1.930e-02 | -3.95 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 50 |
NRXN1,GPM6A |
1.937e-02 | -3.94 | Constitutive Signaling by Aberrant PI3K in Cancer | REACTOME pathways | R-HSA-2219530 | 65 | 2 | 10285 | 34 |
ERBB4,NRG3 |
1.944e-02 | -3.94 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 2 | 18204 | 50 |
SORBS1,SLC4A4 |
1.944e-02 | -3.94 | regulation of glucose transmembrane transport | biological process | GO:0010827 | 78 | 2 | 18204 | 50 |
SLC1A2,SORBS1 |
1.947e-02 | -3.94 | cytoskeleton | cellular component | GO:0005856 | 2412 | 12 | 19108 | 50 |
CLU,GFAP,DGKG,DTNA,FMN2,SORBS1,TNIK,PARD3,CTNNA2,NEBL,ABLIM1,MACF1 |
1.950e-02 | -3.94 | Wnt signaling pathway | KEGG pathways | hsa04310 | 143 | 3 | 7161 | 29 |
PLCB1,CAMK2G,MAPK10 |
1.950e-02 | -3.94 | Wnt signaling pathway | KEGG pathways | ko04310 | 143 | 3 | 7161 | 29 |
PLCB1,MAPK10,CAMK2G |
1.956e-02 | -3.93 | structural molecule activity | molecular function | GO:0005198 | 793 | 6 | 18094 | 49 |
GFAP,APOE,CTNNA2,MACF1,NEBL,TNC |
1.968e-02 | -3.93 | Activation of TRKA receptors | REACTOME pathways | R-HSA-187015 | 6 | 1 | 10285 | 34 |
NTRK2 |
1.974e-02 | -3.93 | PSEN2 (presenilin 2) | protein interactions | 5664 | 84 | 2 | 19454 | 50 |
GFAP,CTNND2 |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
ERBB4,NTRK2 |
1.985e-02 | -3.92 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 2 | 18094 | 49 |
SLC1A2,SLC4A4 |
1.990e-02 | -3.92 | Regulation of lipolysis in adipocytes | KEGG pathways | hsa04923 | 54 | 2 | 7161 | 29 |
PRKG1,ADCY2 |
1.991e-02 | -3.92 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 5 | 19454 | 50 |
TNIK,PARD3,CLU,ABLIM1,DTNA |
1.996e-02 | -3.91 | caveola | cellular component | GO:0005901 | 83 | 2 | 19108 | 50 |
SORBS1,ATP1A2 |
2.015e-02 | -3.90 | skin-upper_arm-malignant_melanoma | COSMIC cancer mutations | skin-upper_arm-malignant_melanoma | 553 | 5 | 16828 | 48 |
ERBB4,SLC4A4,PLCB1,FMN2,LRP1B |
2.021e-02 | -3.90 | CH_dom | interpro domains | IPR001715 | 81 | 2 | 18521 | 50 |
NAV2,MACF1 |
2.022e-02 | -3.90 | Phospholipase D signaling pathway | KEGG pathways | hsa04072 | 145 | 3 | 7161 | 29 |
ADCY2,DGKG,PLCB1 |
2.022e-02 | -3.90 | Phospholipase D signaling pathway | KEGG pathways | ko04072 | 145 | 3 | 7161 | 29 |
ADCY2,PLCB1,DGKG |
2.026e-02 | -3.90 | regulation of cellular component biogenesis | biological process | GO:0044087 | 1016 | 7 | 18204 | 50 |
NTRK2,NRXN1,CLU,MACF1,GPM6A,GFAP,APOE |
2.032e-02 | -3.90 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 49 |
NTRK2,ERBB4 |
2.038e-02 | -3.89 | INSM1 (INSM transcriptional repressor 1) | protein interactions | 3642 | 8 | 1 | 19454 | 50 |
SORBS1 |
2.038e-02 | -3.89 | Chmp2a (charged multivesicular body protein 2A) | protein interactions | 68953 | 8 | 1 | 19454 | 50 |
CLU |
2.038e-02 | -3.89 | UBALD2 (UBA like domain containing 2) | protein interactions | 283991 | 8 | 1 | 19454 | 50 |
GFAP |
2.038e-02 | -3.89 | NKAIN3 (sodium/potassium transporting ATPase interacting 3) | protein interactions | 286183 | 8 | 1 | 19454 | 50 |
GFAP |
2.042e-02 | -3.89 | negative regulation of cell migration | biological process | GO:0030336 | 381 | 4 | 18204 | 50 |
NRG3,PLCB1,PRKG1,APOE |
2.051e-02 | -3.89 | Signaling by PTK6 | REACTOME pathways | R-HSA-8848021 | 67 | 2 | 10285 | 34 |
NRG3,ERBB4 |
2.055e-02 | -3.88 | PRKCD (protein kinase C delta) | protein interactions | 5580 | 227 | 3 | 19454 | 50 |
CAMK2G,MACF1,PLCB1 |
2.059e-02 | -3.88 | ErbB Signaling Pathway | WikiPathways | WP673 | 54 | 2 | 5310 | 22 |
NRG3,ERBB4 |
2.063e-02 | -3.88 | FAM171A1 (family with sequence similarity 171 member A1) | protein interactions | 221061 | 86 | 2 | 19454 | 50 |
PARD3,NTRK2 |
2.063e-02 | -3.88 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 50 |
GPM6A,SORBS1 |
2.068e-02 | -3.88 | CH_dom_sf | interpro domains | IPR036872 | 82 | 2 | 18521 | 50 |
NAV2,MACF1 |
2.075e-02 | -3.88 | spherical high-density lipoprotein particle | cellular component | GO:0034366 | 8 | 1 | 19108 | 50 |
CLU |
2.075e-02 | -3.88 | zonula adherens | cellular component | GO:0005915 | 8 | 1 | 19108 | 50 |
SORBS1 |
2.099e-02 | -3.86 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 43 |
GPC5 |
2.099e-02 | -3.86 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 43 |
MACF1 |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
RYR3,MACF1,DGKG |
2.103e-02 | -3.86 | VANGL1 (VANGL planar cell polarity protein 1) | protein interactions | 81839 | 229 | 3 | 19454 | 50 |
NTRK2,PARD3,ERBB4 |
2.133e-02 | -3.85 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 46 | 16828 | 48 |
PITPNC1,ATP1A2,PLCB1,TNIK,LRP1B,ERBB4,NAV2,GLIS3,NKAIN3,TNC,SLC1A2,NRXN1,NEBL,NTM,PRKG1,CAMK2G,DTNA,GPC5,RFX4,NRG3,LSAMP,CLU,RORA,MACF1,HPSE2,MGAT4C,SORBS1,GPM6A,FMN2,GFAP,RYR3,DGKG,NTRK2,CNTN1,MSI2,ADCY2,CDH20,PARD3,CTNND2,NPAS3,DCLK2,SLC14A1,SOX5,SLC4A4,ABLIM1,TRPM3 |
2.135e-02 | -3.85 | regulation of steroid biosynthetic process | biological process | GO:0050810 | 82 | 2 | 18204 | 50 |
APOE,PRKG1 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | AC_N | interpro domains | IPR032628 | 8 | 1 | 18521 | 50 |
ADCY2 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.140e-02 | -3.84 | Adcy | interpro domains | IPR030672 | 8 | 1 | 18521 | 50 |
ADCY2 |
2.140e-02 | -3.84 | RFX-like | interpro domains | IPR039779 | 8 | 1 | 18521 | 50 |
RFX4 |
2.140e-02 | -3.84 | TRPM_SLOG | interpro domains | IPR041491 | 8 | 1 | 18521 | 50 |
TRPM3 |
2.146e-02 | -3.84 | CDC37 (cell division cycle 37, HSP90 cochaperone) | protein interactions | 11140 | 623 | 5 | 19454 | 50 |
CAMK2G,APOE,NTRK2,DCLK2,GFAP |
2.146e-02 | -3.84 | cyclic nucleotide-dependent protein kinase activity | molecular function | GO:0004690 | 8 | 1 | 18094 | 49 |
PRKG1 |
2.146e-02 | -3.84 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 49 |
ATP1A2 |
2.146e-02 | -3.84 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 49 |
ATP1A2 |
2.146e-02 | -3.84 | urea transmembrane transporter activity | molecular function | GO:0015204 | 8 | 1 | 18094 | 49 |
SLC14A1 |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
NTM,CNTN1,LSAMP,NTRK2 |
2.157e-02 | -3.84 | FYN (FYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 2534 | 414 | 4 | 19454 | 50 |
ERBB4,CTNND2,NTRK2,CNTN1 |
2.157e-02 | -3.84 | Receptor L-domain | gene3d domains | 3.80.20.20 | 7 | 1 | 14470 | 45 |
ERBB4 |
2.157e-02 | -3.84 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 1 | 14470 | 45 |
SLC1A2 |
2.157e-02 | -3.84 | Ammonium transporter AmtB like domains | gene3d domains | 1.10.3430.10 | 7 | 1 | 14470 | 45 |
SLC14A1 |
2.159e-02 | -3.84 | SRC (SRC proto-oncogene, non-receptor tyrosine kinase) | protein interactions | 6714 | 624 | 5 | 19454 | 50 |
GFAP,SLC14A1,SORBS1,ERBB4,MSI2 |
2.161e-02 | -3.83 | Cysteine Rich Protein | gene3d domains | 2.10.110.10 | 73 | 2 | 14470 | 45 |
NEBL,ABLIM1 |
2.172e-02 | -3.83 | regulation of cell junction assembly | biological process | GO:1901888 | 217 | 3 | 18204 | 50 |
MACF1,NRXN1,NTRK2 |
2.175e-02 | -3.83 | phosphatidylinositol-4,5-bisphosphate binding | molecular function | GO:0005546 | 84 | 2 | 18094 | 49 |
PARD3,PLCB1 |
2.175e-02 | -3.83 | CTSB (cathepsin B) | protein interactions | 1508 | 232 | 3 | 19454 | 50 |
MSI2,APOE,CST3 |
2.175e-02 | -3.83 | Corticotropin Activation of Cortisol Production | SMPDB pathways | SMP0000310 | 5 | 1 | 1369 | 6 |
ADCY2 |
2.177e-02 | -3.83 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | meiotic cytokinesis | biological process | GO:0033206 | 8 | 1 | 18204 | 50 |
FMN2 |
2.177e-02 | -3.83 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | central nervous system myelin formation | biological process | GO:0032289 | 8 | 1 | 18204 | 50 |
CNTN1 |
2.177e-02 | -3.83 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 50 |
CTNNA2 |
2.177e-02 | -3.83 | cellular response to vasopressin | biological process | GO:1904117 | 8 | 1 | 18204 | 50 |
PLCB1 |
2.177e-02 | -3.83 | positive regulation of CoA-transferase activity | biological process | GO:1905920 | 8 | 1 | 18204 | 50 |
APOE |
2.177e-02 | -3.83 | positive regulation of amyloid-beta clearance | biological process | GO:1900223 | 8 | 1 | 18204 | 50 |
APOE |
2.177e-02 | -3.83 | regulation of chaperone-mediated autophagy | biological process | GO:1904714 | 8 | 1 | 18204 | 50 |
GFAP |
2.177e-02 | -3.83 | ion channel modulating, G protein-coupled receptor signaling pathway | biological process | GO:0099105 | 8 | 1 | 18204 | 50 |
PLCB1 |
2.177e-02 | -3.83 | response to vasopressin | biological process | GO:1904116 | 8 | 1 | 18204 | 50 |
PLCB1 |
2.177e-02 | -3.83 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 50 |
ATP1A2 |
2.177e-02 | -3.83 | phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway | biological process | GO:0007207 | 8 | 1 | 18204 | 50 |
PLCB1 |
2.177e-02 | -3.83 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | regulation of Cdc42 protein signal transduction | biological process | GO:0032489 | 8 | 1 | 18204 | 50 |
APOE |
2.177e-02 | -3.83 | triglyceride-rich lipoprotein particle remodeling | biological process | GO:0034370 | 8 | 1 | 18204 | 50 |
APOE |
2.182e-02 | -3.82 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 49 |
ABLIM1 |
2.182e-02 | -3.82 | DCX | pfam domains | PF03607 | 8 | 1 | 17795 | 49 |
DCLK2 |
2.182e-02 | -3.82 | LSDAT_euk | pfam domains | PF18139 | 8 | 1 | 17795 | 49 |
TRPM3 |
2.182e-02 | -3.82 | AC_N | pfam domains | PF16214 | 8 | 1 | 17795 | 49 |
ADCY2 |
2.184e-02 | -3.82 | regulation of amine transport | biological process | GO:0051952 | 83 | 2 | 18204 | 50 |
PRKG1,ATP1A2 |
2.203e-02 | -3.82 | SH3_domain | interpro domains | IPR001452 | 222 | 3 | 18521 | 50 |
SORBS1,MACF1,NEBL |
2.209e-02 | -3.81 | positive regulation of cell communication | biological process | GO:0010647 | 1792 | 10 | 18204 | 50 |
MACF1,GPC5,ERBB4,SORBS1,GFAP,APOE,NTRK2,TNIK,NRXN1,PLCB1 |
2.216e-02 | -3.81 | Alzheimers Disease | WikiPathways | WP2059 | 148 | 3 | 5310 | 22 |
APOE,PLCB1,RYR3 |
2.224e-02 | -3.81 | regulation of synaptic plasticity | biological process | GO:0048167 | 219 | 3 | 18204 | 50 |
NTRK2,APOE,GFAP |
2.225e-02 | -3.81 | positive regulation of signaling | biological process | GO:0023056 | 1794 | 10 | 18204 | 50 |
SORBS1,GFAP,APOE,NTRK2,TNIK,NRXN1,PLCB1,MACF1,GPC5,ERBB4 |
2.233e-02 | -3.80 | stem cell development | biological process | GO:0048864 | 84 | 2 | 18204 | 50 |
ERBB4,MSI2 |
2.233e-02 | -3.80 | peripheral nervous system development | biological process | GO:0007422 | 84 | 2 | 18204 | 50 |
NTRK2,PARD3 |
2.246e-02 | -3.80 | CTDSPL (CTD small phosphatase like) | protein interactions | 10217 | 90 | 2 | 19454 | 50 |
DTNA,FMN2 |
2.246e-02 | -3.80 | FGFR1OP2 (FGFR1 oncogene partner 2) | protein interactions | 26127 | 90 | 2 | 19454 | 50 |
CAMK2G,TNIK |
2.249e-02 | -3.79 | large_intestine-rectum | COSMIC cancer mutations | large_intestine-rectum | 569 | 5 | 16828 | 48 |
ADCY2,CNTN1,PRKG1,ERBB4,FMN2 |
2.250e-02 | -3.79 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 50 |
ATP1A2,NRXN1,TNC |
2.258e-02 | -3.79 | regulation of metal ion transport | biological process | GO:0010959 | 393 | 4 | 18204 | 50 |
ATP1A2,NKAIN3,CNTN1,CAMK2G |
2.260e-02 | -3.79 | bone-knee-chondrosarcoma-synovial | COSMIC cancer mutations | bone-knee-chondrosarcoma-synovial | 8 | 1 | 16828 | 48 |
CNTN1 |
2.260e-02 | -3.79 | synovial | COSMIC cancer mutations | synovial | 8 | 1 | 16828 | 48 |
CNTN1 |
2.264e-02 | -3.79 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 37 |
MACF1 |
2.289e-02 | -3.78 | supramolecular fiber organization | biological process | GO:0097435 | 593 | 5 | 18204 | 50 |
CST3,SORBS1,GFAP,NEBL,FMN2 |
2.290e-02 | -3.78 | MUC4 (mucin 4, cell surface associated) | protein interactions | 4585 | 9 | 1 | 19454 | 50 |
ERBB4 |
2.290e-02 | -3.78 | LSB3 (Lsb3p) | protein interactions | 850580 | 9 | 1 | 19454 | 50 |
GFAP |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.290e-02 | -3.78 | CACNA2D3 (calcium voltage-gated channel auxiliary subunit alpha2delta 3) | protein interactions | 55799 | 9 | 1 | 19454 | 50 |
APOE |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | CAMK2N1 (calcium/calmodulin dependent protein kinase II inhibitor 1) | protein interactions | 55450 | 9 | 1 | 19454 | 50 |
CAMK2G |
2.290e-02 | -3.78 | LINC02582 (long intergenic non-protein coding RNA 2582) | protein interactions | 100505817 | 9 | 1 | 19454 | 50 |
APOE |
2.292e-02 | -3.78 | Neurofascin interactions | REACTOME pathways | R-HSA-447043 | 7 | 1 | 10285 | 34 |
CNTN1 |
2.292e-02 | -3.78 | TRIO (trio Rho guanine nucleotide exchange factor) | protein interactions | 7204 | 91 | 2 | 19454 | 50 |
PARD3,NAV2 |
2.292e-02 | -3.78 | PTPN21 (protein tyrosine phosphatase non-receptor type 21) | protein interactions | 11099 | 91 | 2 | 19454 | 50 |
NRG3,ERBB4 |
2.292e-02 | -3.78 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 2 | 19454 | 50 |
TNIK,SORBS1 |
2.294e-02 | -3.77 | Flecainide Action Pathway | SMPDB pathways | SMP0000331 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Practolol Action Pathway | SMPDB pathways | SMP0000669 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Metoprolol Action Pathway | SMPDB pathways | SMP0000302 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Bupranolol Action Pathway | SMPDB pathways | SMP0000670 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Acebutolol Action Pathway | SMPDB pathways | SMP0000296 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Bopindolol Action Pathway | SMPDB pathways | SMP0000657 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Nisoldipine Action Pathway | SMPDB pathways | SMP0000381 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Pindolol Action Pathway | SMPDB pathways | SMP0000306 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Arbutamine Action Pathway | SMPDB pathways | SMP0000664 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Timolol Action Pathway | SMPDB pathways | SMP0000659 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Metipranolol Action Pathway | SMPDB pathways | SMP0000667 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Nebivolol Action Pathway | SMPDB pathways | SMP0000366 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Nadolol Action Pathway | SMPDB pathways | SMP0000303 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Fosphenytoin (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000326 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Bevantolol Action Pathway | SMPDB pathways | SMP0000668 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Sotalol Action Pathway | SMPDB pathways | SMP0000660 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Amiodarone Action Pathway | SMPDB pathways | SMP0000665 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Carteolol Action Pathway | SMPDB pathways | SMP0000658 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Quinidine Action Pathway | SMPDB pathways | SMP0000323 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Ibutilide Action Pathway | SMPDB pathways | SMP0000332 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Esmolol Action Pathway | SMPDB pathways | SMP0000301 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Nitrendipine Action Pathway | SMPDB pathways | SMP0000382 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Amlodipine Action Pathway | SMPDB pathways | SMP0000376 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Felodipine Action Pathway | SMPDB pathways | SMP0000377 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Atenolol Action Pathway | SMPDB pathways | SMP0000298 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Penbutolol Action Pathway | SMPDB pathways | SMP0000305 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Mexiletine Action Pathway | SMPDB pathways | SMP0000329 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Muscle/Heart Contraction | SMPDB pathways | SMP0000588 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Bisoprolol Action Pathway | SMPDB pathways | SMP0000300 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Procainamide (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000324 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Epinephrine Action Pathway | SMPDB pathways | SMP0000661 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Nifedipine Action Pathway | SMPDB pathways | SMP0000379 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Levobunolol Action Pathway | SMPDB pathways | SMP0000666 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Betaxolol Action Pathway | SMPDB pathways | SMP0000299 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Diltiazem Action Pathway | SMPDB pathways | SMP0000359 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Disopyramide Action Pathway | SMPDB pathways | SMP0000325 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Dobutamine Action Pathway | SMPDB pathways | SMP0000662 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Propranolol Action Pathway | SMPDB pathways | SMP0000307 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Isoprenaline Action Pathway | SMPDB pathways | SMP0000663 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Verapamil Action Pathway | SMPDB pathways | SMP0000375 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Nimodipine Action Pathway | SMPDB pathways | SMP0000380 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Alprenolol Action Pathway | SMPDB pathways | SMP0000297 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Isradipine Action Pathway | SMPDB pathways | SMP0000378 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.294e-02 | -3.77 | Oxprenolol Action Pathway | SMPDB pathways | SMP0000304 | 57 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
2.294e-02 | -3.77 | Tocainide Action Pathway | SMPDB pathways | SMP0000330 | 57 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.315e-02 | -3.77 | negative regulation of cell motility | biological process | GO:2000146 | 396 | 4 | 18204 | 50 |
NRG3,PLCB1,PRKG1,APOE |
2.324e-02 | -3.76 | LCOR (ligand dependent nuclear receptor corepressor) | protein interactions | 84458 | 238 | 3 | 19454 | 50 |
CLU,LRP1B,MACF1 |
2.326e-02 | -3.76 | EGF_1 | prosite domains | PS00022 | 174 | 3 | 12186 | 43 |
LRP1B,NRG3,TNC |
2.331e-02 | -3.76 | astrocyte end-foot | cellular component | GO:0097450 | 9 | 1 | 19108 | 50 |
GFAP |
2.331e-02 | -3.76 | flotillin complex | cellular component | GO:0016600 | 9 | 1 | 19108 | 50 |
SORBS1 |
2.334e-02 | -3.76 | central nervous system neuron development | biological process | GO:0021954 | 86 | 2 | 18204 | 50 |
DCLK2,NTRK2 |
2.334e-02 | -3.76 | protein localization to cell junction | biological process | GO:1902414 | 86 | 2 | 18204 | 50 |
ERBB4,NRXN1 |
2.336e-02 | -3.76 | Calcium Regulation in the Cardiac Cell | WikiPathways | WP536 | 151 | 3 | 5310 | 22 |
ADCY2,RYR3,CAMK2G |
2.341e-02 | -3.75 | upper_aerodigestive_tract-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-carcinoma | 383 | 4 | 16828 | 48 |
ERBB4,NTRK2,TNIK,CAMK2G |
2.341e-02 | -3.75 | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 48 |
TNIK,NTRK2,ERBB4,CAMK2G |
2.341e-02 | -3.75 | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 48 |
CAMK2G,ERBB4,NTRK2,TNIK |
2.341e-02 | -3.75 | salivary_gland-carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma | 383 | 4 | 16828 | 48 |
CAMK2G,ERBB4,TNIK,NTRK2 |
2.341e-02 | -3.75 | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 48 |
TNIK,NTRK2,ERBB4,CAMK2G |
2.342e-02 | -3.75 | establishment of protein localization | biological process | GO:0045184 | 1291 | 8 | 18204 | 50 |
GFAP,APOE,CLU,FMN2,PARD3,CAMK2G,MACF1,LRP1B |
2.346e-02 | -3.75 | cellular response to oxygen-containing compound | biological process | GO:1901701 | 1047 | 7 | 18204 | 50 |
SORBS1,RORA,PLCB1,SLC1A2,RYR3,ADCY2,TNC |
2.346e-02 | -3.75 | response to oxygen-containing compound | biological process | GO:1901700 | 1546 | 9 | 18204 | 50 |
ADCY2,RYR3,TNC,APOE,ATP1A2,RORA,SORBS1,SLC1A2,PLCB1 |
2.367e-02 | -3.74 | regulation of signaling | biological process | GO:0023051 | 3534 | 16 | 18204 | 50 |
ERBB4,GPC5,PLCB1,TNIK,DGKG,NTRK2,APOE,CTNND2,MACF1,NRG3,NRXN1,ATP1A2,RORA,GFAP,CLU,SORBS1 |
2.371e-02 | -3.74 | Labetalol Action Pathway | SMPDB pathways | SMP0000368 | 58 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.371e-02 | -3.74 | Carvedilol Action Pathway | SMPDB pathways | SMP0000367 | 58 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.387e-02 | -3.74 | EDTRNSPORT | prints domains | PR00173 | 7 | 1 | 5227 | 18 |
SLC1A2 |
2.401e-02 | -3.73 | ERBIN (erbb2 interacting protein) | protein interactions | 55914 | 241 | 3 | 19454 | 50 |
PARD3,NTRK2,CTNND2 |
2.404e-02 | -3.73 | DNA-bd_RFX | interpro domains | IPR003150 | 9 | 1 | 18521 | 50 |
RFX4 |
2.404e-02 | -3.73 | Doublecortin_dom | interpro domains | IPR003533 | 9 | 1 | 18521 | 50 |
DCLK2 |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.408e-02 | -3.73 | regulation of cell communication | biological process | GO:0010646 | 3541 | 16 | 18204 | 50 |
APOE,PLCB1,DGKG,TNIK,NTRK2,GPC5,ERBB4,GFAP,ATP1A2,RORA,CLU,SORBS1,NRG3,NRXN1,MACF1,CTNND2 |
2.410e-02 | -3.73 | regulation of cell growth | biological process | GO:0001558 | 401 | 4 | 18204 | 50 |
MACF1,APOE,TNC,NRG3 |
2.420e-02 | -3.72 | ACTG1 (actin gamma 1) | protein interactions | 71 | 429 | 4 | 19454 | 50 |
FMN2,TNIK,APOE,ABLIM1 |
2.424e-02 | -3.72 | Long-term depression | KEGG pathways | hsa04730 | 60 | 2 | 7161 | 29 |
PRKG1,PLCB1 |
2.424e-02 | -3.72 | Long-term depression | KEGG pathways | ko04730 | 60 | 2 | 7161 | 29 |
PRKG1,PLCB1 |
2.426e-02 | -3.72 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 45 | 16828 | 48 |
CLU,LSAMP,RORA,MACF1,HPSE2,NRG3,PRKG1,DTNA,CAMK2G,GPC5,NEBL,TNC,APOE,NKAIN3,SLC1A2,NRXN1,ERBB4,NAV2,GLIS3,TNIK,PLCB1,LRP1B,PITPNC1,ATP1A2,SLC4A4,SOX5,ABLIM1,TRPM3,DCLK2,SLC14A1,PARD3,CTNND2,NPAS3,ADCY2,CDH20,NTRK2,CNTN1,MSI2,DGKG,FMN2,GPM6A,SORBS1,GFAP,RYR3,MGAT4C |
2.426e-02 | -3.72 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 45 | 16828 | 48 |
LSAMP,CLU,RORA,MACF1,HPSE2,NRG3,PRKG1,DTNA,CAMK2G,GPC5,NEBL,APOE,NKAIN3,TNC,SLC1A2,NRXN1,ERBB4,NAV2,GLIS3,PLCB1,TNIK,LRP1B,PITPNC1,ATP1A2,SOX5,SLC4A4,ABLIM1,TRPM3,DCLK2,SLC14A1,PARD3,CTNND2,NPAS3,ADCY2,CDH20,NTRK2,CNTN1,MSI2,DGKG,GPM6A,FMN2,SORBS1,GFAP,RYR3,MGAT4C |
2.435e-02 | -3.72 | TTR (transthyretin) | protein interactions | 7276 | 94 | 2 | 19454 | 50 |
CLU,CTNND2 |
2.435e-02 | -3.72 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 50 |
ABLIM1,TNIK |
2.435e-02 | -3.72 | GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) | protein interactions | 2902 | 94 | 2 | 19454 | 50 |
CAMK2G,NTRK2 |
2.445e-02 | -3.71 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 1 | 12186 | 43 |
SLC1A2 |
2.445e-02 | -3.71 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 1 | 12186 | 43 |
SLC1A2 |
2.446e-02 | -3.71 | sterol catabolic process | biological process | GO:0016127 | 9 | 1 | 18204 | 50 |
APOE |
2.446e-02 | -3.71 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 50 |
NRXN1 |
2.446e-02 | -3.71 | negative regulation of cellular extravasation | biological process | GO:0002692 | 9 | 1 | 18204 | 50 |
PLCB1 |
2.446e-02 | -3.71 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 50 |
CLU |
2.446e-02 | -3.71 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 50 |
CLU |
2.446e-02 | -3.71 | mesenchymal-epithelial cell signaling | biological process | GO:0060638 | 9 | 1 | 18204 | 50 |
TNC |
2.446e-02 | -3.71 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 50 |
ATP1A2 |
2.446e-02 | -3.71 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 50 |
RYR3 |
2.446e-02 | -3.71 | interleukin-12-mediated signaling pathway | biological process | GO:0035722 | 9 | 1 | 18204 | 50 |
PLCB1 |
2.446e-02 | -3.71 | cholesterol catabolic process | biological process | GO:0006707 | 9 | 1 | 18204 | 50 |
APOE |
2.449e-02 | -3.71 | lower_third | COSMIC cancer mutations | lower_third | 7961 | 30 | 16828 | 48 |
RYR3,LRP1B,SORBS1,PLCB1,FMN2,ATP1A2,MGAT4C,NRXN1,CNTN1,NTRK2,TNC,NAV2,ERBB4,DGKG,GPC5,CTNND2,NPAS3,PRKG1,PARD3,CDH20,ADCY2,NEBL,HPSE2,MACF1,TRPM3,RORA,SOX5,SLC4A4,NRG3,DCLK2 |
2.450e-02 | -3.71 | Lidocaine (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000328 | 59 | 2 | 1369 | 6 |
PLCB1,ATP1A2 |
2.450e-02 | -3.71 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 5 | 16828 | 48 |
LRP1B,PLCB1,FMN2,ERBB4,SLC4A4 |
2.452e-02 | -3.71 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 49 |
SLC4A4 |
2.452e-02 | -3.71 | RFX_DNA_binding | pfam domains | PF02257 | 9 | 1 | 17795 | 49 |
RFX4 |
2.462e-02 | -3.70 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 45 |
ABLIM1 |
2.464e-02 | -3.70 | nucleotide binding | molecular function | GO:0000166 | 2128 | 11 | 18094 | 49 |
MAPK10,NAV2,NTRK2,DGKG,DCLK2,ERBB4,TNIK,ADCY2,CAMK2G,PRKG1,ATP1A2 |
2.472e-02 | -3.70 | nucleoside phosphate binding | molecular function | GO:1901265 | 2129 | 11 | 18094 | 49 |
TNIK,CAMK2G,ADCY2,PRKG1,ATP1A2,NAV2,MAPK10,DGKG,NTRK2,DCLK2,ERBB4 |
2.479e-02 | -3.70 | DDX31 (DEAD-box helicase 31) | protein interactions | 64794 | 244 | 3 | 19454 | 50 |
CLU,PRKG1,CST3 |
2.483e-02 | -3.70 | STRIP1 (striatin interacting protein 1) | protein interactions | 85369 | 95 | 2 | 19454 | 50 |
CAMK2G,TNIK |
2.487e-02 | -3.69 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 2 | 18204 | 50 |
APOE,SORBS1 |
2.504e-02 | -3.69 | Calponin-like domain | gene3d domains | 1.10.418.10 | 79 | 2 | 14470 | 45 |
NAV2,MACF1 |
2.514e-02 | -3.68 | intermediate filament cytoskeleton | cellular component | GO:0045111 | 241 | 3 | 19108 | 50 |
GFAP,MACF1,DTNA |
2.532e-02 | -3.68 | SOCS2 (suppressor of cytokine signaling 2) | protein interactions | 8835 | 96 | 2 | 19454 | 50 |
NTRK2,ERBB4 |
2.541e-02 | -3.67 | DOA4 (ubiquitin-specific protease DOA4) | protein interactions | 851641 | 10 | 1 | 19454 | 50 |
NAV2 |
2.541e-02 | -3.67 | ZNF563 (zinc finger protein 563) | protein interactions | 147837 | 10 | 1 | 19454 | 50 |
LRP1B |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | EREG (epiregulin) | protein interactions | 2069 | 10 | 1 | 19454 | 50 |
ERBB4 |
2.541e-02 | -3.67 | PTPRT (protein tyrosine phosphatase receptor type T) | protein interactions | 11122 | 10 | 1 | 19454 | 50 |
ERBB4 |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | CHRDL1 (chordin like 1) | protein interactions | 91851 | 10 | 1 | 19454 | 50 |
LRP1B |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.546e-02 | -3.67 | regulation of biological process | biological process | GO:0050789 | 12079 | 40 | 18204 | 50 |
DTNA,NPAS3,PLCB1,PITPNC1,NTRK2,GLIS3,SLC4A4,CNTN1,ADCY2,NRG3,MAPK10,RORA,ATP1A2,SORBS1,CST3,HPSE2,SOX5,PARD3,CAMK2G,DCLK2,CTNNA2,PRKG1,GPM6A,CTNND2,MACF1,SLC1A2,TNIK,DGKG,RFX4,APOE,TNC,ERBB4,GPC5,NRXN1,GFAP,NKAIN3,CLU,FMN2,MSI2,RYR3 |
2.579e-02 | -3.66 | biological regulation | biological process | GO:0065007 | 12501 | 41 | 18204 | 50 |
ADCY2,CNTN1,SLC4A4,GLIS3,PITPNC1,NTRK2,DTNA,PLCB1,NPAS3,CTNND2,GPM6A,MACF1,PRKG1,CTNNA2,CAMK2G,DCLK2,SOX5,HPSE2,PARD3,NAV2,SORBS1,CST3,RORA,ATP1A2,NRG3,MAPK10,ERBB4,GPC5,TNC,APOE,RFX4,DGKG,TNIK,SLC1A2,MSI2,RYR3,FMN2,NKAIN3,CLU,GFAP,NRXN1 |
2.581e-02 | -3.66 | BTG3 (BTG anti-proliferation factor 3) | protein interactions | 10950 | 97 | 2 | 19454 | 50 |
CLU,DCLK2 |
2.585e-02 | -3.66 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 50 |
TNIK,SOX5,DGKG |
2.585e-02 | -3.66 | ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) | protein interactions | 25 | 248 | 3 | 19454 | 50 |
SORBS1,ERBB4,CTNND2 |
2.592e-02 | -3.65 | LIM_DOMAIN_2 | prosite domains | PS50023 | 71 | 2 | 12186 | 43 |
ABLIM1,NEBL |
2.592e-02 | -3.65 | LIM_DOMAIN_1 | prosite domains | PS00478 | 71 | 2 | 12186 | 43 |
NEBL,ABLIM1 |
2.598e-02 | -3.65 | CH | smart domains | SM00033 | 66 | 2 | 9717 | 37 |
NAV2,MACF1 |
2.606e-02 | -3.65 | Dopamine Activation of Neurological Reward System | SMPDB pathways | SMP0000308 | 6 | 1 | 1369 | 6 |
ADCY2 |
2.606e-02 | -3.65 | Intracellular Signalling Through PGD2 receptor and Prostaglandin D2 | SMPDB pathways | SMP0000343 | 6 | 1 | 1369 | 6 |
ADCY2 |
2.606e-02 | -3.65 | Phospholipase C Signaling Pathway | SMPDB pathways | SMP0063783 | 6 | 1 | 1369 | 6 |
PLCB1 |
2.612e-02 | -3.65 | GAN (gigaxonin) | protein interactions | 8139 | 249 | 3 | 19454 | 50 |
GFAP,CTNNA2,PLCB1 |
2.615e-02 | -3.64 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 34 |
GPC5 |
2.615e-02 | -3.64 | Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | REACTOME pathways | R-HSA-434316 | 8 | 1 | 10285 | 34 |
PLCB1 |
2.615e-02 | -3.64 | Free fatty acids regulate insulin secretion | REACTOME pathways | R-HSA-400451 | 8 | 1 | 10285 | 34 |
PLCB1 |
2.615e-02 | -3.64 | Downregulation of ERBB4 signaling | REACTOME pathways | R-HSA-1253288 | 8 | 1 | 10285 | 34 |
ERBB4 |
2.617e-02 | -3.64 | sarcoplasm | cellular component | GO:0016528 | 96 | 2 | 19108 | 50 |
RYR3,CAMK2G |
2.629e-02 | -3.64 | Myometrial Relaxation and Contraction Pathways | WikiPathways | WP289 | 158 | 3 | 5310 | 22 |
ADCY2,RYR3,CAMK2G |
2.631e-02 | -3.64 | FRAS1 (Fraser extracellular matrix complex subunit 1) | protein interactions | 80144 | 98 | 2 | 19454 | 50 |
HPSE2,MGAT4C |
2.636e-02 | -3.64 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 37 |
MACF1 |
2.644e-02 | -3.63 | actin filament-based process | biological process | GO:0030029 | 616 | 5 | 18204 | 50 |
SORBS1,PRKG1,NEBL,TNIK,FMN2 |
2.645e-02 | -3.63 | protein tetramerization | biological process | GO:0051262 | 92 | 2 | 18204 | 50 |
TRPM3,RYR3 |
2.646e-02 | -3.63 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 50 |
NRXN1 |
2.646e-02 | -3.63 | human chr9q33.1 | chromosome location | human chr9q33.1 | 14 | 1 | 26134 | 50 |
TNC |
2.648e-02 | -3.63 | ankle | COSMIC cancer mutations | ankle | 398 | 4 | 16828 | 48 |
PLCB1,ERBB4,PARD3,NRG3 |
2.649e-02 | -3.63 | negative regulation of locomotion | biological process | GO:0040013 | 413 | 4 | 18204 | 50 |
APOE,PRKG1,PLCB1,NRG3 |
2.667e-02 | -3.62 | Endothelins | Pathway Interaction DB | endothelinpathway | 53 | 2 | 2226 | 11 |
ADCY2,PLCB1 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | Doublecortin_dom_sf | interpro domains | IPR036572 | 10 | 1 | 18521 | 50 |
DCLK2 |
2.668e-02 | -3.62 | Diacylglycerol_kin_accessory | interpro domains | IPR000756 | 10 | 1 | 18521 | 50 |
DGKG |
2.668e-02 | -3.62 | DGK | interpro domains | IPR037607 | 10 | 1 | 18521 | 50 |
DGKG |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | MIR_motif | interpro domains | IPR016093 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.676e-02 | -3.62 | neurotrophin binding | molecular function | GO:0043121 | 10 | 1 | 18094 | 49 |
NTRK2 |
2.676e-02 | -3.62 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 49 |
PITPNC1 |
2.678e-02 | -3.62 | YWHAE (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon) | protein interactions | 7531 | 1150 | 7 | 19454 | 50 |
NAV2,CAMK2G,ABLIM1,DCLK2,MACF1,SORBS1,PARD3 |
2.680e-02 | -3.62 | TPP1 (tripeptidyl peptidase 1) | protein interactions | 1200 | 99 | 2 | 19454 | 50 |
DGKG,APOE |
2.690e-02 | -3.62 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 4 | 18204 | 50 |
SLC1A2,DTNA,NRXN1,APOE |
2.690e-02 | -3.62 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 4 | 18204 | 50 |
APOE,SLC1A2,DTNA,NRXN1 |
2.699e-02 | -3.61 | intermediate filament cytoskeleton organization | biological process | GO:0045104 | 93 | 2 | 18204 | 50 |
MACF1,GFAP |
2.699e-02 | -3.61 | regulation of extent of cell growth | biological process | GO:0061387 | 93 | 2 | 18204 | 50 |
APOE,MACF1 |
2.714e-02 | -3.61 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | cellular response to cocaine | biological process | GO:0071314 | 10 | 1 | 18204 | 50 |
SLC1A2 |
2.714e-02 | -3.61 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 1 | 18204 | 50 |
PARD3 |
2.714e-02 | -3.61 | substrate-independent telencephalic tangential migration | biological process | GO:0021826 | 10 | 1 | 18204 | 50 |
NRG3 |
2.714e-02 | -3.61 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | regulation of behavioral fear response | biological process | GO:2000822 | 10 | 1 | 18204 | 50 |
APOE |
2.714e-02 | -3.61 | nitric oxide-cGMP-mediated signaling | biological process | GO:0038060 | 10 | 1 | 18204 | 50 |
APOE |
2.714e-02 | -3.61 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 50 |
SOX5 |
2.714e-02 | -3.61 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 50 |
RYR3 |
2.714e-02 | -3.61 | negative regulation of sterol biosynthetic process | biological process | GO:0106119 | 10 | 1 | 18204 | 50 |
APOE |
2.714e-02 | -3.61 | urea transmembrane transport | biological process | GO:0071918 | 10 | 1 | 18204 | 50 |
SLC14A1 |
2.714e-02 | -3.61 | substrate-independent telencephalic tangential interneuron migration | biological process | GO:0021843 | 10 | 1 | 18204 | 50 |
NRG3 |
2.714e-02 | -3.61 | mitochondrial fragmentation involved in apoptotic process | biological process | GO:0043653 | 10 | 1 | 18204 | 50 |
ERBB4 |
2.714e-02 | -3.61 | retinal rod cell development | biological process | GO:0046548 | 10 | 1 | 18204 | 50 |
NTRK2 |
2.714e-02 | -3.61 | cAMP biosynthetic process | biological process | GO:0006171 | 10 | 1 | 18204 | 50 |
ADCY2 |
2.714e-02 | -3.61 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | negative regulation of cholesterol biosynthetic process | biological process | GO:0045541 | 10 | 1 | 18204 | 50 |
APOE |
2.714e-02 | -3.61 | cellular response to brain-derived neurotrophic factor stimulus | biological process | GO:1990416 | 10 | 1 | 18204 | 50 |
NTRK2 |
2.714e-02 | -3.61 | high-density lipoprotein particle assembly | biological process | GO:0034380 | 10 | 1 | 18204 | 50 |
APOE |
2.714e-02 | -3.61 | trans-synaptic signaling, modulating synaptic transmission | biological process | GO:0099550 | 10 | 1 | 18204 | 50 |
NTRK2 |
2.714e-02 | -3.61 | regulation of CoA-transferase activity | biological process | GO:1905918 | 10 | 1 | 18204 | 50 |
APOE |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
NTRK2,ERBB4 |
2.719e-02 | -3.60 | EGF-type_Asp/Asn_hydroxyl_site | interpro domains | IPR000152 | 95 | 2 | 18521 | 50 |
LRP1B,NRXN1 |
2.720e-02 | -3.60 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 49 |
SLC4A4 |
2.720e-02 | -3.60 | DAGK_acc | pfam domains | PF00609 | 10 | 1 | 17795 | 49 |
DGKG |
2.720e-02 | -3.60 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 49 |
NPAS3 |
2.720e-02 | -3.60 | MIR | pfam domains | PF02815 | 10 | 1 | 17795 | 49 |
RYR3 |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
GPM6A,ATP1A2 |
2.731e-02 | -3.60 | APBA1 (amyloid beta precursor protein binding family A member 1) | protein interactions | 320 | 100 | 2 | 19454 | 50 |
ABLIM1,NRXN1 |
2.731e-02 | -3.60 | EDEM2 (ER degradation enhancing alpha-mannosidase like protein 2) | protein interactions | 55741 | 100 | 2 | 19454 | 50 |
CLU,HPSE2 |
2.733e-02 | -3.60 | positive regulation of transport | biological process | GO:0051050 | 844 | 6 | 18204 | 50 |
APOE,CLU,SORBS1,SLC1A2,PLCB1,CNTN1 |
2.752e-02 | -3.59 | intermediate filament-based process | biological process | GO:0045103 | 94 | 2 | 18204 | 50 |
MACF1,GFAP |
2.753e-02 | -3.59 | blood circulation | biological process | GO:0008015 | 418 | 4 | 18204 | 50 |
NAV2,PRKG1,APOE,ATP1A2 |
2.756e-02 | -3.59 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 50 |
DTNA,ATP1A2,RYR3 |
2.756e-02 | -3.59 | protein localization to cell periphery | biological process | GO:1990778 | 238 | 3 | 18204 | 50 |
ERBB4,TNIK,MACF1 |
2.765e-02 | -3.59 | Doublecortin domain | gene3d domains | 3.10.20.230 | 9 | 1 | 14470 | 45 |
DCLK2 |
2.776e-02 | -3.58 | LMO2 (LIM domain only 2) | protein interactions | 4005 | 255 | 3 | 19454 | 50 |
SOX5,GFAP,PRKG1 |
2.777e-02 | -3.58 | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-aldosterone_producing | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-aldosterone_producing | 91 | 2 | 16828 | 48 |
LRP1B,ADCY2 |
2.781e-02 | -3.58 | PRKCG (protein kinase C gamma) | protein interactions | 5582 | 101 | 2 | 19454 | 50 |
PARD3,GFAP |
2.785e-02 | -3.58 | Downstream signal transduction | REACTOME pathways | R-HSA-186763 | 352 | 4 | 10285 | 34 |
CAMK2G,ADCY2,NRG3,ERBB4 |
2.786e-02 | -3.58 | positive regulation of signal transduction | biological process | GO:0009967 | 1593 | 9 | 18204 | 50 |
ERBB4,GPC5,MACF1,PLCB1,NRXN1,NTRK2,TNIK,APOE,SORBS1 |
2.789e-02 | -3.58 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 43 |
ABLIM1 |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 50 |
NRXN1 |
2.792e-02 | -3.58 | MSRB1 (methionine sulfoxide reductase B1) | protein interactions | 51734 | 11 | 1 | 19454 | 50 |
CLU |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | SCN3A (sodium voltage-gated channel alpha subunit 3) | protein interactions | 6328 | 11 | 1 | 19454 | 50 |
CNTN1 |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | IRAG1 (inositol 1,4,5-triphosphate receptor associated 1) | protein interactions | 10335 | 11 | 1 | 19454 | 50 |
PRKG1 |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | ADCY5 (adenylate cyclase 5) | protein interactions | 111 | 11 | 1 | 19454 | 50 |
ADCY2 |
2.796e-02 | -3.58 | protein transport | biological process | GO:0015031 | 1086 | 7 | 18204 | 50 |
FMN2,CAMK2G,MACF1,LRP1B,APOE,GFAP,CLU |
2.807e-02 | -3.57 | calcium ion transmembrane import into cytosol | biological process | GO:0097553 | 95 | 2 | 18204 | 50 |
PLCB1,RYR3 |
2.807e-02 | -3.57 | cardiac muscle cell differentiation | biological process | GO:0055007 | 95 | 2 | 18204 | 50 |
NEBL,PRKG1 |
2.809e-02 | -3.57 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 5 | 18204 | 50 |
ERBB4,NTRK2,NRG3,PLCB1,SORBS1 |
2.831e-02 | -3.56 | Alzheimer's disease | KEGG pathways | hsa05010 | 165 | 3 | 7161 | 29 |
PLCB1,RYR3,APOE |
2.831e-02 | -3.56 | Alzheimer's disease | KEGG pathways | ko05010 | 165 | 3 | 7161 | 29 |
PLCB1,APOE,RYR3 |
2.832e-02 | -3.56 | PDLIM7 (PDZ and LIM domain 7) | protein interactions | 9260 | 257 | 3 | 19454 | 50 |
ABLIM1,PARD3,GFAP |
2.832e-02 | -3.56 | human chr18q12.3 | chromosome location | human chr18q12.3 | 15 | 1 | 26134 | 50 |
SLC14A1 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.832e-02 | -3.56 | human chr10p12.31 | chromosome location | human chr10p12.31 | 15 | 1 | 26134 | 50 |
NEBL |
2.832e-02 | -3.56 | GRAP2 (GRB2 related adaptor protein 2) | protein interactions | 9402 | 102 | 2 | 19454 | 50 |
GFAP,ERBB4 |
2.832e-02 | -3.56 | KRTAP6-1 (keratin associated protein 6-1) | protein interactions | 337966 | 102 | 2 | 19454 | 50 |
CAMK2G,GLIS3 |
2.842e-02 | -3.56 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 50 |
TNC |
2.862e-02 | -3.55 | negative regulation of response to wounding | biological process | GO:1903035 | 96 | 2 | 18204 | 50 |
APOE,PRKG1 |
2.863e-02 | -3.55 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | 1803 | 10 | 16828 | 48 |
HPSE2,TRPM3,CNTN1,NTRK2,FMN2,SOX5,SLC1A2,RFX4,NRG3,DGKG |
2.863e-02 | -3.55 | functioning | COSMIC cancer mutations | functioning | 1803 | 10 | 16828 | 48 |
NRG3,RFX4,DGKG,TRPM3,HPSE2,CNTN1,SOX5,SLC1A2,NTRK2,FMN2 |
2.869e-02 | -3.55 | cell surface | cellular component | GO:0009986 | 896 | 6 | 19108 | 50 |
GPC5,NRXN1,ATP1A2,SLC4A4,SLC1A2,CLU |
2.881e-02 | -3.55 | developmental growth | biological process | GO:0048589 | 424 | 4 | 18204 | 50 |
PRKG1,ERBB4,TNC,SLC1A2 |
2.881e-02 | -3.55 | growth | biological process | GO:0040007 | 424 | 4 | 18204 | 50 |
TNC,SLC1A2,ERBB4,PRKG1 |
2.884e-02 | -3.55 | ZDHHC5 (zinc finger DHHC-type palmitoyltransferase 5) | protein interactions | 25921 | 103 | 2 | 19454 | 50 |
NTRK2,PARD3 |
2.888e-02 | -3.54 | DAP12 signaling | REACTOME pathways | R-HSA-2424491 | 356 | 4 | 10285 | 34 |
CAMK2G,NRG3,ERBB4,ADCY2 |
2.891e-02 | -3.54 | aldosterone_producing | COSMIC cancer mutations | aldosterone_producing | 93 | 2 | 16828 | 48 |
LRP1B,ADCY2 |
2.891e-02 | -3.54 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 7 | 18094 | 49 |
RYR3,SLC4A4,TRPM3,SLC1A2,GPM6A,ATP1A2,SLC14A1 |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
LSAMP,NTRK2,NTM,CNTN1 |
2.917e-02 | -3.53 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 50 |
SLC1A2,GFAP |
2.917e-02 | -3.53 | positive regulation of JNK cascade | biological process | GO:0046330 | 97 | 2 | 18204 | 50 |
TNIK,PLCB1 |
2.917e-02 | -3.53 | acylglycerol metabolic process | biological process | GO:0006639 | 97 | 2 | 18204 | 50 |
DGKG,APOE |
2.929e-02 | -3.53 | EF-hand_7 | pfam domains | PF13499 | 97 | 2 | 17795 | 49 |
DGKG,MACF1 |
2.931e-02 | -3.53 | Tyr_kinase_rcpt_2_CS | interpro domains | IPR002011 | 11 | 1 | 18521 | 50 |
NTRK2 |
2.937e-02 | -3.53 | Terminal pathway of complement | REACTOME pathways | R-HSA-166665 | 9 | 1 | 10285 | 34 |
CLU |
2.940e-02 | -3.53 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 2 | 12186 | 43 |
APOE,GLIS3 |
2.940e-02 | -3.53 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 49 |
NRXN1 |
2.940e-02 | -3.53 | ATP-dependent diacylglycerol kinase activity | molecular function | GO:0004143 | 11 | 1 | 18094 | 49 |
DGKG |
2.940e-02 | -3.53 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 49 |
SLC1A2 |
2.964e-02 | -3.52 | basolateral plasma membrane | cellular component | GO:0016323 | 257 | 3 | 19108 | 50 |
ERBB4,SLC4A4,SLC14A1 |
2.968e-02 | -3.52 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 4 | 18204 | 50 |
RYR3,APOE,ATP1A2,SLC4A4 |
2.968e-02 | -3.52 | negative regulation of response to external stimulus | biological process | GO:0032102 | 428 | 4 | 18204 | 50 |
RORA,APOE,PRKG1,CTNNA2 |
2.971e-02 | -3.52 | response to abiotic stimulus | biological process | GO:0009628 | 1100 | 7 | 18204 | 50 |
FMN2,TNC,RORA,ATP1A2,NRXN1,SLC1A2,MAPK10 |
2.972e-02 | -3.52 | neutral lipid metabolic process | biological process | GO:0006638 | 98 | 2 | 18204 | 50 |
APOE,DGKG |
2.974e-02 | -3.52 | LIM | smart domains | SM00132 | 71 | 2 | 9717 | 37 |
NEBL,ABLIM1 |
2.976e-02 | -3.51 | Long-term potentiation | KEGG pathways | hsa04720 | 67 | 2 | 7161 | 29 |
PLCB1,CAMK2G |
2.976e-02 | -3.51 | Long-term potentiation | KEGG pathways | ko04720 | 67 | 2 | 7161 | 29 |
PLCB1,CAMK2G |
2.981e-02 | -3.51 | negative regulation of neuron migration | biological process | GO:2001223 | 11 | 1 | 18204 | 50 |
NRG3 |
2.981e-02 | -3.51 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 1 | 18204 | 50 |
SLC1A2 |
2.981e-02 | -3.51 | regulation of Schwann cell proliferation | biological process | GO:0010624 | 11 | 1 | 18204 | 50 |
GFAP |
2.981e-02 | -3.51 | physiological cardiac muscle hypertrophy | biological process | GO:0003301 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.981e-02 | -3.51 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | lipid phosphorylation | biological process | GO:0046834 | 11 | 1 | 18204 | 50 |
DGKG |
2.981e-02 | -3.51 | ectodermal placode formation | biological process | GO:0060788 | 11 | 1 | 18204 | 50 |
NRG3 |
2.981e-02 | -3.51 | cellular response to interleukin-12 | biological process | GO:0071349 | 11 | 1 | 18204 | 50 |
PLCB1 |
2.981e-02 | -3.51 | glutamate secretion | biological process | GO:0014047 | 11 | 1 | 18204 | 50 |
NTRK2 |
2.981e-02 | -3.51 | positive regulation of acrosome reaction | biological process | GO:2000344 | 11 | 1 | 18204 | 50 |
PLCB1 |
2.981e-02 | -3.51 | cell growth involved in cardiac muscle cell development | biological process | GO:0061049 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.981e-02 | -3.51 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 1 | 18204 | 50 |
SLC1A2 |
2.981e-02 | -3.51 | ectodermal placode morphogenesis | biological process | GO:0071697 | 11 | 1 | 18204 | 50 |
NRG3 |
2.981e-02 | -3.51 | regulation of fear response | biological process | GO:1903365 | 11 | 1 | 18204 | 50 |
APOE |
2.981e-02 | -3.51 | interleukin-15-mediated signaling pathway | biological process | GO:0035723 | 11 | 1 | 18204 | 50 |
PLCB1 |
2.981e-02 | -3.51 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | negative regulation of platelet aggregation | biological process | GO:0090331 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.981e-02 | -3.51 | cellular response to interleukin-15 | biological process | GO:0071350 | 11 | 1 | 18204 | 50 |
PLCB1 |
2.981e-02 | -3.51 | regulation of receptor catabolic process | biological process | GO:2000644 | 11 | 1 | 18204 | 50 |
APOE |
2.981e-02 | -3.51 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 50 |
RYR3 |
2.981e-02 | -3.51 | Bergmann glial cell differentiation | biological process | GO:0060020 | 11 | 1 | 18204 | 50 |
GFAP |
2.981e-02 | -3.51 | physiological muscle hypertrophy | biological process | GO:0003298 | 11 | 1 | 18204 | 50 |
PRKG1 |
2.981e-02 | -3.51 | pyramidal neuron development | biological process | GO:0021860 | 11 | 1 | 18204 | 50 |
DCLK2 |
2.981e-02 | -3.51 | egg activation | biological process | GO:0007343 | 11 | 1 | 18204 | 50 |
PLCB1 |
2.981e-02 | -3.51 | negative regulation of cholesterol metabolic process | biological process | GO:0090206 | 11 | 1 | 18204 | 50 |
APOE |
2.981e-02 | -3.51 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.999e-02 | -3.51 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 3 | 18204 | 50 |
MACF1,GFAP,NTRK2 |
3.007e-02 | -3.50 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 37 |
ABLIM1 |
3.028e-02 | -3.50 | phospholipid transport | biological process | GO:0015914 | 99 | 2 | 18204 | 50 |
PITPNC1,APOE |
3.028e-02 | -3.50 | regulation of neurotransmitter transport | biological process | GO:0051588 | 99 | 2 | 18204 | 50 |
ATP1A2,GFAP |
3.034e-02 | -3.50 | response to wounding | biological process | GO:0009611 | 431 | 4 | 18204 | 50 |
DGKG,TNC,SLC1A2,MACF1 |
3.034e-02 | -3.50 | G-Protein Signaling Through Tubby Proteins | SMPDB pathways | SMP0089843 | 7 | 1 | 1369 | 6 |
PLCB1 |
3.034e-02 | -3.50 | Vasopressin Regulation of Water Homeostasis | SMPDB pathways | SMP0000322 | 7 | 1 | 1369 | 6 |
ADCY2 |
3.034e-02 | -3.50 | g-Secretase Mediated ErbB4 Signalling Pathway | SMPDB pathways | SMP0089975 | 7 | 1 | 1369 | 6 |
ERBB4 |
3.036e-02 | -3.49 | NRAS (NRAS proto-oncogene, GTPase) | protein interactions | 4893 | 683 | 5 | 19454 | 50 |
FMN2,PLCB1,TNIK,MACF1,NAV2 |
3.040e-02 | -3.49 | USP6NL (USP6 N-terminal like) | protein interactions | 9712 | 106 | 2 | 19454 | 50 |
NTRK2,PARD3 |
3.042e-02 | -3.49 | PTPN20 (protein tyrosine phosphatase non-receptor type 20) | protein interactions | 26095 | 12 | 1 | 19454 | 50 |
ERBB4 |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.042e-02 | -3.49 | INTS4P2 (integrator complex subunit 4 pseudogene 2) | protein interactions | 644619 | 12 | 1 | 19454 | 50 |
GFAP |
3.042e-02 | -3.49 | SMIM20 (small integral membrane protein 20) | protein interactions | 389203 | 12 | 1 | 19454 | 50 |
ERBB4 |
3.042e-02 | -3.49 | NTF4 (neurotrophin 4) | protein interactions | 4909 | 12 | 1 | 19454 | 50 |
NTRK2 |
3.042e-02 | -3.49 | OAS2 (2'-5'-oligoadenylate synthetase 2) | protein interactions | 4939 | 12 | 1 | 19454 | 50 |
PRKG1 |
3.042e-02 | -3.49 | Pard6b (par-6 family cell polarity regulator beta) | protein interactions | 58220 | 12 | 1 | 19454 | 50 |
PARD3 |
3.042e-02 | -3.49 | MMP25 (matrix metallopeptidase 25) | protein interactions | 64386 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | KIF26A (kinesin family member 26A) | protein interactions | 26153 | 12 | 1 | 19454 | 50 |
MAPK10 |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
LRP1B |
3.042e-02 | -3.49 | MYBPHL (myosin binding protein H like) | protein interactions | 343263 | 12 | 1 | 19454 | 50 |
GFAP |
3.058e-02 | -3.49 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 6 | 19454 | 50 |
PARD3,CTNNA2,SORBS1,APOE,DTNA,CTNND2 |
3.059e-02 | -3.49 | NAKATPASE | prints domains | PR00121 | 9 | 1 | 5227 | 18 |
ATP1A2 |
3.068e-02 | -3.48 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 45 |
SLC4A4 |
3.085e-02 | -3.48 | regulation of dendrite development | biological process | GO:0050773 | 100 | 2 | 18204 | 50 |
DGKG,TNIK |
3.085e-02 | -3.48 | response to alkaloid | biological process | GO:0043279 | 100 | 2 | 18204 | 50 |
SLC1A2,RYR3 |
3.093e-02 | -3.48 | regulation of muscle system process | biological process | GO:0090257 | 249 | 3 | 18204 | 50 |
ATP1A2,PRKG1,CAMK2G |
3.096e-02 | -3.48 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 50 |
TNC |
3.096e-02 | -3.48 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 50 |
ATP1A2 |
3.097e-02 | -3.47 | HSPA5 (heat shock protein family A (Hsp70) member 5) | protein interactions | 3309 | 1455 | 8 | 19454 | 50 |
CLU,GPC5,HPSE2,DTNA,APOE,GFAP,LRP1B,PARD3 |
3.099e-02 | -3.47 | Signaling by EGFR | REACTOME pathways | R-HSA-177929 | 364 | 4 | 10285 | 34 |
CAMK2G,NRG3,ERBB4,ADCY2 |
3.107e-02 | -3.47 | MCAM (melanoma cell adhesion molecule) | protein interactions | 4162 | 464 | 4 | 19454 | 50 |
CTNNA2,TNIK,CNTN1,PLCB1 |
3.132e-02 | -3.46 | RFX_DBD | prosite domains | PS51526 | 9 | 1 | 12186 | 43 |
RFX4 |
3.132e-02 | -3.46 | DC | prosite domains | PS50309 | 9 | 1 | 12186 | 43 |
DCLK2 |
3.132e-02 | -3.46 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 43 |
CST3 |
3.137e-02 | -3.46 | amide binding | molecular function | GO:0033218 | 254 | 3 | 18094 | 49 |
CST3,CLU,APOE |
3.139e-02 | -3.46 | regulation of protein localization | biological process | GO:0032880 | 872 | 6 | 18204 | 50 |
APOE,SORBS1,PLCB1,ERBB4,GPC5,DCLK2 |
3.142e-02 | -3.46 | cholesterol homeostasis | biological process | GO:0042632 | 101 | 2 | 18204 | 50 |
APOE,RORA |
3.142e-02 | -3.46 | regulation of glucose metabolic process | biological process | GO:0010906 | 101 | 2 | 18204 | 50 |
SORBS1,RORA |
3.142e-02 | -3.46 | regulation of carbohydrate biosynthetic process | biological process | GO:0043255 | 101 | 2 | 18204 | 50 |
SORBS1,PRKG1 |
3.147e-02 | -3.46 | CLASP1 (cytoplasmic linker associated protein 1) | protein interactions | 23332 | 108 | 2 | 19454 | 50 |
MACF1,DCLK2 |
3.147e-02 | -3.46 | ALDH3B1 (aldehyde dehydrogenase 3 family member B1) | protein interactions | 221 | 108 | 2 | 19454 | 50 |
GFAP,FMN2 |
3.147e-02 | -3.46 | BIN1 (bridging integrator 1) | protein interactions | 274 | 108 | 2 | 19454 | 50 |
GPM6A,CLU |
3.149e-02 | -3.46 | PFN1 (profilin 1) | protein interactions | 5216 | 466 | 4 | 19454 | 50 |
MACF1,FMN2,ABLIM1,CAMK2G |
3.151e-02 | -3.46 | VCL (vinculin) | protein interactions | 7414 | 268 | 3 | 19454 | 50 |
NEBL,MACF1,SORBS1 |
3.165e-02 | -3.45 | Human Thyroid Stimulating Hormone (TSH) signaling pathway | WikiPathways | WP2032 | 68 | 2 | 5310 | 22 |
PLCB1,ADCY2 |
3.169e-02 | -3.45 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 4 | 18204 | 50 |
SLC4A4,RYR3,ATP1A2,APOE |
3.189e-02 | -3.45 | SH3 Domains | gene3d domains | 2.30.30.40 | 223 | 3 | 14470 | 45 |
MACF1,NEBL,SORBS1 |
3.192e-02 | -3.44 | Opioid Signalling | REACTOME pathways | R-HSA-111885 | 85 | 2 | 10285 | 34 |
ADCY2,PLCB1 |
3.193e-02 | -3.44 | MAP_kinase_CS | interpro domains | IPR003527 | 12 | 1 | 18521 | 50 |
MAPK10 |
3.193e-02 | -3.44 | PLC_EF-hand-like | interpro domains | IPR015359 | 12 | 1 | 18521 | 50 |
PLCB1 |
3.199e-02 | -3.44 | sterol homeostasis | biological process | GO:0055092 | 102 | 2 | 18204 | 50 |
APOE,RORA |
3.200e-02 | -3.44 | PRR20A (proline rich 20A) | protein interactions | 122183 | 109 | 2 | 19454 | 50 |
SOX5,TRPM3 |
3.200e-02 | -3.44 | SIPA1L3 (signal induced proliferation associated 1 like 3) | protein interactions | 23094 | 109 | 2 | 19454 | 50 |
PARD3,GFAP |
3.203e-02 | -3.44 | adenylate cyclase binding | molecular function | GO:0008179 | 12 | 1 | 18094 | 49 |
ADCY2 |
3.204e-02 | -3.44 | human chr9q21.33 | chromosome location | human chr9q21.33 | 17 | 1 | 26134 | 50 |
NTRK2 |
3.233e-02 | -3.43 | SH3DOMAIN | prints domains | PR00452 | 83 | 2 | 5227 | 18 |
SORBS1,NEBL |
3.240e-02 | -3.43 | EGF | smart domains | SM00181 | 184 | 3 | 9717 | 37 |
LRP1B,TNC,NRXN1 |
3.243e-02 | -3.43 | Axon guidance | KEGG pathways | ko04360 | 174 | 3 | 7161 | 29 |
CAMK2G,PARD3,ABLIM1 |
3.243e-02 | -3.43 | Axon guidance | KEGG pathways | hsa04360 | 174 | 3 | 7161 | 29 |
ABLIM1,PARD3,CAMK2G |
3.246e-02 | -3.43 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 45 | 16828 | 48 |
TNC,SLC1A2,NRXN1,NAV2,ERBB4,GLIS3,PLCB1,TNIK,LRP1B,PITPNC1,ATP1A2,CLU,LSAMP,RORA,HPSE2,MACF1,NRG3,RFX4,NTM,PRKG1,CAMK2G,DTNA,GPC5,NEBL,NTRK2,CNTN1,MSI2,DGKG,GPM6A,FMN2,SORBS1,GFAP,RYR3,MGAT4C,SLC4A4,SOX5,ABLIM1,TRPM3,DCLK2,SLC14A1,PARD3,CTNND2,NPAS3,ADCY2,CDH20 |
3.248e-02 | -3.43 | auditory behavior | biological process | GO:0031223 | 12 | 1 | 18204 | 50 |
NRXN1 |
3.248e-02 | -3.43 | neurotransmitter-gated ion channel clustering | biological process | GO:0072578 | 12 | 1 | 18204 | 50 |
APOE |
3.248e-02 | -3.43 | urea transport | biological process | GO:0015840 | 12 | 1 | 18204 | 50 |
SLC14A1 |
3.248e-02 | -3.43 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 50 |
SLC1A2 |
3.248e-02 | -3.43 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 50 |
CST3 |
3.248e-02 | -3.43 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 50 |
CST3 |
3.248e-02 | -3.43 | response to interleukin-15 | biological process | GO:0070672 | 12 | 1 | 18204 | 50 |
PLCB1 |
3.248e-02 | -3.43 | negative regulation of smooth muscle contraction | biological process | GO:0045986 | 12 | 1 | 18204 | 50 |
PRKG1 |
3.248e-02 | -3.43 | response to interleukin-12 | biological process | GO:0070671 | 12 | 1 | 18204 | 50 |
PLCB1 |
3.256e-02 | -3.42 | EF-hand_like | pfam domains | PF09279 | 12 | 1 | 17795 | 49 |
PLCB1 |
3.258e-02 | -3.42 | Adenylate cyclase activating pathway | REACTOME pathways | R-HSA-170660 | 10 | 1 | 10285 | 34 |
ADCY2 |
3.258e-02 | -3.42 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 1 | 10285 | 34 |
SLC4A4 |
3.258e-02 | -3.42 | Activation of the AP-1 family of transcription factors | REACTOME pathways | R-HSA-450341 | 10 | 1 | 10285 | 34 |
MAPK10 |
3.258e-02 | -3.42 | Acetylcholine regulates insulin secretion | REACTOME pathways | R-HSA-399997 | 10 | 1 | 10285 | 34 |
PLCB1 |
3.263e-02 | -3.42 | peptide binding | molecular function | GO:0042277 | 258 | 3 | 18094 | 49 |
APOE,CLU,CST3 |
3.270e-02 | -3.42 | nervous system process | biological process | GO:0050877 | 1376 | 8 | 18204 | 50 |
ATP1A2,APOE,NAV2,ABLIM1,PLCB1,NRXN1,NTRK2,CTNNA2 |
3.272e-02 | -3.42 | large_cell_carcinoma | COSMIC cancer mutations | large_cell_carcinoma | 849 | 6 | 16828 | 48 |
TNIK,NTRK2,PRKG1,CAMK2G,ERBB4,DCLK2 |
3.272e-02 | -3.42 | lung-carcinoma-large_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-large_cell_carcinoma | 849 | 6 | 16828 | 48 |
DCLK2,ERBB4,PRKG1,TNIK,NTRK2,CAMK2G |
3.273e-02 | -3.42 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 18 | 16828 | 48 |
NAV2,GLIS3,APOE,TNC,RORA,CLU,TRPM3,MACF1,ADCY2,CDH20,PARD3,SORBS1,FMN2,LRP1B,CAMK2G,RYR3,NPAS3,CTNND2 |
3.287e-02 | -3.42 | Axon guidance | REACTOME pathways | R-HSA-422475 | 549 | 5 | 10285 | 34 |
ABLIM1,NRG3,ERBB4,CNTN1,CAMK2G |
3.291e-02 | -3.41 | NCAN (neurocan) | protein interactions | 1463 | 13 | 1 | 19454 | 50 |
TNC |
3.291e-02 | -3.41 | RNASE4 (ribonuclease A family member 4) | protein interactions | 6038 | 13 | 1 | 19454 | 50 |
LRP1B |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | JAM2 (junctional adhesion molecule 2) | protein interactions | 58494 | 13 | 1 | 19454 | 50 |
PARD3 |
3.291e-02 | -3.41 | NPR2 (natriuretic peptide receptor 2) | protein interactions | 4882 | 13 | 1 | 19454 | 50 |
CAMK2G |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | ANKH (ANKH inorganic pyrophosphate transport regulator) | protein interactions | 56172 | 13 | 1 | 19454 | 50 |
APOE |
3.291e-02 | -3.41 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 50 |
NRXN1 |
3.292e-02 | -3.41 | DAP12 interactions | REACTOME pathways | R-HSA-2172127 | 371 | 4 | 10285 | 34 |
NRG3,ERBB4,ADCY2,CAMK2G |
3.305e-02 | -3.41 | CH | prosite domains | PS50021 | 81 | 2 | 12186 | 43 |
NAV2,MACF1 |
3.318e-02 | -3.41 | positive regulation of growth | biological process | GO:0045927 | 256 | 3 | 18204 | 50 |
ERBB4,PLCB1,MACF1 |
3.318e-02 | -3.41 | protein complex oligomerization | biological process | GO:0051259 | 256 | 3 | 18204 | 50 |
TRPM3,SLC1A2,RYR3 |
3.320e-02 | -3.41 | Fc epsilon receptor (FCERI) signaling | REACTOME pathways | R-HSA-2454202 | 372 | 4 | 10285 | 34 |
CAMK2G,MAPK10,NRG3,ERBB4 |
3.331e-02 | -3.40 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | REACTOME pathways | R-HSA-6811558 | 87 | 2 | 10285 | 34 |
NRG3,ERBB4 |
3.350e-02 | -3.40 | cytoplasmic side of lysosomal membrane | cellular component | GO:0098574 | 13 | 1 | 19108 | 50 |
GFAP |
3.350e-02 | -3.40 | chylomicron | cellular component | GO:0042627 | 13 | 1 | 19108 | 50 |
APOE |
3.350e-02 | -3.40 | postsynaptic cytosol | cellular component | GO:0099524 | 13 | 1 | 19108 | 50 |
PLCB1 |
3.363e-02 | -3.39 | EDA (ectodysplasin A) | protein interactions | 1896 | 112 | 2 | 19454 | 50 |
GPM6A,ERBB4 |
3.363e-02 | -3.39 | TSC22D4 (TSC22 domain family member 4) | protein interactions | 81628 | 112 | 2 | 19454 | 50 |
ABLIM1,CLU |
3.373e-02 | -3.39 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 2 | 18204 | 50 |
SOX5,RORA |
3.373e-02 | -3.39 | gland morphogenesis | biological process | GO:0022612 | 105 | 2 | 18204 | 50 |
TNC,NRG3 |
3.373e-02 | -3.39 | response to interleukin-1 | biological process | GO:0070555 | 105 | 2 | 18204 | 50 |
PLCB1,RORA |
3.373e-02 | -3.39 | cellular response to alcohol | biological process | GO:0097306 | 105 | 2 | 18204 | 50 |
ADCY2,TNC |
3.377e-02 | -3.39 | DCX | smart domains | SM00537 | 9 | 1 | 9717 | 37 |
DCLK2 |
3.381e-02 | -3.39 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 8 | 18204 | 50 |
ERBB4,SOX5,MACF1,NTRK2,NRXN1,PLCB1,GFAP,APOE |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.394e-02 | -3.38 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 18 |
SLC4A4 |
3.402e-02 | -3.38 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 49 |
ATP1A2,RORA |
3.432e-02 | -3.37 | cellular response to ketone | biological process | GO:1901655 | 106 | 2 | 18204 | 50 |
ADCY2,TNC |
3.432e-02 | -3.37 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 3 | 16828 | 48 |
MACF1,TNIK,MGAT4C |
3.434e-02 | -3.37 | Signaling by PDGF | REACTOME pathways | R-HSA-186797 | 376 | 4 | 10285 | 34 |
ADCY2,ERBB4,NRG3,CAMK2G |
3.457e-02 | -3.36 | TJP2 (tight junction protein 2) | protein interactions | 9414 | 278 | 3 | 19454 | 50 |
PARD3,SORBS1,NEBL |
3.460e-02 | -3.36 | phosphatidylinositol bisphosphate binding | molecular function | GO:1902936 | 108 | 2 | 18094 | 49 |
PARD3,PLCB1 |
3.462e-02 | -3.36 | Dimetindene H1-Antihistamine Action | SMPDB pathways | SMP0057582 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Cyclizine H1-Antihistamine Action | SMPDB pathways | SMP0058923 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Phenbenzamine H1-Antihistamine Action | SMPDB pathways | SMP0059702 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Azatadine H1-Antihistamine Action | SMPDB pathways | SMP0059865 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Quetiapine H1-Antihistamine Action | SMPDB pathways | SMP0062884 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Chlorphenamine H1-Antihistamine Action | SMPDB pathways | SMP0056661 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Tolpropamine H1-Antihistamine Action | SMPDB pathways | SMP0062621 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Quifenadine H1-Antihistamine Action | SMPDB pathways | SMP0060743 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Hydroxyzine H1-Antihistamine Action | SMPDB pathways | SMP0058936 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Mebhydrolin H1-Antihistamine Action | SMPDB pathways | SMP0061052 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Talastine H1-Antihistamine Action | SMPDB pathways | SMP0057586 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Histapyrrodine H1-Antihistamine Action | SMPDB pathways | SMP0058732 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Pyrrobutamine H1-Antihistamine Action | SMPDB pathways | SMP0062887 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Astemizole H1-Antihistamine Action | SMPDB pathways | SMP0059897 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Promethazine H1-Antihistamine Action | SMPDB pathways | SMP0059211 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Ketotifen H1-Antihistamine Action | SMPDB pathways | SMP0059868 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Thenalidine H1-Antihistamine Action | SMPDB pathways | SMP0062894 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Thiazinamium H1-Antihistamine Action | SMPDB pathways | SMP0060742 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Bromodiphenhydramine H1-Antihistamine Action | SMPDB pathways | SMP0058813 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Emedastine H1-Antihistamine Action | SMPDB pathways | SMP0061040 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Mepyramine H1-Antihistamine Action | SMPDB pathways | SMP0057583 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Cetirizine H1-Antihistamine Action | SMPDB pathways | SMP0059058 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Azelastine H1-Antihistamine Action | SMPDB pathways | SMP0060741 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Latrepirdine H1-Antihistamine Action | SMPDB pathways | SMP0062623 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Dexchlorpheniramine H1-Antihistamine Action | SMPDB pathways | SMP0056811 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Orphenadrine H1-Antihistamine Action | SMPDB pathways | SMP0058808 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Chlorphenoxamine H1-Antihistamine Action | SMPDB pathways | SMP0058903 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Desloratadine H1-Antihistamine Action | SMPDB pathways | SMP0060201 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Flunarizine H1-Antihistamine Action | SMPDB pathways | SMP0061047 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Tritoqualine H1-Antihistamine Action | SMPDB pathways | SMP0062895 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Hydroxyethylpromethazine H1-Antihistamine Action | SMPDB pathways | SMP0059710 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Fexofenadine H1-Antihistamine Action | SMPDB pathways | SMP0060218 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Pheniramine H1-Antihistamine Action | SMPDB pathways | SMP0056662 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Temelastine H1-Antihistamine Action | SMPDB pathways | SMP0062880 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Triprolidine H1-Antihistamine Action | SMPDB pathways | SMP0057581 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Chlorcyclizine H1-Antihistamine Action | SMPDB pathways | SMP0058931 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Mirtazapine H1-Antihistamine Action | SMPDB pathways | SMP0062885 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Embramine H1-Antihistamine Action | SMPDB pathways | SMP0062622 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Meclizine H1-Antihistamine Action | SMPDB pathways | SMP0058956 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Epinastine H1-Antihistamine Action | SMPDB pathways | SMP0061191 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Lysophosphatidic Acid LPA3 Signalling | SMPDB pathways | SMP0063755 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Phenindamine H1-Antihistamine Action | SMPDB pathways | SMP0061190 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Diphenhydramine H1-Antihistamine Action | SMPDB pathways | SMP0058785 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Bilastine H1-Antihistamine Action | SMPDB pathways | SMP0060170 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Thenyldiamine H1-Antihistamine Action | SMPDB pathways | SMP0062624 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Chloropyramine H1-Antihistamine Action | SMPDB pathways | SMP0057585 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Thonzylamine H1-Antihistamine Action | SMPDB pathways | SMP0058769 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Dexbrompheniramine H1-Antihistamine Action | SMPDB pathways | SMP0057580 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Alcaftadine H1-Antihistamine Action | SMPDB pathways | SMP0062881 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Levocabastine H1-Antihistamine Action | SMPDB pathways | SMP0060224 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Alimemazine H1-Antihistamine Action | SMPDB pathways | SMP0059689 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Cyproheptadine H1-Antihistamine Action | SMPDB pathways | SMP0059694 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Cinnarizine H1-Antihistamine Action | SMPDB pathways | SMP0059110 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Terfenadine H1-Antihistamine Action | SMPDB pathways | SMP0060208 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Loratadine H1-Antihistamine Action | SMPDB pathways | SMP0060195 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Methapyrilene H1-Antihistamine Action | SMPDB pathways | SMP0058741 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Buclizine H1-Antihistamine Action | SMPDB pathways | SMP0058964 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Olopatadine H1-Antihistamine Action | SMPDB pathways | SMP0060740 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Phenyltoloxamine H1-Antihistamine Action | SMPDB pathways | SMP0058916 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Acrivastine H1-Antihistamine Action | SMPDB pathways | SMP0059881 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Bepotastine H1-Antihistamine Action | SMPDB pathways | SMP0060058 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Clocinizine H1-Antihistamine Action | SMPDB pathways | SMP0062788 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Carbinoxamine H1-Antihistamine Action | SMPDB pathways | SMP0058797 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Mequitazine H1-Antihistamine Action | SMPDB pathways | SMP0059720 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Deptropine H1-Antihistamine Action | SMPDB pathways | SMP0062883 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Brompheniramine H1-Antihistamine Action | SMPDB pathways | SMP0057579 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Mizolastine H1-Antihistamine Action | SMPDB pathways | SMP0060230 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Levocetirizine H1-Antihistamine Action | SMPDB pathways | SMP0059114 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Doxepin H1-Antihistamine Action | SMPDB pathways | SMP0059872 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Ebastine H1-Antihistamine Action | SMPDB pathways | SMP0060204 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Isothipendyl H1-Antihistamine Action | SMPDB pathways | SMP0059716 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Rupatadine H1-Antihistamine Action | SMPDB pathways | SMP0060235 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Betahistine H1-Antihistamine Action | SMPDB pathways | SMP0060744 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Clemastine H1-Antihistamine Action | SMPDB pathways | SMP0058891 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Pimethixene H1-Antihistamine Action | SMPDB pathways | SMP0062886 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Fenethazine H1-Antihistamine Action | SMPDB pathways | SMP0059707 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Histamine H1 Receptor Activation | SMPDB pathways | SMP0063452 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Doxylamine H1-Antihistamine Action | SMPDB pathways | SMP0058803 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Tripelennamine H1-Antihistamine Action | SMPDB pathways | SMP0057587 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Homochlorcyclizine H1-Antihistamine Action | SMPDB pathways | SMP0062795 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Antazoline H1-Antihistamine Action | SMPDB pathways | SMP0057584 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Propiomazine H1-Antihistamine Action | SMPDB pathways | SMP0062625 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Oxomemazine H1-Antihistamine Action | SMPDB pathways | SMP0059738 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Bamipine H1-Antihistamine Action | SMPDB pathways | SMP0062882 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Oxatomide H1-Antihistamine Action | SMPDB pathways | SMP0059044 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin | SMPDB pathways | SMP0000354 | 8 | 1 | 1369 | 6 |
ADCY2 |
3.462e-02 | -3.36 | Methdilazine H1-Antihistamine Action | SMPDB pathways | SMP0059730 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.462e-02 | -3.36 | Diphenylpyraline H1-Antihistamine Action | SMPDB pathways | SMP0058908 | 8 | 1 | 1369 | 6 |
PLCB1 |
3.465e-02 | -3.36 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 49 |
ATP1A2 |
3.465e-02 | -3.36 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 49 |
SLC4A4 |
3.469e-02 | -3.36 | negative regulation of protein metabolic process | biological process | GO:0051248 | 893 | 6 | 18204 | 50 |
APOE,CLU,CST3,FMN2,PARD3,NTRK2 |
3.474e-02 | -3.36 | MIR | prosite domains | PS50919 | 10 | 1 | 12186 | 43 |
RYR3 |
3.500e-02 | -3.35 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 2 | 18521 | 50 |
RYR3,TRPM3 |
3.514e-02 | -3.35 | phospholipid efflux | biological process | GO:0033700 | 13 | 1 | 18204 | 50 |
APOE |
3.514e-02 | -3.35 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 50 |
NRXN1 |
3.514e-02 | -3.35 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 50 |
RORA |
3.514e-02 | -3.35 | nervous system process involved in regulation of systemic arterial blood pressure | biological process | GO:0001976 | 13 | 1 | 18204 | 50 |
NAV2 |
3.514e-02 | -3.35 | regulation of dendritic spine maintenance | biological process | GO:1902950 | 13 | 1 | 18204 | 50 |
APOE |
3.514e-02 | -3.35 | ectodermal placode development | biological process | GO:0071696 | 13 | 1 | 18204 | 50 |
NRG3 |
3.514e-02 | -3.35 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | negative regulation of homotypic cell-cell adhesion | biological process | GO:0034111 | 13 | 1 | 18204 | 50 |
PRKG1 |
3.514e-02 | -3.35 | cellular response to vitamin D | biological process | GO:0071305 | 13 | 1 | 18204 | 50 |
TNC |
3.514e-02 | -3.35 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 50 |
CTNNA2 |
3.514e-02 | -3.35 | olfactory bulb interneuron differentiation | biological process | GO:0021889 | 13 | 1 | 18204 | 50 |
ERBB4 |
3.514e-02 | -3.35 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 50 |
RORA |
3.514e-02 | -3.35 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 47 | 16828 | 48 |
DGKG,CNTN1,NTRK2,MSI2,MGAT4C,GFAP,SORBS1,FMN2,GPM6A,RYR3,DCLK2,SLC14A1,ABLIM1,SOX5,SLC4A4,TRPM3,CDH20,ADCY2,PARD3,NPAS3,CTNND2,ERBB4,NAV2,GLIS3,SLC1A2,TNC,APOE,NRXN1,ATP1A2,PITPNC1,LRP1B,PLCB1,TNIK,CST3,NRG3,RFX4,RORA,LSAMP,CLU,MACF1,HPSE2,NEBL,PRKG1,NTM,GPC5,CAMK2G,DTNA |
3.514e-02 | -3.35 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 47 | 16828 | 48 |
RFX4,NRG3,CST3,HPSE2,MACF1,RORA,CLU,LSAMP,NEBL,GPC5,DTNA,CAMK2G,PRKG1,NTM,GLIS3,NAV2,ERBB4,NRXN1,SLC1A2,TNC,APOE,ATP1A2,PITPNC1,LRP1B,TNIK,PLCB1,SLC14A1,DCLK2,TRPM3,ABLIM1,SOX5,SLC4A4,CDH20,ADCY2,NPAS3,CTNND2,PARD3,DGKG,MSI2,CNTN1,NTRK2,MGAT4C,RYR3,GFAP,GPM6A,SORBS1,FMN2 |
3.522e-02 | -3.35 | Ldl_recept_b | pfam domains | PF00058 | 13 | 1 | 17795 | 49 |
LRP1B |
3.530e-02 | -3.34 | CDH2 (cadherin 2) | protein interactions | 1000 | 115 | 2 | 19454 | 50 |
CTNND2,PARD3 |
3.530e-02 | -3.34 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 2 | 19454 | 50 |
SOX5,PARD3 |
3.530e-02 | -3.34 | DTNA (dystrobrevin alpha) | protein interactions | 1837 | 115 | 2 | 19454 | 50 |
PARD3,NTRK2 |
3.539e-02 | -3.34 | HRAS (HRas proto-oncogene, GTPase) | protein interactions | 3265 | 712 | 5 | 19454 | 50 |
NAV2,MAPK10,PLCB1,PARD3,TNIK |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | GAGE1 (G antigen 1) | protein interactions | 2543 | 14 | 1 | 19454 | 50 |
PRKG1 |
3.540e-02 | -3.34 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 1 | 19454 | 50 |
NRXN1 |
3.540e-02 | -3.34 | BOD1L2 (biorientation of chromosomes in cell division 1 like 2) | protein interactions | 284257 | 14 | 1 | 19454 | 50 |
FMN2 |
3.540e-02 | -3.34 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 50 |
CST3 |
3.540e-02 | -3.34 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 50 |
CAMK2G |
3.540e-02 | -3.34 | Stag2 (STAG2 cohesin complex component) | protein interactions | 20843 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 50 |
LRP1B |
3.540e-02 | -3.34 | Aifm1 (apoptosis-inducing factor, mitochondrion-associated 1) | protein interactions | 26926 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.540e-02 | -3.34 | CHAT (choline O-acetyltransferase) | protein interactions | 1103 | 14 | 1 | 19454 | 50 |
CAMK2G |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | TPSAB1 (tryptase alpha/beta 1) | protein interactions | 7177 | 14 | 1 | 19454 | 50 |
CAMK2G |
3.540e-02 | -3.34 | CABS1 (calcium binding protein, spermatid associated 1) | protein interactions | 85438 | 14 | 1 | 19454 | 50 |
GFAP |
3.540e-02 | -3.34 | CFAP58 (cilia and flagella associated protein 58) | protein interactions | 159686 | 14 | 1 | 19454 | 50 |
NAV2 |
3.540e-02 | -3.34 | IFNA8 (interferon alpha 8) | protein interactions | 3445 | 14 | 1 | 19454 | 50 |
APOE |
3.540e-02 | -3.34 | SH3YL1 (SH3 and SYLF domain containing 1) | protein interactions | 26751 | 14 | 1 | 19454 | 50 |
GFAP |
3.544e-02 | -3.34 | PI3K/AKT Signaling in Cancer | REACTOME pathways | R-HSA-2219528 | 90 | 2 | 10285 | 34 |
NRG3,ERBB4 |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.578e-02 | -3.33 | structural constituent of cytoskeleton | molecular function | GO:0005200 | 110 | 2 | 18094 | 49 |
CTNNA2,GFAP |
3.586e-02 | -3.33 | RBBP8 (RB binding protein 8, endonuclease) | protein interactions | 5932 | 116 | 2 | 19454 | 50 |
CTNNA2,CLU |
3.586e-02 | -3.33 | FCGRT (Fc gamma receptor and transporter) | protein interactions | 2217 | 116 | 2 | 19454 | 50 |
CLU,CNTN1 |
3.588e-02 | -3.33 | cGMP signaling | KEGG pathways | hsa_M00694 | 9 | 1 | 7161 | 29 |
PRKG1 |
3.588e-02 | -3.33 | cGMP signaling | KEGG pathways | M00694 | 9 | 1 | 7161 | 29 |
PRKG1 |
3.588e-02 | -3.33 | Heparan sulfate degradation | KEGG pathways | M00078 | 9 | 1 | 7161 | 29 |
HPSE2 |
3.588e-02 | -3.33 | Heparan sulfate degradation | KEGG pathways | hsa_M00078 | 9 | 1 | 7161 | 29 |
HPSE2 |
3.589e-02 | -3.33 | plasma membrane raft | cellular component | GO:0044853 | 114 | 2 | 19108 | 50 |
SORBS1,ATP1A2 |
3.592e-02 | -3.33 | regulation of MAPK cascade | biological process | GO:0043408 | 669 | 5 | 18204 | 50 |
APOE,PLCB1,ERBB4,NTRK2,TNIK |
3.592e-02 | -3.33 | PRKACA (protein kinase cAMP-activated catalytic subunit alpha) | protein interactions | 5566 | 486 | 4 | 19454 | 50 |
PARD3,GFAP,TNIK,SLC4A4 |
3.603e-02 | -3.32 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 50 |
CLU |
3.620e-02 | -3.32 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 3 | 18204 | 50 |
GPC5,APOE,CTNND2 |
3.627e-02 | -3.32 | Ion_trans | pfam domains | PF00520 | 109 | 2 | 17795 | 49 |
TRPM3,RYR3 |
3.635e-02 | -3.31 | Chemokine signaling pathway | KEGG pathways | ko04062 | 182 | 3 | 7161 | 29 |
ADCY2,PLCB1,PARD3 |
3.635e-02 | -3.31 | Chemokine signaling pathway | KEGG pathways | hsa04062 | 182 | 3 | 7161 | 29 |
ADCY2,PLCB1,PARD3 |
3.647e-02 | -3.31 | Dppa3 (developmental pluripotency-associated 3) | protein interactions | 73708 | 284 | 3 | 19454 | 50 |
ATP1A2,MSI2,CAMK2G |
3.668e-02 | -3.31 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 5 | 19454 | 50 |
DTNA,TNIK,MACF1,PARD3,FMN2 |
3.670e-02 | -3.30 | - | gene3d domains | 3.10.450.50 | 12 | 1 | 14470 | 45 |
CAMK2G |
3.670e-02 | -3.30 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 45 |
CTNNA2 |
3.670e-02 | -3.30 | EV release from cardiac cells and their functional effects | WikiPathways | WP3297 | 9 | 1 | 5310 | 22 |
ERBB4 |
3.672e-02 | -3.30 | positive regulation of cell junction assembly | biological process | GO:1901890 | 110 | 2 | 18204 | 50 |
NTRK2,NRXN1 |
3.676e-02 | -3.30 | heterocyclic compound binding | molecular function | GO:1901363 | 2263 | 11 | 18094 | 49 |
DCLK2,ERBB4,NAV2,MAPK10,DGKG,NTRK2,PRKG1,ATP1A2,TNIK,CAMK2G,ADCY2 |
3.677e-02 | -3.30 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 5 | 16828 | 48 |
TNIK,ABLIM1,PRKG1,TRPM3,MACF1 |
3.689e-02 | -3.30 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 34 |
LSAMP,NTM |
3.694e-02 | -3.30 | sulfur compound binding | molecular function | GO:1901681 | 271 | 3 | 18094 | 49 |
APOE,HPSE2,NAV2 |
3.699e-02 | -3.30 | SIPA1L2 (signal induced proliferation associated 1 like 2) | protein interactions | 57568 | 118 | 2 | 19454 | 50 |
PARD3,GFAP |
3.699e-02 | -3.30 | CEACAM8 (CEA cell adhesion molecule 8) | protein interactions | 1088 | 118 | 2 | 19454 | 50 |
APOE,CLU |
3.702e-02 | -3.30 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 37 |
NTRK2,ERBB4 |
3.704e-02 | -3.30 | blood microparticle | cellular component | GO:0072562 | 116 | 2 | 19108 | 50 |
APOE,CLU |
3.715e-02 | -3.29 | LDLR_classB_rpt | interpro domains | IPR000033 | 14 | 1 | 18521 | 50 |
LRP1B |
3.715e-02 | -3.29 | Neurexin-like | interpro domains | IPR003585 | 14 | 1 | 18521 | 50 |
NRXN1 |
3.715e-02 | -3.29 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 48 |
FMN2,SLC4A4,CNTN1 |
3.717e-02 | -3.29 | regulation of phosphate metabolic process | biological process | GO:0019220 | 1154 | 7 | 18204 | 50 |
APOE,NTRK2,TNIK,PRKG1,PARD3,SLC4A4,ERBB4 |
3.727e-02 | -3.29 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 49 |
MACF1 |
3.727e-02 | -3.29 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 1 | 18094 | 49 |
SLC1A2 |
3.732e-02 | -3.29 | regulation of phosphorus metabolic process | biological process | GO:0051174 | 1155 | 7 | 18204 | 50 |
PRKG1,ERBB4,PARD3,SLC4A4,APOE,TNIK,NTRK2 |
3.735e-02 | -3.29 | bladder | COSMIC cancer mutations | bladder | 14112 | 45 | 16828 | 48 |
CTNND2,NPAS3,PARD3,ADCY2,CDH20,TRPM3,SLC4A4,SOX5,ABLIM1,SLC14A1,DCLK2,RYR3,FMN2,SORBS1,GPM6A,GFAP,MGAT4C,MSI2,NTRK2,CNTN1,DGKG,CAMK2G,DTNA,GPC5,NTM,PRKG1,NEBL,HPSE2,MACF1,CLU,LSAMP,RORA,NRG3,RFX4,TNIK,PLCB1,LRP1B,PITPNC1,ATP1A2,NRXN1,TNC,SLC1A2,GLIS3,NAV2,ERBB4 |
3.735e-02 | -3.29 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 45 | 16828 | 48 |
PITPNC1,ATP1A2,PLCB1,TNIK,LRP1B,GLIS3,ERBB4,NAV2,NRXN1,TNC,SLC1A2,NEBL,CAMK2G,DTNA,GPC5,NTM,PRKG1,RFX4,NRG3,MACF1,HPSE2,LSAMP,CLU,RORA,MGAT4C,RYR3,GPM6A,SORBS1,FMN2,GFAP,DGKG,MSI2,NTRK2,CNTN1,ADCY2,CDH20,CTNND2,NPAS3,PARD3,SLC14A1,DCLK2,TRPM3,SLC4A4,SOX5,ABLIM1 |
3.745e-02 | -3.28 | DAGKa | smart domains | SM00045 | 10 | 1 | 9717 | 37 |
DGKG |
3.745e-02 | -3.28 | MIR | smart domains | SM00472 | 10 | 1 | 9717 | 37 |
RYR3 |
3.756e-02 | -3.28 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 2 | 19454 | 50 |
CLU,APOE |
3.756e-02 | -3.28 | ANKRD26 (ankyrin repeat domain containing 26) | protein interactions | 22852 | 119 | 2 | 19454 | 50 |
PARD3,NTRK2 |
3.759e-02 | -3.28 | human chr8p21.1 | chromosome location | human chr8p21.1 | 20 | 1 | 26134 | 50 |
CLU |
3.779e-02 | -3.28 | cellular response to forskolin | biological process | GO:1904322 | 14 | 1 | 18204 | 50 |
ADCY2 |
3.779e-02 | -3.28 | positive regulation of phospholipid transport | biological process | GO:2001140 | 14 | 1 | 18204 | 50 |
APOE |
3.779e-02 | -3.28 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | mechanosensory behavior | biological process | GO:0007638 | 14 | 1 | 18204 | 50 |
NRXN1 |
3.779e-02 | -3.28 | negative regulation of long-term synaptic potentiation | biological process | GO:1900272 | 14 | 1 | 18204 | 50 |
APOE |
3.779e-02 | -3.28 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | response to forskolin | biological process | GO:1904321 | 14 | 1 | 18204 | 50 |
ADCY2 |
3.779e-02 | -3.28 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 50 |
RYR3 |
3.779e-02 | -3.28 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 50 |
SLC1A2 |
3.779e-02 | -3.28 | protein localization to postsynaptic specialization membrane | biological process | GO:0099633 | 14 | 1 | 18204 | 50 |
ERBB4 |
3.779e-02 | -3.28 | neurotransmitter receptor localization to postsynaptic specialization membrane | biological process | GO:0099645 | 14 | 1 | 18204 | 50 |
ERBB4 |
3.779e-02 | -3.28 | regulation of skeletal muscle adaptation | biological process | GO:0014733 | 14 | 1 | 18204 | 50 |
CAMK2G |
3.788e-02 | -3.27 | NPR1 (natriuretic peptide receptor 1) | protein interactions | 4881 | 15 | 1 | 19454 | 50 |
PRKG1 |
3.788e-02 | -3.27 | DEFB123 (defensin beta 123) | protein interactions | 245936 | 15 | 1 | 19454 | 50 |
LRP1B |
3.788e-02 | -3.27 | PCSK1N (proprotein convertase subtilisin/kexin type 1 inhibitor) | protein interactions | 27344 | 15 | 1 | 19454 | 50 |
MGAT4C |
3.788e-02 | -3.27 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 1 | 19454 | 50 |
CLU |
3.788e-02 | -3.27 | TAFA5 (TAFA chemokine like family member 5) | protein interactions | 25817 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | OLFM3 (olfactomedin 3) | protein interactions | 118427 | 15 | 1 | 19454 | 50 |
LRP1B |
3.788e-02 | -3.27 | XIRP1 (xin actin binding repeat containing 1) | protein interactions | 165904 | 15 | 1 | 19454 | 50 |
NEBL |
3.794e-02 | -3.27 | rhythmic process | biological process | GO:0048511 | 270 | 3 | 18204 | 50 |
MAPK10,NTRK2,RORA |
3.796e-02 | -3.27 | regulation of membrane potential | biological process | GO:0042391 | 463 | 4 | 18204 | 50 |
NRXN1,NTRK2,SLC4A4,ATP1A2 |
3.797e-02 | -3.27 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 3 | 18094 | 49 |
ATP1A2,SLC4A4,SLC1A2 |
3.810e-02 | -3.27 | CEP128 (centrosomal protein 128) | protein interactions | 145508 | 289 | 3 | 19454 | 50 |
SORBS1,NEBL,ABLIM1 |
3.815e-02 | -3.27 | RECEPTOR_TYR_KIN_II | prosite domains | PS00239 | 11 | 1 | 12186 | 43 |
NTRK2 |
3.818e-02 | -3.27 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 8 | 16828 | 48 |
RYR3,CTNND2,HPSE2,MACF1,TRPM3,LRP1B,ATP1A2,ERBB4 |
3.837e-02 | -3.26 | Negative regulation of the PI3K/AKT network | REACTOME pathways | R-HSA-199418 | 94 | 2 | 10285 | 34 |
ERBB4,NRG3 |
3.855e-02 | -3.26 | low-density lipoprotein particle | cellular component | GO:0034362 | 15 | 1 | 19108 | 50 |
APOE |
3.855e-02 | -3.26 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 50 |
SLC1A2 |
3.866e-02 | -3.25 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 3 | 18094 | 49 |
PLCB1,PITPNC1,PARD3 |
3.873e-02 | -3.25 | regulation of monoatomic ion transport | biological process | GO:0043269 | 466 | 4 | 18204 | 50 |
CAMK2G,CNTN1,ATP1A2,NKAIN3 |
3.873e-02 | -3.25 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 41 | 16828 | 48 |
NTM,PARD3,PRKG1,NPAS3,CTNND2,GPC5,NEBL,ADCY2,CDH20,SOX5,RORA,ABLIM1,LSAMP,CLU,TRPM3,HPSE2,MACF1,SLC14A1,NRG3,RFX4,GFAP,PLCB1,GPM6A,FMN2,TNIK,SORBS1,LRP1B,RYR3,MGAT4C,ATP1A2,PITPNC1,SLC1A2,NTRK2,NKAIN3,TNC,CNTN1,NRXN1,ERBB4,NAV2,DGKG,GLIS3 |
3.884e-02 | -3.25 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 47 | 16828 | 48 |
ATP1A2,PITPNC1,LRP1B,PLCB1,TNIK,NAV2,ERBB4,GLIS3,SLC1A2,APOE,NKAIN3,TNC,NRXN1,NEBL,PRKG1,NTM,GPC5,DTNA,CAMK2G,RFX4,NRG3,RORA,LSAMP,CLU,MACF1,HPSE2,MGAT4C,GFAP,SORBS1,GPM6A,FMN2,RYR3,DGKG,CNTN1,NTRK2,MSI2,CDH20,ADCY2,PARD3,NPAS3,CTNND2,DCLK2,SLC14A1,ABLIM1,SLC4A4,SOX5,TRPM3 |
3.887e-02 | -3.25 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 18 | 16828 | 48 |
GLIS3,NAV2,MACF1,TRPM3,CLU,RORA,TNC,APOE,CDH20,ADCY2,CTNND2,NPAS3,RYR3,CAMK2G,LRP1B,FMN2,SORBS1,PARD3 |
3.887e-02 | -3.25 | Lysophosphatidic Acid LPA1 Signalling | SMPDB pathways | SMP0063746 | 9 | 1 | 1369 | 6 |
PLCB1 |
3.887e-02 | -3.25 | Intracellular Signalling Through FSH Receptor and Follicle Stimulating Hormone | SMPDB pathways | SMP0000333 | 9 | 1 | 1369 | 6 |
ADCY2 |
3.887e-02 | -3.25 | Excitatory Neural Signalling Through 5-HTR 7 and Serotonin | SMPDB pathways | SMP0000311 | 9 | 1 | 1369 | 6 |
ADCY2 |
3.887e-02 | -3.25 | Lysophosphatidic Acid LPA2 Signalling | SMPDB pathways | SMP0063753 | 9 | 1 | 1369 | 6 |
PLCB1 |
3.887e-02 | -3.25 | Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | SMPDB pathways | SMP0000312 | 9 | 1 | 1369 | 6 |
ADCY2 |
3.887e-02 | -3.25 | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | SMPDB pathways | SMP0000309 | 9 | 1 | 1369 | 6 |
ADCY2 |
3.887e-02 | -3.25 | Intracellular Signalling Through Histamine H2 Receptor and Histamine | SMPDB pathways | SMP0000335 | 9 | 1 | 1369 | 6 |
ADCY2 |
3.896e-02 | -3.25 | EGF_2 | prosite domains | PS01186 | 213 | 3 | 12186 | 43 |
TNC,NRG3,LRP1B |
3.898e-02 | -3.24 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 34 |
GPC5 |
3.898e-02 | -3.24 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 34 |
GPC5 |
3.898e-02 | -3.24 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 3 | 16828 | 48 |
RYR3,SLC1A2,SOX5 |
3.918e-02 | -3.24 | negative regulation of protein catabolic process | biological process | GO:0042177 | 114 | 2 | 18204 | 50 |
FMN2,CST3 |
3.918e-02 | -3.24 | negative regulation of small molecule metabolic process | biological process | GO:0062014 | 114 | 2 | 18204 | 50 |
PRKG1,APOE |
3.930e-02 | -3.24 | SLMAP (sarcolemma associated protein) | protein interactions | 7871 | 122 | 2 | 19454 | 50 |
CAMK2G,TNIK |
3.935e-02 | -3.24 | skin-acral-malignant_melanoma | COSMIC cancer mutations | skin-acral-malignant_melanoma | 264 | 3 | 16828 | 48 |
FMN2,PARD3,CDH20 |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.943e-02 | -3.23 | human chr10q23.1 | chromosome location | human chr10q23.1 | 21 | 1 | 26134 | 50 |
NRG3 |
3.950e-02 | -3.23 | basal plasma membrane | cellular component | GO:0009925 | 288 | 3 | 19108 | 50 |
ERBB4,SLC4A4,SLC14A1 |
3.956e-02 | -3.23 | import into cell | biological process | GO:0098657 | 687 | 5 | 18204 | 50 |
LRP1B,GFAP,ATP1A2,APOE,SLC1A2 |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | FH2_Formin | interpro domains | IPR015425 | 15 | 1 | 18521 | 50 |
FMN2 |
3.975e-02 | -3.23 | NTF2-like_dom_sf | interpro domains | IPR032710 | 15 | 1 | 18521 | 50 |
CAMK2G |
3.975e-02 | -3.23 | Diacylglycerol_kinase_cat_dom | interpro domains | IPR001206 | 15 | 1 | 18521 | 50 |
DGKG |
3.975e-02 | -3.23 | PLipase_C_Pinositol-sp_Y | interpro domains | IPR001711 | 15 | 1 | 18521 | 50 |
PLCB1 |
3.975e-02 | -3.23 | FH2_Formin_sf | interpro domains | IPR042201 | 15 | 1 | 18521 | 50 |
FMN2 |
3.975e-02 | -3.23 | PI-PLC_fam | interpro domains | IPR001192 | 15 | 1 | 18521 | 50 |
PLCB1 |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.988e-02 | -3.22 | tropomyosin binding | molecular function | GO:0005523 | 15 | 1 | 18094 | 49 |
NEBL |
3.988e-02 | -3.22 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 49 |
PITPNC1 |
3.988e-02 | -3.22 | low-density lipoprotein particle receptor activity | molecular function | GO:0005041 | 15 | 1 | 18094 | 49 |
LRP1B |
3.988e-02 | -3.22 | filamin binding | molecular function | GO:0031005 | 15 | 1 | 18094 | 49 |
NEBL |
3.988e-02 | -3.22 | 3'-5' DNA helicase activity | molecular function | GO:0043138 | 15 | 1 | 18094 | 49 |
NAV2 |
3.988e-02 | -3.22 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 43 |
RYR3,DGKG,MACF1 |
3.988e-02 | -3.22 | ITPR1 (inositol 1,4,5-trisphosphate receptor type 1) | protein interactions | 3708 | 123 | 2 | 19454 | 50 |
PRKG1,CAMK2G |
3.988e-02 | -3.22 | GNAQ (G protein subunit alpha q) | protein interactions | 2776 | 123 | 2 | 19454 | 50 |
GPM6A,PLCB1 |
4.002e-02 | -3.22 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 2 | 18094 | 49 |
SLC1A2,SLC4A4 |
4.019e-02 | -3.21 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 8 | 16828 | 48 |
RYR3,HPSE2,CTNND2,MACF1,TRPM3,LRP1B,ERBB4,ATP1A2 |
4.020e-02 | -3.21 | MAPRE1 (microtubule associated protein RP/EB family member 1) | protein interactions | 22919 | 504 | 4 | 19454 | 50 |
MACF1,CAMK2G,ABLIM1,NAV2 |
4.035e-02 | -3.21 | DUS1L (dihydrouridine synthase 1 like) | protein interactions | 64118 | 16 | 1 | 19454 | 50 |
CAMK2G |
4.035e-02 | -3.21 | CAMK1G (calcium/calmodulin dependent protein kinase IG) | protein interactions | 57172 | 16 | 1 | 19454 | 50 |
CAMK2G |
4.035e-02 | -3.21 | GABRR1 (gamma-aminobutyric acid type A receptor subunit rho1) | protein interactions | 2569 | 16 | 1 | 19454 | 50 |
PRKG1 |
4.035e-02 | -3.21 | CYP2C8 (cytochrome P450 family 2 subfamily C member 8) | protein interactions | 1558 | 16 | 1 | 19454 | 50 |
APOE |
4.035e-02 | -3.21 | TMEM134 (transmembrane protein 134) | protein interactions | 80194 | 16 | 1 | 19454 | 50 |
ERBB4 |
4.035e-02 | -3.21 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | IFFO2 (intermediate filament family orphan 2) | protein interactions | 126917 | 16 | 1 | 19454 | 50 |
GFAP |
4.035e-02 | -3.21 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 1 | 19454 | 50 |
MACF1 |
4.036e-02 | -3.21 | skin-malignant_melanoma | COSMIC cancer mutations | skin-malignant_melanoma | 15741 | 48 | 16828 | 48 |
CST3,RFX4,NRG3,RORA,LSAMP,CLU,HPSE2,MACF1,NEBL,NTM,PRKG1,CAMK2G,DTNA,GPC5,ERBB4,NAV2,GLIS3,SLC1A2,NKAIN3,APOE,TNC,NRXN1,ATP1A2,PITPNC1,PLCB1,TNIK,LRP1B,DCLK2,SLC14A1,SOX5,SLC4A4,ABLIM1,TRPM3,ADCY2,CDH20,PARD3,NPAS3,CTNND2,DGKG,NTRK2,CNTN1,MSI2,MGAT4C,GFAP,SORBS1,GPM6A,FMN2,RYR3 |
4.042e-02 | -3.21 | Phenytoin (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000327 | 77 | 2 | 1369 | 6 |
ATP1A2,PLCB1 |
4.043e-02 | -3.21 | lipoprotein catabolic process | biological process | GO:0042159 | 15 | 1 | 18204 | 50 |
APOE |
4.043e-02 | -3.21 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | positive regulation of glycogen biosynthetic process | biological process | GO:0045725 | 15 | 1 | 18204 | 50 |
SORBS1 |
4.043e-02 | -3.21 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 50 |
RORA |
4.043e-02 | -3.21 | positive regulation of cholesterol metabolic process | biological process | GO:0090205 | 15 | 1 | 18204 | 50 |
APOE |
4.043e-02 | -3.21 | pyramidal neuron differentiation | biological process | GO:0021859 | 15 | 1 | 18204 | 50 |
DCLK2 |
4.043e-02 | -3.21 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 50 |
SLC1A2 |
4.043e-02 | -3.21 | negative regulation of amino acid transport | biological process | GO:0051956 | 15 | 1 | 18204 | 50 |
PRKG1 |
4.043e-02 | -3.21 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | regulation of inositol phosphate biosynthetic process | biological process | GO:0010919 | 15 | 1 | 18204 | 50 |
PRKG1 |
4.043e-02 | -3.21 | peripheral nervous system neuron development | biological process | GO:0048935 | 15 | 1 | 18204 | 50 |
NTRK2 |
4.043e-02 | -3.21 | peripheral nervous system neuron differentiation | biological process | GO:0048934 | 15 | 1 | 18204 | 50 |
NTRK2 |
4.043e-02 | -3.21 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 50 |
SOX5 |
4.043e-02 | -3.21 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 50 |
MACF1 |
4.043e-02 | -3.21 | regulation of phospholipid transport | biological process | GO:2001138 | 15 | 1 | 18204 | 50 |
APOE |
4.043e-02 | -3.21 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | collateral sprouting | biological process | GO:0048668 | 15 | 1 | 18204 | 50 |
PRKG1 |
4.043e-02 | -3.21 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 50 |
RYR3 |
4.047e-02 | -3.21 | CEBPA (CCAAT enhancer binding protein alpha) | protein interactions | 1050 | 124 | 2 | 19454 | 50 |
MACF1,GFAP |
4.053e-02 | -3.21 | FH2 | pfam domains | PF02181 | 15 | 1 | 17795 | 49 |
FMN2 |
4.053e-02 | -3.21 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 49 |
TNIK |
4.053e-02 | -3.21 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 49 |
ATP1A2 |
4.053e-02 | -3.21 | PI-PLC-Y | pfam domains | PF00387 | 15 | 1 | 17795 | 49 |
PLCB1 |
4.053e-02 | -3.21 | DAGK_cat | pfam domains | PF00781 | 15 | 1 | 17795 | 49 |
DGKG |
4.061e-02 | -3.20 | stomach-carcinoma-adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-adenocarcinoma | 15150 | 47 | 16828 | 48 |
ATP1A2,PITPNC1,TNIK,PLCB1,LRP1B,ERBB4,NAV2,GLIS3,SLC1A2,APOE,TNC,NRXN1,NEBL,NTM,PRKG1,CAMK2G,DTNA,GPC5,CST3,NRG3,RFX4,RORA,LSAMP,CLU,MACF1,HPSE2,MGAT4C,GFAP,GPM6A,FMN2,SORBS1,RYR3,DGKG,NTRK2,CNTN1,MSI2,ADCY2,CDH20,PARD3,NPAS3,CTNND2,DCLK2,SLC14A1,SOX5,SLC4A4,ABLIM1,TRPM3 |
4.069e-02 | -3.20 | LZTS2 (leucine zipper tumor suppressor 2) | protein interactions | 84445 | 506 | 4 | 19454 | 50 |
PARD3,NEBL,GFAP,SORBS1 |
4.070e-02 | -3.20 | Composition of Lipid Particles | WikiPathways | WP3601 | 10 | 1 | 5310 | 22 |
APOE |
4.077e-02 | -3.20 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 21 | 16828 | 48 |
PRKG1,LRP1B,PLCB1,TNIK,PARD3,CTNND2,NPAS3,CAMK2G,PITPNC1,ADCY2,CLU,LSAMP,CNTN1,ABLIM1,RORA,NTRK2,SOX5,MSI2,DCLK2,DGKG,ERBB4 |
4.077e-02 | -3.20 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 21 | 16828 | 48 |
MSI2,SOX5,NTRK2,RORA,ABLIM1,CNTN1,LSAMP,CLU,ERBB4,DGKG,DCLK2,CAMK2G,NPAS3,CTNND2,PARD3,PLCB1,TNIK,LRP1B,PRKG1,ADCY2,PITPNC1 |
4.077e-02 | -3.20 | positive regulation of response to stimulus | biological process | GO:0048584 | 2266 | 11 | 18204 | 50 |
MACF1,ERBB4,GPC5,FMN2,CLU,SORBS1,APOE,NRXN1,TNIK,NTRK2,PLCB1 |
4.079e-02 | -3.20 | TJP1 (tight junction protein 1) | protein interactions | 7082 | 297 | 3 | 19454 | 50 |
PARD3,NEBL,DTNA |
4.080e-02 | -3.20 | actin filament organization | biological process | GO:0007015 | 278 | 3 | 18204 | 50 |
FMN2,NEBL,SORBS1 |
4.085e-02 | -3.20 | acral | COSMIC cancer mutations | acral | 268 | 3 | 16828 | 48 |
PARD3,FMN2,CDH20 |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
NTM,CNTN1,LSAMP,NTRK2 |
4.106e-02 | -3.19 | TCHP (trichoplein keratin filament binding) | protein interactions | 84260 | 125 | 2 | 19454 | 50 |
PARD3,GFAP |
4.107e-02 | -3.19 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 2 | 18204 | 50 |
NRXN1,NTRK2 |
4.107e-02 | -3.19 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 50 |
TNIK |
4.127e-02 | -3.19 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 1 | 26134 | 50 |
LSAMP |
4.155e-02 | -3.18 | CNMP_BINDING_2 | prosite domains | PS00889 | 12 | 1 | 12186 | 43 |
PRKG1 |
4.155e-02 | -3.18 | MAPK | prosite domains | PS01351 | 12 | 1 | 12186 | 43 |
MAPK10 |
4.159e-02 | -3.18 | circulatory system development | biological process | GO:0072359 | 933 | 6 | 18204 | 50 |
NTRK2,RORA,APOE,ERBB4,NEBL,PRKG1 |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
PITPNC1,GPM6A |
4.193e-02 | -3.17 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 50 |
NRG3,PLCB1,MAPK10,TNIK,NTRK2,SORBS1,CNTN1,ERBB4,MACF1,CTNND2 |
4.195e-02 | -3.17 | positive regulation of cellular metabolic process | biological process | GO:0031325 | 3164 | 14 | 18204 | 50 |
ERBB4,CNTN1,GLIS3,SLC4A4,TNC,APOE,RFX4,NTRK2,TNIK,NPAS3,PLCB1,SORBS1,CLU,RORA |
4.216e-02 | -3.17 | ARRB1 (arrestin beta 1) | protein interactions | 408 | 301 | 3 | 19454 | 50 |
LRP1B,MAPK10,DGKG |
4.226e-02 | -3.16 | DES (desmin) | protein interactions | 1674 | 127 | 2 | 19454 | 50 |
DTNA,GFAP |
4.235e-02 | -3.16 | cNMP-bd_CS | interpro domains | IPR018488 | 16 | 1 | 18521 | 50 |
PRKG1 |
4.248e-02 | -3.16 | MAP kinase activity | molecular function | GO:0004707 | 16 | 1 | 18094 | 49 |
MAPK10 |
4.248e-02 | -3.16 | misfolded protein binding | molecular function | GO:0051787 | 16 | 1 | 18094 | 49 |
CLU |
4.248e-02 | -3.16 | cGMP binding | molecular function | GO:0030553 | 16 | 1 | 18094 | 49 |
PRKG1 |
4.248e-02 | -3.16 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 49 |
RORA |
4.248e-02 | -3.16 | MAP kinase kinase activity | molecular function | GO:0004708 | 16 | 1 | 18094 | 49 |
MAPK10 |
4.248e-02 | -3.16 | lamin binding | molecular function | GO:0005521 | 16 | 1 | 18094 | 49 |
PLCB1 |
4.248e-02 | -3.16 | adenylate cyclase activity | molecular function | GO:0004016 | 16 | 1 | 18094 | 49 |
ADCY2 |
4.265e-02 | -3.15 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 3 | 18204 | 50 |
TNIK,CTNND2,MACF1 |
4.269e-02 | -3.15 | - | gene3d domains | 2.20.25.10 | 14 | 1 | 14470 | 45 |
TNC |
4.269e-02 | -3.15 | - | gene3d domains | 2.60.200.40 | 14 | 1 | 14470 | 45 |
DGKG |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | CNTN2 (contactin 2) | protein interactions | 6900 | 17 | 1 | 19454 | 50 |
CNTN1 |
4.282e-02 | -3.15 | CLEC4M (C-type lectin domain family 4 member M) | protein interactions | 10332 | 17 | 1 | 19454 | 50 |
GFAP |
4.282e-02 | -3.15 | SCN1B (sodium voltage-gated channel beta subunit 1) | protein interactions | 6324 | 17 | 1 | 19454 | 50 |
CNTN1 |
4.282e-02 | -3.15 | SHD (Src homology 2 domain containing transforming protein D) | protein interactions | 56961 | 17 | 1 | 19454 | 50 |
ERBB4 |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | C16orf92 (chromosome 16 open reading frame 92) | protein interactions | 146378 | 17 | 1 | 19454 | 50 |
APOE |
4.282e-02 | -3.15 | KRTAP19-3 (keratin associated protein 19-3) | protein interactions | 337970 | 17 | 1 | 19454 | 50 |
CAMK2G |
4.282e-02 | -3.15 | FAM163B (family with sequence similarity 163 member B) | protein interactions | 642968 | 17 | 1 | 19454 | 50 |
CAMK2G |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.286e-02 | -3.15 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 2 | 19454 | 50 |
SOX5,MACF1 |
4.296e-02 | -3.15 | phospholipid binding | molecular function | GO:0005543 | 489 | 4 | 18094 | 49 |
APOE,PLCB1,PITPNC1,PARD3 |
4.299e-02 | -3.15 | regulation of nervous system process | biological process | GO:0031644 | 120 | 2 | 18204 | 50 |
PARD3,NRXN1 |
4.307e-02 | -3.14 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | positive regulation of membrane protein ectodomain proteolysis | biological process | GO:0051044 | 16 | 1 | 18204 | 50 |
APOE |
4.307e-02 | -3.14 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 50 |
SLC1A2 |
4.307e-02 | -3.14 | low-density lipoprotein particle remodeling | biological process | GO:0034374 | 16 | 1 | 18204 | 50 |
APOE |
4.307e-02 | -3.14 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | response to ether | biological process | GO:0045472 | 16 | 1 | 18204 | 50 |
PLCB1 |
4.307e-02 | -3.14 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 50 |
NRXN1 |
4.311e-02 | -3.14 | human chr5p15.31 | chromosome location | human chr5p15.31 | 23 | 1 | 26134 | 50 |
ADCY2 |
4.311e-02 | -3.14 | human chr2q34 | chromosome location | human chr2q34 | 23 | 1 | 26134 | 50 |
ERBB4 |
4.311e-02 | -3.14 | Lysophosphatidic Acid LPA5 Signalling | SMPDB pathways | SMP0063757 | 10 | 1 | 1369 | 6 |
PLCB1 |
4.311e-02 | -3.14 | Lysophosphatidic Acid LPA4 Signalling | SMPDB pathways | SMP0063756 | 10 | 1 | 1369 | 6 |
PLCB1 |
4.311e-02 | -3.14 | Intracellular Signalling Through LHCGR Receptor and Luteinizing Hormone/Choriogonadotropin | SMPDB pathways | SMP0000338 | 10 | 1 | 1369 | 6 |
ADCY2 |
4.319e-02 | -3.14 | SH3 | prosite domains | PS50002 | 222 | 3 | 12186 | 43 |
NEBL,MACF1,SORBS1 |
4.321e-02 | -3.14 | CARM1 (coactivator associated arginine methyltransferase 1) | protein interactions | 10498 | 304 | 3 | 19454 | 50 |
RORA,CAMK2G,DTNA |
4.333e-02 | -3.14 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 43 |
NTRK2,ERBB4 |
4.358e-02 | -3.13 | protein complex involved in cell-matrix adhesion | cellular component | GO:0098637 | 17 | 1 | 19108 | 50 |
TNC |
4.358e-02 | -3.13 | apical dendrite | cellular component | GO:0097440 | 17 | 1 | 19108 | 50 |
CLU |
4.370e-02 | -3.13 | Visual phototransduction | REACTOME pathways | R-HSA-2187338 | 101 | 2 | 10285 | 34 |
GPC5,APOE |
4.381e-02 | -3.13 | TYRKINASE | prints domains | PR00109 | 98 | 2 | 5227 | 18 |
ERBB4,NTRK2 |
4.423e-02 | -3.12 | primary_central_nervous_system_lymphoma | COSMIC cancer mutations | primary_central_nervous_system_lymphoma | 683 | 5 | 16828 | 48 |
PARD3,LRP1B,NRXN1,MACF1,NRG3 |
4.423e-02 | -3.12 | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | 683 | 5 | 16828 | 48 |
MACF1,NRG3,NRXN1,LRP1B,PARD3 |
4.424e-02 | -3.12 | Ig-like_fold | interpro domains | IPR013783 | 721 | 5 | 18521 | 50 |
TNC,LSAMP,NTRK2,NTM,CNTN1 |
4.426e-02 | -3.12 | neuron projection terminus | cellular component | GO:0044306 | 128 | 2 | 19108 | 50 |
SLC1A2,NTRK2 |
4.432e-02 | -3.12 | negative regulation of cellular component organization | biological process | GO:0051129 | 709 | 5 | 18204 | 50 |
CST3,CLU,CTNNA2,GFAP,APOE |
4.451e-02 | -3.11 | identical protein binding | molecular function | GO:0042802 | 2043 | 10 | 18094 | 49 |
PLCB1,ERBB4,SLC4A4,NTRK2,CST3,MSI2,APOE,PRKG1,GFAP,CAMK2G |
4.453e-02 | -3.11 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 45 | 16828 | 48 |
NRXN1,NKAIN3,TNC,SLC1A2,GLIS3,NAV2,ERBB4,TNIK,PLCB1,LRP1B,PITPNC1,ATP1A2,MACF1,HPSE2,CLU,LSAMP,RORA,RFX4,NRG3,DTNA,CAMK2G,GPC5,NTM,PRKG1,NEBL,NTRK2,CNTN1,DGKG,RYR3,SORBS1,FMN2,GPM6A,GFAP,MGAT4C,TRPM3,SLC4A4,SOX5,ABLIM1,SLC14A1,DCLK2,CTNND2,NPAS3,PARD3,ADCY2,CDH20 |
4.475e-02 | -3.11 | positive regulation of macromolecule biosynthetic process | biological process | GO:0010557 | 2592 | 12 | 18204 | 50 |
CNTN1,ERBB4,TNC,GLIS3,NTRK2,NPAS3,PLCB1,SORBS1,CLU,RFX4,APOE,RORA |
4.476e-02 | -3.11 | FBXO22 (F-box protein 22) | protein interactions | 26263 | 522 | 4 | 19454 | 50 |
SORBS1,RYR3,NAV2,APOE |
4.492e-02 | -3.10 | muscle cell differentiation | biological process | GO:0042692 | 289 | 3 | 18204 | 50 |
NEBL,RORA,PRKG1 |
4.493e-02 | -3.10 | ATP-NAD_kinase_N | interpro domains | IPR017438 | 17 | 1 | 18521 | 50 |
DGKG |
4.493e-02 | -3.10 | A/G_cyclase_CS | interpro domains | IPR018297 | 17 | 1 | 18521 | 50 |
ADCY2 |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.493e-02 | -3.10 | NAD/diacylglycerol_kinase_sf | interpro domains | IPR016064 | 17 | 1 | 18521 | 50 |
DGKG |
4.493e-02 | -3.10 | PLipase_C_PInositol-sp_X_dom | interpro domains | IPR000909 | 17 | 1 | 18521 | 50 |
PLCB1 |
4.494e-02 | -3.10 | LDLRB | prosite domains | PS51120 | 13 | 1 | 12186 | 43 |
LRP1B |
4.499e-02 | -3.10 | ITCH (itchy E3 ubiquitin protein ligase) | protein interactions | 83737 | 309 | 3 | 19454 | 50 |
RORA,ERBB4,GLIS3 |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | ZNF224 (zinc finger protein 224) | protein interactions | 7767 | 18 | 1 | 19454 | 50 |
LRP1B |
4.529e-02 | -3.09 | SELL (selectin L) | protein interactions | 6402 | 18 | 1 | 19454 | 50 |
PRKG1 |
4.529e-02 | -3.09 | ACAP1 (ArfGAP with coiled-coil, ankyrin repeat and PH domains 1) | protein interactions | 9744 | 18 | 1 | 19454 | 50 |
NEBL |
4.529e-02 | -3.09 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 50 |
PARD3 |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | Lck (lymphocyte protein tyrosine kinase) | protein interactions | 16818 | 18 | 1 | 19454 | 50 |
APOE |
4.529e-02 | -3.09 | CYP2E1 (cytochrome P450 family 2 subfamily E member 1) | protein interactions | 1571 | 18 | 1 | 19454 | 50 |
CLU |
4.529e-02 | -3.09 | ADAT2 (adenosine deaminase tRNA specific 2) | protein interactions | 134637 | 18 | 1 | 19454 | 50 |
NAV2 |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.530e-02 | -3.09 | STRN (striatin) | protein interactions | 6801 | 132 | 2 | 19454 | 50 |
TNIK,CAMK2G |
4.533e-02 | -3.09 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 34 |
ABLIM1 |
4.551e-02 | -3.09 | Z disc | cellular component | GO:0030018 | 130 | 2 | 19108 | 50 |
NEBL,RYR3 |
4.560e-02 | -3.09 | cardiocyte differentiation | biological process | GO:0035051 | 124 | 2 | 18204 | 50 |
PRKG1,NEBL |
4.560e-02 | -3.09 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 2 | 18204 | 50 |
APOE,SORBS1 |
4.560e-02 | -3.09 | action potential | biological process | GO:0001508 | 124 | 2 | 18204 | 50 |
ATP1A2,NTRK2 |
4.567e-02 | -3.09 | Formin, FH2 domain | gene3d domains | 1.20.58.2220 | 15 | 1 | 14470 | 45 |
FMN2 |
4.570e-02 | -3.09 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 50 |
TNIK |
4.570e-02 | -3.09 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | retinal rod cell differentiation | biological process | GO:0060221 | 17 | 1 | 18204 | 50 |
NTRK2 |
4.570e-02 | -3.09 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | positive regulation of vascular permeability | biological process | GO:0043117 | 17 | 1 | 18204 | 50 |
APOE |
4.570e-02 | -3.09 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | negative regulation of triglyceride metabolic process | biological process | GO:0090209 | 17 | 1 | 18204 | 50 |
APOE |
4.570e-02 | -3.09 | positive regulation of meiotic nuclear division | biological process | GO:0045836 | 17 | 1 | 18204 | 50 |
PLCB1 |
4.570e-02 | -3.09 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 50 |
SLC1A2 |
4.570e-02 | -3.09 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 50 |
RYR3 |
4.570e-02 | -3.09 | fatty acid homeostasis | biological process | GO:0055089 | 17 | 1 | 18204 | 50 |
APOE |
4.570e-02 | -3.09 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 50 |
CTNNA2 |
4.570e-02 | -3.09 | branch elongation of an epithelium | biological process | GO:0060602 | 17 | 1 | 18204 | 50 |
TNC |
4.570e-02 | -3.09 | preganglionic parasympathetic fiber development | biological process | GO:0021783 | 17 | 1 | 18204 | 50 |
NAV2 |
4.570e-02 | -3.09 | regulation of inclusion body assembly | biological process | GO:0090083 | 17 | 1 | 18204 | 50 |
CLU |
4.570e-02 | -3.09 | positive regulation of glycogen metabolic process | biological process | GO:0070875 | 17 | 1 | 18204 | 50 |
SORBS1 |
4.570e-02 | -3.09 | regulation of fertilization | biological process | GO:0080154 | 17 | 1 | 18204 | 50 |
PLCB1 |
4.570e-02 | -3.09 | mammary gland epithelial cell differentiation | biological process | GO:0060644 | 17 | 1 | 18204 | 50 |
ERBB4 |
4.570e-02 | -3.09 | high-density lipoprotein particle remodeling | biological process | GO:0034375 | 17 | 1 | 18204 | 50 |
APOE |
4.579e-02 | -3.08 | signaling receptor binding | molecular function | GO:0005102 | 1493 | 8 | 18094 | 49 |
GFAP,APOE,NRG3,NRXN1,SORBS1,TNC,CLU,ERBB4 |
4.581e-02 | -3.08 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 49 |
CST3 |
4.581e-02 | -3.08 | PI-PLC-X | pfam domains | PF00388 | 17 | 1 | 17795 | 49 |
PLCB1 |
4.581e-02 | -3.08 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 49 |
DTNA |
4.598e-02 | -3.08 | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 120 | 2 | 16828 | 48 |
CTNND2,FMN2 |
4.606e-02 | -3.08 | Stimuli-sensing channels | REACTOME pathways | R-HSA-2672351 | 104 | 2 | 10285 | 34 |
RYR3,TRPM3 |
4.626e-02 | -3.07 | actomyosin structure organization | biological process | GO:0031032 | 125 | 2 | 18204 | 50 |
SORBS1,NEBL |
4.626e-02 | -3.07 | cellular component assembly involved in morphogenesis | biological process | GO:0010927 | 125 | 2 | 18204 | 50 |
NEBL,CNTN1 |
4.626e-02 | -3.07 | memory | biological process | GO:0007613 | 125 | 2 | 18204 | 50 |
PLCB1,APOE |
4.626e-02 | -3.07 | cerebral cortex development | biological process | GO:0021987 | 125 | 2 | 18204 | 50 |
PLCB1,NTRK2 |
4.626e-02 | -3.07 | mammary gland development | biological process | GO:0030879 | 125 | 2 | 18204 | 50 |
NRG3,ERBB4 |
4.626e-02 | -3.07 | cellular anatomical entity morphogenesis | biological process | GO:0032989 | 125 | 2 | 18204 | 50 |
CNTN1,NEBL |
4.627e-02 | -3.07 | basal part of cell | cellular component | GO:0045178 | 307 | 3 | 19108 | 50 |
SLC14A1,ERBB4,SLC4A4 |
4.642e-02 | -3.07 | extracellular region | cellular component | GO:0005576 | 4350 | 17 | 19108 | 50 |
GPC5,HPSE2,APOE,GPM6A,NEBL,TNIK,SLC4A4,CST3,ERBB4,TNC,ATP1A2,PLCB1,CNTN1,LSAMP,NTM,NRG3,CLU |
4.647e-02 | -3.07 | SOS-mediated signalling | REACTOME pathways | R-HSA-112412 | 245 | 3 | 10285 | 34 |
NRG3,ERBB4,CAMK2G |
4.647e-02 | -3.07 | SHC1 events in EGFR signaling | REACTOME pathways | R-HSA-180336 | 245 | 3 | 10285 | 34 |
CAMK2G,ERBB4,NRG3 |
4.647e-02 | -3.07 | GRB2 events in EGFR signaling | REACTOME pathways | R-HSA-179812 | 245 | 3 | 10285 | 34 |
ERBB4,NRG3,CAMK2G |
4.647e-02 | -3.07 | RAF/MAP kinase cascade | REACTOME pathways | R-HSA-5673001 | 245 | 3 | 10285 | 34 |
CAMK2G,NRG3,ERBB4 |
4.653e-02 | -3.07 | EGFR (epidermal growth factor receptor) | protein interactions | 1956 | 3105 | 13 | 19454 | 50 |
CLU,PARD3,SORBS1,CTNNA2,NTRK2,ABLIM1,CTNND2,DTNA,CAMK2G,ERBB4,TNC,TRPM3,TNIK |
4.654e-02 | -3.07 | channel activity | molecular function | GO:0015267 | 502 | 4 | 18094 | 49 |
GPM6A,RYR3,SLC14A1,TRPM3 |
4.667e-02 | -3.06 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 2 | 16828 | 48 |
DTNA,CDH20 |
4.677e-02 | -3.06 | human chr20p12.3 | chromosome location | human chr20p12.3 | 25 | 1 | 26134 | 50 |
PLCB1 |
4.682e-02 | -3.06 | passive transmembrane transporter activity | molecular function | GO:0022803 | 503 | 4 | 18094 | 49 |
RYR3,GPM6A,SLC14A1,TRPM3 |
4.693e-02 | -3.06 | limbic system development | biological process | GO:0021761 | 126 | 2 | 18204 | 50 |
DCLK2,ATP1A2 |
4.716e-02 | -3.05 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 2 | 19454 | 50 |
CAMK2G,ABLIM1 |
4.725e-02 | -3.05 | regulation of ERK1 and ERK2 cascade | biological process | GO:0070372 | 295 | 3 | 18204 | 50 |
NTRK2,ERBB4,APOE |
4.734e-02 | -3.05 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 6 |
RORA |
4.746e-02 | -3.05 | regulation of anatomical structure size | biological process | GO:0090066 | 498 | 4 | 18204 | 50 |
ATP1A2,APOE,PRKG1,MACF1 |
4.746e-02 | -3.05 | Growth_fac_rcpt_cys_sf | interpro domains | IPR009030 | 129 | 2 | 18521 | 50 |
LRP1B,ERBB4 |
4.752e-02 | -3.05 | Nucleotide_cyclase | interpro domains | IPR029787 | 18 | 1 | 18521 | 50 |
ADCY2 |
4.752e-02 | -3.05 | A/G_cyclase | interpro domains | IPR001054 | 18 | 1 | 18521 | 50 |
ADCY2 |
4.752e-02 | -3.05 | Furin_repeat | interpro domains | IPR006212 | 18 | 1 | 18521 | 50 |
ERBB4 |
4.752e-02 | -3.05 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 1 | 18521 | 50 |
ATP1A2 |
4.760e-02 | -3.05 | negative regulation of neuron projection development | biological process | GO:0010977 | 127 | 2 | 18204 | 50 |
GFAP,APOE |
4.760e-02 | -3.05 | cell-cell junction assembly | biological process | GO:0007043 | 127 | 2 | 18204 | 50 |
PARD3,CDH20 |
4.760e-02 | -3.05 | response to amino acid | biological process | GO:0043200 | 127 | 2 | 18204 | 50 |
NTRK2,SLC1A2 |
4.766e-02 | -3.04 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 1 | 18094 | 49 |
SLC1A2 |
4.766e-02 | -3.04 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 49 |
PITPNC1 |
4.766e-02 | -3.04 | lipoprotein particle receptor activity | molecular function | GO:0030228 | 18 | 1 | 18094 | 49 |
LRP1B |
4.766e-02 | -3.04 | GABA receptor binding | molecular function | GO:0050811 | 18 | 1 | 18094 | 49 |
ERBB4 |
4.766e-02 | -3.04 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 1 | 18094 | 49 |
RYR3 |
4.766e-02 | -3.04 | transmembrane receptor protein tyrosine kinase activator activity | molecular function | GO:0030297 | 18 | 1 | 18094 | 49 |
NRG3 |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
CNTN1 |
4.774e-02 | -3.04 | HBEGF (heparin binding EGF like growth factor) | protein interactions | 1839 | 19 | 1 | 19454 | 50 |
ERBB4 |
4.774e-02 | -3.04 | RRAD (RRAD, Ras related glycolysis inhibitor and calcium channel regulator) | protein interactions | 6236 | 19 | 1 | 19454 | 50 |
CAMK2G |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | ZNF532 (zinc finger protein 532) | protein interactions | 55205 | 19 | 1 | 19454 | 50 |
ERBB4 |
4.774e-02 | -3.04 | LTC4S (leukotriene C4 synthase) | protein interactions | 4056 | 19 | 1 | 19454 | 50 |
CAMK2G |
4.774e-02 | -3.04 | Trp53 (transformation related protein 53) | protein interactions | 22059 | 19 | 1 | 19454 | 50 |
MAPK10 |
4.774e-02 | -3.04 | EGFL6 (EGF like domain multiple 6) | protein interactions | 25975 | 19 | 1 | 19454 | 50 |
LRP1B |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | FBXO27 (F-box protein 27) | protein interactions | 126433 | 19 | 1 | 19454 | 50 |
CLU |
4.774e-02 | -3.04 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | GCHFR (GTP cyclohydrolase I feedback regulator) | protein interactions | 2644 | 19 | 1 | 19454 | 50 |
NEBL |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | PLCB2 (phospholipase C beta 2) | protein interactions | 5330 | 19 | 1 | 19454 | 50 |
PLCB1 |
4.774e-02 | -3.04 | OSM (oncostatin M) | protein interactions | 5008 | 19 | 1 | 19454 | 50 |
TRPM3 |
4.774e-02 | -3.04 | Mtx1 (metaxin 1) | protein interactions | 17827 | 19 | 1 | 19454 | 50 |
CAMK2G |
4.774e-02 | -3.04 | PDP2 (pyruvate dehydrogenase phosphatase catalytic subunit 2) | protein interactions | 57546 | 19 | 1 | 19454 | 50 |
GFAP |
4.774e-02 | -3.04 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.774e-02 | -3.04 | KCNF1 (potassium voltage-gated channel modifier subfamily F member 1) | protein interactions | 3754 | 19 | 1 | 19454 | 50 |
GFAP |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.776e-02 | -3.04 | Proteoglycans in cancer | KEGG pathways | ko05205 | 203 | 3 | 7161 | 29 |
CAMK2G,HPSE2,ERBB4 |
4.776e-02 | -3.04 | Proteoglycans in cancer | KEGG pathways | hsa05205 | 203 | 3 | 7161 | 29 |
CAMK2G,HPSE2,ERBB4 |
4.782e-02 | -3.04 | regulation of multicellular organismal development | biological process | GO:2000026 | 1484 | 8 | 18204 | 50 |
MACF1,PARD3,SOX5,ERBB4,GFAP,PLCB1,NTRK2,NRXN1 |
4.802e-02 | -3.04 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 48 | 16828 | 48 |
SLC14A1,DCLK2,TRPM3,ABLIM1,SLC4A4,SOX5,CDH20,ADCY2,NPAS3,CTNND2,PARD3,DGKG,MSI2,CNTN1,NTRK2,MGAT4C,RYR3,GFAP,FMN2,GPM6A,SORBS1,NRG3,RFX4,CST3,HPSE2,MACF1,RORA,CLU,LSAMP,NEBL,GPC5,DTNA,CAMK2G,PRKG1,NTM,GLIS3,ERBB4,NAV2,NRXN1,SLC1A2,TNC,APOE,NKAIN3,ATP1A2,PITPNC1,LRP1B,PLCB1,TNIK |
4.822e-02 | -3.03 | cell population proliferation | biological process | GO:0008283 | 726 | 5 | 18204 | 50 |
GFAP,RORA,CLU,HPSE2,SOX5 |
4.832e-02 | -3.03 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 50 |
CTNND2 |
4.832e-02 | -3.03 | regulation of establishment of endothelial barrier | biological process | GO:1903140 | 18 | 1 | 18204 | 50 |
PLCB1 |
4.832e-02 | -3.03 | cardiac myofibril assembly | biological process | GO:0055003 | 18 | 1 | 18204 | 50 |
NEBL |
4.832e-02 | -3.03 | response to misfolded protein | biological process | GO:0051788 | 18 | 1 | 18204 | 50 |
CLU |
4.832e-02 | -3.03 | positive regulation of myelination | biological process | GO:0031643 | 18 | 1 | 18204 | 50 |
PARD3 |
4.832e-02 | -3.03 | myelin maintenance | biological process | GO:0043217 | 18 | 1 | 18204 | 50 |
CLU |
4.832e-02 | -3.03 | regulation of endothelial cell development | biological process | GO:1901550 | 18 | 1 | 18204 | 50 |
PLCB1 |
4.832e-02 | -3.03 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 50 |
ATP1A2 |
4.832e-02 | -3.03 | regulation of protein kinase C signaling | biological process | GO:0090036 | 18 | 1 | 18204 | 50 |
DGKG |
4.832e-02 | -3.03 | regulation of acrosome reaction | biological process | GO:0060046 | 18 | 1 | 18204 | 50 |
PLCB1 |
4.832e-02 | -3.03 | negative regulation of anoikis | biological process | GO:2000811 | 18 | 1 | 18204 | 50 |
NTRK2 |
4.832e-02 | -3.03 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 50 |
CST3 |
4.836e-02 | -3.03 | Signalling to p38 via RIT and RIN | REACTOME pathways | R-HSA-187706 | 249 | 3 | 10285 | 34 |
NRG3,ERBB4,CAMK2G |
4.836e-02 | -3.03 | ARMS-mediated activation | REACTOME pathways | R-HSA-170984 | 249 | 3 | 10285 | 34 |
NRG3,ERBB4,CAMK2G |
4.842e-02 | -3.03 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 50 |
DGKG,SOX5 |
4.843e-02 | -3.03 | ASX_HYDROXYL | prosite domains | PS00010 | 100 | 2 | 12186 | 43 |
LRP1B,NRXN1 |
4.844e-02 | -3.03 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 1 | 17795 | 49 |
ATP1A2 |
4.844e-02 | -3.03 | Guanylate_cyc | pfam domains | PF00211 | 18 | 1 | 17795 | 49 |
ADCY2 |
4.848e-02 | -3.03 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 2 | 10285 | 34 |
SLC1A2,SLC4A4 |
4.849e-02 | -3.03 | N-Glycan antennae elongation | REACTOME pathways | R-HSA-975577 | 15 | 1 | 10285 | 34 |
MGAT4C |
4.849e-02 | -3.03 | Adenylate cyclase inhibitory pathway | REACTOME pathways | R-HSA-170670 | 15 | 1 | 10285 | 34 |
ADCY2 |
4.849e-02 | -3.03 | Inhibition of adenylate cyclase pathway | REACTOME pathways | R-HSA-997269 | 15 | 1 | 10285 | 34 |
ADCY2 |
4.859e-02 | -3.02 | cytosolic region | cellular component | GO:0099522 | 19 | 1 | 19108 | 50 |
PLCB1 |
4.859e-02 | -3.02 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 50 |
TNIK |
4.859e-02 | -3.02 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 50 |
GPM6A |
4.859e-02 | -3.02 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 50 |
ATP1A2 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.865e-02 | -3.02 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 22 |
RYR3 |
4.884e-02 | -3.02 | Frs2-mediated activation | REACTOME pathways | R-HSA-170968 | 250 | 3 | 10285 | 34 |
NRG3,ERBB4,CAMK2G |
4.906e-02 | -3.01 | FXR1 (FMR1 autosomal homolog 1) | protein interactions | 8087 | 538 | 4 | 19454 | 50 |
CLU,CAMK2G,GFAP,SOX5 |
4.921e-02 | -3.01 | cellular response to hormone stimulus | biological process | GO:0032870 | 504 | 4 | 18204 | 50 |
SORBS1,ATP1A2,PLCB1,TNC |
4.932e-02 | -3.01 | MAPK1/MAPK3 signaling | REACTOME pathways | R-HSA-5684996 | 251 | 3 | 10285 | 34 |
CAMK2G,ERBB4,NRG3 |
4.940e-02 | -3.01 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 3 | 19454 | 50 |
SORBS1,MACF1,DTNA |
4.946e-02 | -3.01 | knee | COSMIC cancer mutations | knee | 125 | 2 | 16828 | 48 |
CNTN1,ERBB4 |
4.951e-02 | -3.01 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 4 | 18204 | 50 |
SLC4A4,ATP1A2,APOE,RYR3 |
4.951e-02 | -3.01 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 50 |
SORBS1,RYR3,SLC1A2,PLCB1 |
4.968e-02 | -3.00 | SPCS2 (signal peptidase complex subunit 2) | protein interactions | 9789 | 139 | 2 | 19454 | 50 |
MGAT4C,GPC5 |
4.980e-02 | -3.00 | Prolonged ERK activation events | REACTOME pathways | R-HSA-169893 | 252 | 3 | 10285 | 34 |
NRG3,ERBB4,CAMK2G |
4.983e-02 | -3.00 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 2 | 17795 | 49 |
NTRK2,ERBB4 |